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 Antibiotic misuse and overuse has prompted bacteria to rapidly develop 
resistance, thereby hindering the efficacy of these chemotherapeutics. Due to antibiotic 
resistant strains expeditiously disseminating, antimicrobial resistance has been labeled as 
one of the greatest threats to human health globally. An emerging alternative 
antimicrobial strategy involves using bacteriophage-derived enzymes, termed endolysins. 
Endolysins are peptidoglycan hydrolases that liberate lytic bacteriophage virions late in 
the infection cycle by cleaving critical covalent bonds in the bacterial cell wall. As a 
result, the high intracellular osmotic pressure induces cell lysis.  Antimicrobial strategies 
have been devised involving the extrinsic application of recombinant endolysins to 
susceptible Gram-positive pathogens. The efficacy of these enzymes has been validated 
in vitro and in vivo, with no resistance observed to date. One such example is the 
streptococcal-specific endolysin PlyC. This endolysin is currently the most 
bacteriolytically-active and possesses the ability to lyse human and animal pathogens 
known to cause serious health complications. Unfortunately, like numerous other 




With a long-term goal of using endolysins for industrial applications, furthering the 
development of a thermolabile translational antimicrobial with a short shelf life is 
ambitious. The main objective of this dissertation is to develop and validate 
bioengineering strategies for thermostabilizing bacteriolytic enzymes. Using PlyC as the 
model enzyme, we first used a rationale-based computational screening methodology to 
identify stabilizing mutations to a thermosusceptible region of the catalytic subunit, 
PlyCA. One mutation, T406R, caused a 2.27°C increase in thermodynamic stability and a 
16 fold improvement in kinetic stability. Next, we developed a substantiated novel 
directed evolution protocol that involves randomly incorporating mutations into a 
bacteriolytic enzyme followed by a screening process that effectively identifies mutations 
that are stabilizing. Finally, applying multiple rounds of directed evolution to PlyC 
allowed for the identification of a thermostabilizing mutation, N211H, which increased 
the thermodynamic stability by 4.10°C and kinetic stability 18.8 fold. Combining the 
N211H and T406R mutations was additive in terms of thermal stability, with 
thermodynamic and kinetic stability enhancements of 7.46°C and 28.72 kcal/mol 
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Introduction and Literature Review 
 
 
Antibiotics and Resistance Development 
The discovery and consequent medicinal application of antibiotics has long been 
considered one of the most important findings in modern medicine. Since their 
introduction in the 1940s, the antimicrobial efficacy of antibiotics has translated to a 
significant reduction in human morbidity and mortality provoked by pathogenic bacteria 
(Andersson and Hughes, 2010). However, the intensive use of antibiotics (estimated in 
2002 to be 100,000-200,000 tonnes per annum worldwide (Wise, 2002)) and subsequent 
misuse has dramatically increased the frequency of pathogen resistance formation in 
hospital and community environments. According to the Antibiotic Resistance Genes 
Database (ARDB), there is now an estimated 23,000 potential resistance genes (r genes) 
of nearly 400 different types predicted from available bacterial genome sequences (Liu 
and Pop, 2009). The loss in antimicrobial efficacy instituted by these resistance genes, 
coupled with the significant decrease in new antibiotic development due to market failure 
and regulatory disincentives, has provoked the Infectious Disease Society of America 
(IDSA) to label antimicrobial resistance as one of the greatest threats to human health on 
a global scale (Infectious Disease Society of America, 2011).  
 
Antibiotic Discovery and Resistance Timeline 
Antimicrobials are among the most successful chemotherapeutics in the history of 
medicine. These agents have been exploited over millennia to control and prevent many 





and mortality, thereby saving countless lives. Unfortunately, the modern antibiotic era 
has been met with rapid and wide-spread resistance formation by bacterial pathogens, 
thus stimulating a transition to a post-antibiotic era where medical advances to date are 
negated (Guay, 2008; Lew et al., 2008; Woodford and Livermore, 2009). As a result, 
there is clear definitive need for an alternative antimicrobial approach to common non-
efficacious chemotherapeutics.  
The use of antimicrobial agents long outdates the modern antibiotic era. Prior to 
identifying and investigating the causative agents of infectious disease in a laboratory 
setting, therapeutic progress relied solely on the unpredictability of chance and empirical 
observation. For this reason, the earliest examples of successful antimicrobials employed 
by mankind are natural products. For example, Chinese herbalists for millennia used 
qinghaosu (artemisinin), a potent modern day anti-malarial drug, from Artemisia plants as 
a remedy for many illnesses (Cui and Su, 2009). Quinine, an anti-malarial compound 
from the bark of the cinchona tree, and emetine, a compound collected from the 
ipecacuanha root used to treat amoebic dysentery, are two other ancient remedies that 
were initially introduced in the seventeenth century to Europe and South America (Finch 
et al., 2012). Other common herbs used include extract from the male fern Dryopteris 
filix-mas, which helps eradicate tapeworm infections, as well as santonin from the seed-
heads of Artemisia cina and chenopodium oil of Chenopodium ambrosioides, both of 
which act against intestinal roundworms. In addition to herbal-derived remedies and 
contrary to the prevalent notion of initial antibiotic use being confined only to 20
th
 
century, histological studies of skeletal remains from an ancient Sudanese Nubian 





(Armelagos, 1969; Bassett et al., 1980; Cook et al., 1989; Nelson et al., 2010). Moreover, 
since the sixteenth century, mercury had been used for its antibacterial properties to treat 
syphilis infections (Finch et al., 2012).  
The foundation for modern twentieth century chemotherapy was constructed by 
the German scientist Paul Ehrlich during his quest to identify antiprotozoal agents to 
combat the newly discovered parasites of trypanosomiasis, the causative agent of African 
sleeping sickness, and malaria (Finch et al., 2012). Based on the observation that aniline 
and other synthetic dyes could specifically stain these parasites when isolated from the 
tissues of infected patients, Ehrlich rationalized that compounds could be developed that 
would “be able to exert their full action exclusively on the parasite harbored within the 
organism.” It was this key concept that fueled Ehrlich in 1904 to begin a voluminous and 
systematic screening program to uncover safe arsenical derivatives against syphilis, a 
sexually transmitted disease caused by the spirochete Treponema pallidium that was 
endemic and almost incurable at the time. In collaboration with chemist Alfred Bertheim 
and bacteriologist Sahachiro Hata, Ehlrich was able to synthesize and screen hundreds of 
compounds against syphilis-infected rabbits. Five years later in 1909, the sixth arsenical 
compound in the 600
th
 series tested, hence termed compound 606, was experimentally 
shown to fully cure syphilis-infected rabbits and furthermore exhibited significant 
promise as a human therapeutic due the compound’s efficacy and acceptable safety 
profile when treating patients infected with the venereal disease (Ehrlich and Hata, 1910). 
Despite the laborious injection process and side effects associated with compound 606, 
the drug, later known as arsphenamine (Salvarsan), and its improved, less toxic derivative 





sleeping sickness in humans. As a result, this particular antimicrobial represented the 
most actively prescribed drug until being replaced by penicillin in the 1940s (Mahoney et 
al., 1943).  
Although Ehrlich never fulfilled his personal goal of using dyes as a therapeutic 
agent, this conceptual antimicrobial approach paid dividends years later. Scientists at the 
German pharmaceutical company Bayer in 1924 were able to develop a drug named 
suramin (Germanin), which was a colorless derivative of trypan blue dye, to treat the 
parasitic diseases trypanosomiasis and onchocerciasis (Finch et al., 2012). Additionally, 
studying the effects of numerous modifications to Ehrlich’s methylene blue dye prompted 
scientists at Bayer to introduce similar molecular alterations to quinine-like compounds. 
These systematic screens resulted in the development of the world’s first synthetic 
antimalarial drug, plasmochin (pamaquine), and the acridine derivative, atebrin. 
The continued interest in therapeutic dyes ultimately led to the discovery of the 
first broad-spectrum antibacterial agents, termed sulfa drugs or sulfonamides. In 1932, 
Gerhard Domagk, an experimental pathologist at Bayer, screened a large number of 
synthetic dyes for antimicrobial activity. One dye, sulfonamidochrysoidine (KI-730, 
Prontosil), which was synthesized by Bayer chemists Josef Klarer and Fritz Mietzsch, 
demonstrated antibacterial activity against a wide-range of bacterial species known to be 
causative agents for a number of infectious diseases (Domagk, 1935). It was later 
concluded by the Tréfouëls and their colleagues in France that the sulfanilamide chemical 
group of the dye was responsible for the antimicrobial efficacy of the compound. The use 
of subcutaneous sulfanilamide lowered the mortality rate of acute meningococcal 





al., 1984). As a chemical, sulfanilamide, which consists of a sulfonamide functional 
group attached to aniline, was readily used in the dye industry since 1908 and thus was 
not patentable by Bayer as an antimicrobial. The cheap cost of synthesizing this particular 
off-patent chemical group coupled with how simplistic the sulfanilamide moiety was to 
modify ultimately prompted other companies to immediately started mass producing the 
drug for commercial application (Aminov, 2010). Accordingly, with sulfanilamides 
representing the oldest class of antibiotics on market, they also represent one of the most 
broadly distributed cases of drug resistance by virtue of the sulfa drug resistance genes 
being encoded by class 1 integrons, which are mobile genetic elements that can be easily 
transmitted and integrated into the genome of the host bacterium. 
The development of classical antibiotics was instigated by the discovery of the β-
lactam antibiotic penicillin by Alexander Fleming in 1928. Although other scientists 
before Fleming have documented similar observations relating to the antimicrobial 
efficacy of Penicillium, it was his persistent belief in cultivating the active substance 
derived from the mold and utilizing it as a therapeutic agent that set him apart. Early 
attempts by Fleming to exploit penicillin were met with failure, mostly due to the 
inability to devise experimental approaches to successfully purify and concentrate the 
antimicrobial. Due to the work of Howard Florey and Ernest Chain from Oxford 
University, it was not until 1940 that a protocol describing the purification of penicillin in 
sufficient quantities for clinical testing was published (Chain et al., 2005). Their protocol 
led to the mass production and distribution of penicillin in 1943. Interestingly, the first 
reported hospital use of a drug that would be classified today as an antibiotic was 





drug named pyocyanase, which is derived from Pseudomonas aeruginosa (formally 
known as Bacillus pyocyaneus), was prepared in 1899 by the German physicians 
Rudolph Emmerich and Oscar Löw (Emmerich and Löw, 1899). Both P. aeruginosa cells 
and pyocyanase extracts displayed antimicrobial activity against a wide-range of 
pathogenic bacterial species, prompting Emmerich and Löw to attempt to use the 
pyocyanase extract as a therapeutic. Unfortunately, pyocyanase treatment was shortly 
abandoned due to the inherent toxicity and poor efficacy of the extract. 
Despite the drug’s success as an antibacterial agent, penicillin was more effective 
against Gram-positive bacteria species than Gram-negative, thus inciting scientists to 
continue looking for alternative antibiotics. In 1943, the first aminoglycoside antibiotic, 
streptomycin, was discovered by Selman A. Waksman, a Ukrainian émigré, and Albert 
Schatz, who was Waksman’s research student at the time, during a systematic screening 
of soil organisms, namely actinomycetes. The antibacterial spectrum of streptomycin 
perfectly complimented penicillin by inhibiting many Gram-negative bacteria, including 
Mycobacterium tuberculosis (TB).  
Following the conclusion of the Second World War, the discovery of 
streptomycin provoked pharmaceutical companies to start investing in antibiotic drug 
discovery. An immense amount of soil samples from all over the world were screened for 
antibiotic-producing microorganisms and although thousands of newly discovered 
antibiotics failed preliminary toxicity tests, most of the major families of antibiotics had 
been discovered by the mid-1950s, including the peptide antibiotics (e.g. bacitracin 
(1945)), chloramphenicol (1947), the tetracycline antibiotics (e.g. chlortetracycline 





antibiotics (e.g. cycloserine (1955)) and cephalosporin C (1955), which represents the 
second major group of β-lactam antibiotics. In addition to naturally occurring antibiotics, 
synthetic antibiotic compounds have been produced, including the tuberculosis remedy 
isoniazid (1952), as well as the first quinolone antibacterial agent nalidixic acid (1962). 
Overall, the golden era of antibiotic discovery existed between the 1950s and 1970s, with 
only the oxazolidinone antibiotic class being discovered since then.  
There are five basic antibacterial mechanisms utilized by antibiotics that either 
disrupts essential bacterial cell metabolic processes or structures (Finch, 2010). The most 
common mechanism employed by antibiotics involves interfering with peptidoglycan 
biosynthesis through inhibiting cell wall cross-linking or precursors (e.g. penicillins, 
cephalosporins, glycopeptides, carbapenems, monobactams, aztreonam, bacitracin, 
cycloserine, fosfomycin, isoniazid, ethambutol). The second largest class of antibiotics is 
the translation inhibitors, which directly interact with the bacterial 30S (e.g. 
aminoglycosides, tetracyclines) or 50S (e.g. macrolides, chloramphenicol, clindamycin, 
linezolid, streptogramins) ribosomal subunits to suppress protein synthesis. Other 
antibiotic mechanisms include disruption of cell membrane permeability (e.g. polymyxin, 
ionophores), hindrance of DNA (e.g. quinolones, novobiocin, nitrofurans, metronidazole) 
and RNA (e.g. rifampin, isoniazid, bacitracin) synthesis, and antimetabolite activity that 
blocks enzyme-catalyzed reactions of the bacterial cell metabolism, such as mycolic acid 
synthesis inhibitors (e.g. isoniazid) and folic acid synthesis inhibitors (e.g. sulfonamides, 
dapsone, trimethoprim).  





potential of tolerance or resistance to the compound through Darwinian evolution (Davies 
and Davies, 2010). This observation is seen repeatedly with chemotherapeutic agents that 
target disease-causing bacteria, fungi, parasites and viruses. The complexity of these 
biochemical and physiological resistance mechanisms has impeded the formulation of 
effective approaches for the prevention and control of resistance formation.  
Bacterial resistance to antimicrobials has gotten the most attention due to the 
rapid evolution and dissemination of these drug-resistant microorganisms, as well as their 
drastic effect on human morbidity and mortality. Since the discovery and mass 
production of the first class of antibiotics, there are many subsequent examples of 
expeditious antibiotic resistance development after the initial therapeutic introduction of 
the drug.  In addition to the aforementioned resistance formation to sulfa drugs, which 
represents the first class of antibiotics, resistance was observed to penicillin prior to the 
extensive use of the antibiotic. In 1940, two years before the first reported therapeutic use 
of the antibiotic, two members of the penicillin discovery team, Edward Abraham and 
Ernst Chain, identified an enzyme from Staphylococcus, termed penicillinase, which 
could degrade penicillin and render the drug inactive (Abraham and Chain, 1940). Other 
examples of antibiotic resistance include resistance against streptomycin, tetracycline, 
erythromycin, methicillin, spectinomycin, gentamicin, vancomycin, imipenem, 
ceftazidime, levofloxacin, linezolid, daptomycin and ceftaroline (Table 1-1).  
Additionally, bacterial pathogens associated with epidemics of human disease 
have evolved into multidrug-resistant (MDR) forms, particularly in hospital settings, and 





Table 1-1. Antibiotic Resistance Timeline. (Adapted from Centers for Disease Control 
and Prevention, 2013 and Unemo and Shafer, 2011) 
Antibiotic Introduced Resistance Observed Organism 
Penicillin 1942 1940 Staphylococcus 
  1958 Gonococcus 
  
1965 Pneumococcus 
Streptomycin 1949 1958 Gonococcus 
Tetracycline 1950 1959 Shigella 
  1985 Gonococcus 
Erythromycin 1953 1968 Streptococcus 
  1977 Gonococcus 
Methicillin 1960 1962 Staphylococcus 
Spectinomycin 1961 1987 Gonococcus 
Gentamicin 1967 1979 Enterococcus 
Vancomycin 1972 1988 Enterococcus 
  
2002 Staphylococcus 
Imipenem 1985 1998 Enterobacteriaceae 
Ceftazidime 1985 1987 Enterobacteriaceae 
  2001 Gonococcus 
Levofloxacin 1996 1996 Pneumococcus 
Linezolid 2000 2001 Staphylococcus 
Daptomycin 2003 2005 Staphylococcus 















mortality affiliated with these microorganisms. Some examples of nosocomial MDR 
pathogens include Acinetobacter baumanni, Burkholderia cepacia, Campylobacter jejuni, 
Citrobacter freundii, Clostridium difficile, Enterobacter spp., Enterobacter faecium, 
Enterococcus faecalis, Escherichia coli, Haemophilus influenza, Klebsiella pneumoniae, 
N. gonorrhoeae, Proteus mirabilis, P. aeruginosa, Salmonella spp., Serratia spp., 
Staphylococcus aureus, Staphylococcus epidermidis, Stenotrophomonas maltophilia and 
Streptococcus pneumoniae (Davies and Davies, 2010). Particular strains of MDR TB 
have been uncovered and labeled as extensively drug-resistant (XDR) microorganism, 
while MDR strains of Acinetobacter, Pseudomonas and Enterobacteriaceae have been 
characterized as pandrug-resistant (PDR). XDR TB display resistance against isoniazid 
and rifampin, fluoroquinolones and at least one of the three injectable second-line drugs 
(i.e. amikacin, kanamycin or capreomycin) (Dorman and Chaisson, 2007). PDR bacterial 
strains are specifically resistant to the seven antimicrobial agents cefepime, ceftazidime, 
imipenem, meropenem, piperacillin-tazobactam, ciprofloxacin and levofloxacin (Falagas 
and Karageorgopoulos, 2008). With the continual decrease in antibacterial efficacy, the 
lack in development of novel efficacious antibiotics has threatened a regression to the 
pre-antibiotic era.  
Bacterial resistance to antibiotics may be an intrinsic trait of the microorganism 
that renders it naturally resistant, or the bacterium may acquire resistance by either 
inducing mutations to its own DNA or acquiring resistance genes from another source. 
Natural resistance refers to antibiotic resistance of bacteria species without any additional 
genetic alterations. Examples of inherent resistance mechanisms include the lack of an 





efflux pumps, absence of the antibiotic target molecule or structure (e.g. mycoplasma is 
resistant to β-lactam antibiotics due to the absence of a cell wall structure) and physical 
barriers (e.g. restricted permeability of the outer membrane of Gram-negative bacteria) 
(Normark and Normark, 2002).  
Acquired resistance can be accomplished through vertical or horizontal gene 
transfer. Vertical gene transfer (VGT) involves the direct transmission of resistance genes 
that are generated spontaneously in the presence of antibiotics to bacterial progeny during 
DNA replication (Lawrence, 2005). Horizontal gene transfer (HGT) consists of the lateral 
acquisition of plasmid-encoded antibiotic genes that originate from a bacterial or viral 
source. The three HGT methods are equivalent to the three techniques used by bacteria to 
generate genetic diversity, which include conjugation, transformation and transduction 
(Ochman et al., 2000). Conjugation, the main mechanism of HGT, promotes the transfer 
of genetic material through direct cell-to-cell contact between related or unrelated 
bacteria species. Conjugation can also result in the exchange of genetic material between 
different biological domains, such as bacteria and plants, and bacteria and yeast 
(Buchanan-Wollaston et al., 1987; Heinemann and Sprague, 1989). Transformation 
involves the uptake of naked DNA, mainly supplied from the death and lysis of another 
bacterium, through absorption due to the natural competency of the bacterial cell. 
Particular bacteria species, such as N. gonorrhoeae and H. influenza, display perpetual 
competence, whereas other bacteria species, such as S. pneumoniae and Bacillus subtilis, 
are only competent at a certain physiological stage in their life cycle (Dubnau, 1999). 
Finally, new genetic material can be inserted either as an isolated plasmid or integrated 





Although phage are highly ubiquitous in the environment (Jiang and Paul, 1998; 
Schicklmaier and Schmieger, 1995), the spectrum of bacteria that can be transduced 
depends on the presence of a specific receptor molecule on the cell surface. As a result, 
genetic exchange promoted by transduction typically occurs between two related 
bacterial species.  
Inherent and acquired resistance by bacteria exploits several conserved techniques to 
render antibiotics ineffective (Finch, 2010). The main mechanisms include: 
 Expressing enzymes that target and inactive the antibiotic before or after the drug 
enters the bacterial cell 
 Modifying the cell envelope to decrease permeability 
 Expelling the antibiotic from the intracellular environment by transmembrane 
efflux pumps 
 Altering the target to decrease antibiotic binding affinity  
 Evading target recognition by the antibiotic through the acquisition of a novel 
metabolic pathway 
 Protecting the target by producing a protein to prevent the antibiotic from 
reaching it 
These various resistance processes do not exist in isolation and instead rely on the 
cooperation of two or more distinct mechanisms in order to confer any level of resistance.  
 
Health and Economic Implications  





quantities of antibiotics being commonly used to promote the growth of food-producing 
animals, and misuse, with up to 50% of all antibiotics prescribed for people not being 
needed or optimally effective (Centers for Disease Control and Prevention, 2013; Wise, 
2002). The World Health Organization (WHO) and CDC both recognize antibiotic-
resistant microorganisms as one of the greatest threats to human health worldwide due to 
the prolonged illness, greater risk of death and higher economic costs associated with 
these infections. Their rapid emergence and dissemination has prompted world health 
leaders to describe antibiotic-resistant microorganisms as “nightmare bacteria” that “pose 
a catastrophic threat” to people in every country of the world.  Combined with the rapid 
loss of antimicrobial efficacy, the dramatic reduction in antibiotic development over the 
past 30 years has stimulated the prevalence of antimicrobial resistance on a global scale.   
According to the IDSA, nearly two million people in the United States develop 
hospital-acquired infections (HAIs), resulting in nearly 100,000 deaths annually. It is 
estimated that the vast majority of those deaths are caused by antibiotic-resistant 
pathogens. Methicillin-resistant S. aureus (MRSA) alone kills more people in the United 
States every year than emphysema, HIV/AIDS, Parkinson’s disease and homicide 
combined (Klevens et al., 2007). The CDC estimates that of the 140,000 healthcare-
associated Enterobacteriaceae infections in the United State annually, about 9,300 are 
caused by carbapenem-resistant Enterobacteriaceae (CRE). Up to half of all bloodstream 
infections caused by CRE result in death. 
Along with the health complications associated with antimicrobial resistance, the 
non-specific disruption of the normal colonic microflora by broad spectrum antibiotics 





infection (Kelly et al., 1994). Dormant C. difficile spores are germinated upon antibiotic 
treatment, subsequently allowing the actively growing bacteria to readily colonize the 
colon epithelial tissue and flourish due to the decreased commensal microflora 
population. The consequential release of exotoxins by C. difficile causes diffuse colonic 
epithelial necrosis with pseudomembrane formation, causing colitis (Jobe et al., 1995). 
Currently, nearly 250,000 people in the United States each year require hospital care for 
C. difficile infections, culminating in at least 14,000 deaths. Along with CRE and drug-
resistant N. gonorrhoeae, the pathogenicity of C. difficile has caused the CDC to label the 
microorganism as an urgent threat to human health.  
Infections associated with antibiotic-resistant microorganisms continually add 
substantial and avoidable costs to an already overburdened United States healthcare 
system. Antibiotic-resistant infections directly cause prolonged and/or costlier treatments, 
extended hospital stays with additional hospital visits and healthcare use, and increased 
disability and death when compared to antibiotic-susceptible bacteria. The total domestic 
economic ramifications of antibiotic resistance are extensive, yielding an estimated $20 
billion in excess direct healthcare costs in the United States as well as societal costs 
totaling $35 billion due to loss in productivity (Roberts et al., 2009). 
The development of new antibiotics has been impeded by market failure and 
regulatory disincentives. Besides the reduction in therapeutic efficacy caused by 
resistance formation, the introduction of a new antibacterial agent, which is estimated to 
cost between $400-$800 million per approved drug (DiMasi et al., 2003), is not as 
profitable as other therapeutic classes of drugs because of the length of treatment 





weeks in order to cure infectious disease. Alternatively, the treatment of incurable 
chronic diseases, such as heart disease, cancer and diabetes, are typically required to be 
taken over the lifetime of the patient to suppress symptoms. Pharmaceutical and 
biotechnology companies are also deterred from developing new antibiotics because of 
the ambiguous regulatory guidelines. Drug companies have stated there are significant 
regulatory hurdles imposed by the United States Food and Drug Administration (FDA), 
which are attributable to the confusion concerning what studies and evidence the agency 
deems acceptable to demonstrate the safety and efficacy of a new drug (Blaser and 
Bartlett, 2006; Boucher, 2008). Furthermore, the FDA tightened the statistical standard 
that companies must achieve to show antimicrobial efficacy in clinical trials, thereby 
raising drug development costs because of increased clinical trial size and duration 
(Coates et al., 2002). However, the FDA has recently begun taking steps to incentivize 
new antimicrobial development to combat the epidemic of antibiotic-resistant infections. 
As part of the program established by the administration, any drug designated as a 
Qualified Infectious Disease Product (QIDP) gets a priority review and an expedited 
review process. If approved, the drug also then qualifies for an additional five years of 
marketing exclusivity.  
 
Alternative Antimicrobial Approaches 
As global health and economic complications tied to antibiotic resistance become 
more prevalent, there is an increasing need for developing alternative antimicrobial 
approaches. Successfully doing so will improve productivity and quality of life, 





antibacterial therapies currently being investigated include immunotherapy, quorum 
sensing inhibitors, antimicrobial peptides, iron chelators and phage therapy.  
The practice of bacterial vaccine therapy to prevent or cure infectious disease was 
initiated in 1879 when French chemist and microbiologist Louis Pasteur created the first 
live attenuated bacterial vaccine against Pasteurella multocida (Pasteur, 1880). Since 
then, bacterial vaccines have proven to be effective against a variety of pathogens, 
including Bacillus anthracis (1880) (Tigertt, 1980), Vibrio cholera (1884) (Levine and 
Pierce, 1992), Salmonella typhi (1896) (Colebrook, 1954; Kolle and Hetsch, 1929; 
Pfeiffer and Kolle, 1896; Wright and Semple, 1897), Yersinia pestis (1897) (Haffkine, 
1897; Lowy, 1996), Bordetella pertussis (1915) (Luttinger, 1915), Corynebacterium 
diphtheriae (1923) (Glenny and Hopkins, 1923), Clostridium tetani (1926) (Ramon and 
Zoeller, 1926, 1927), Mycobacterium bovis (1927) (Parish, 1965), Neisseria meningitidis 
(1970) (Gotschlich et al., 1969a; Gotschlich et al., 1969b), S. pneumoniae (1977) 
(Austrian et al., 1976) and H. influenzae (1985) (Centers for Disease Control and 
Prevention, 1985). Serum therapy, which involves the administration of immune serum 
(i.e. antiserum) from immunized animals or humans for the treatment and prevention of 
infectious disease, has also displayed antibacterial efficacy since its introduction in 1890 
(Behring and Kitasako, 1890; Buchwald and Pirofski, 2003).  For example, serum 
therapies were able to lower diphtheria mortality from 50-80% to 6-15% (Buchwald and 
Pirofski, 2003) and immunoneutralize the tetanus toxin (Grundbacher, 1992) and 
pyrogenic exotoxins that cause scarlet fever (Buchwald and Pirofski, 2003; Weisse, 
2001). Besides the several drawbacks affiliated with serum therapy, such as the 





different serum preparations, the routine use of bacterial vaccines was diminished over 
the past 70 years due to the advent of antibiotic therapy (Casadevall, 1996).  
Quorum sensing (QS) is defined as a cell-density-dependent regulatory 
mechanism based on the release of low molecular weight signal molecules that 
coordinate the gene expression in a given population of bacteria (Ng and Bassler, 2009). 
The formation and behavior within biofilms, protective microenvironments comprised of 
bacteria and exopolymeric substances (EPS), are regulated through bacterial QS chemical 
signals to stimulate virulence gene expression. At least 65% of pathogenic bacteria are 
linked to bacterial communities which proliferate by forming biofilms (Lewis, 2007), 
which is problematic considering bacteria are typically 1,000 times more resistant to 
antibiotics in these specialized structures than their planktonic counterparts (Koch and 
Hoiby, 2000; Olson et al., 2002). One strategy currently being explored involves using 
quorum sensor inhibitors (QSI) to prevent biofilm biosynthesis. For example, partial 
inhibition of the quorum-sensing receptors LasR and RhlR by the QSI meta-bromo-
thiolactone (mBTL) adequately inhibits production of the pyocyanin toxin as well as 
biofilm formation in P. aeruginosa (O'Loughlin et al., 2013). Anti-biofilm agents, such as 
QSI, have therapeutic potential because of their ability to degrade biofilm structures and 
resensitize the planktonic bacteria to antimicrobials. Taking into account the major health 
complications caused by biofilm growth on prosthetic devices, an anti-biofilm QSI could 
serve as a valuable prophylactic to apply to ventilators, catheters, etc., where the nidus of 
infection can be formed (Tillotson and Theriault, 2013). 
Antimicrobial peptides (AMPs) are a group of gene-encoded low molecular 





2003). These typically cationic (general +2 to +9), amphipathic peptides display 
nonspecific antibacterial activity by instigating cell membrane micellization or 
depolarization (Lohner and Blondelle, 2005; Toke, 2005), inhibiting cell wall 
biosynthesis (Breukink and de Kruijff, 2006; Hasper et al., 2006) or degrading bacterial 
nucleic acids (Vankemmelbeke et al., 2005; Zarivach et al., 2002). Despite nearly two 
decades of identifying or bioengineering AMPs, there has been limited success in the 
clinic (Zhang and Falla, 2006). To date, there are four total cationic AMPs or proteins 
that have advanced to phase 3 clinical trials. These antimicrobials are specific for curing 
or preventing impetigo and diabetic foot ulcers (the frog magainin derivative MSI-78), 
oral mucosaitis (the pig protegrin derivative IB-367; Iseganan), sepsis (the human 
bactericidal permeability protein derivative rBPI23; Neuprex) and catheter-associated 
infections (cattle indolicidin variant CP-226; Omiganan) (Hancock and Sahl, 2006). Of 
the four, only two peptides demonstrated efficacy.  
Iron is essential for many cellular reactions in bacterial pathogens, including 
oxygen transport, energy production and the regulation of gene expression. It has also 
been shown that biofilm formation on abiotic surfaces is largely stimulated by iron, in 
part by regulating surface motility and maintaining the biofilm polysaccharide matrix 
(Banin et al., 2005; Berlutti et al., 2005; Patriquin et al., 2008; Singh, 2004; Singh et al., 
2002). With this understanding, iron chelators have been researched and developed as 
antimicrobial agents to prevent and/or disrupt biofilm structures. For example, iron 
chelators have been effective for the prevention and inhibition of P. aeruginosa biofilms 
on both cystic fibrosis (CF) airway epithelial cells and abiotic surfaces. Lactoferrin, an 





P. aeruginosa adherence (Singh et al., 2002). Ethylenediaminetetraacetic acid (EDTA), a 
general metal chelator, disrupted P. aeruginosa biofilms growing on polycarbonate chips 
(Banin et al., 2006), catheters (Kite et al., 2004; Raad et al., 2003; Yakandawala et al., 
2007) and stainless steel discs (Ayres et al., 1998). Using a cystic fibrosis co-culture 
model, combining tobramycin, the primary antibiotic used to treat CF lung infections, 
with either of the two FDA-approved iron chelators, deferoxamine or deferasirox, 
reduced the established P. aeruginosa biofilm mass by approximately 90% and decreased 
resensitized viable bacteria by 7-log units (Moreau-Marquis et al., 2009). 
 Phages, discovered independently by Frederick Twort and Felix d’Herelle 
respectively in 1915 and 1917, were first used therapeutically in 1919 by d’Herelle to 
successfully treat severe dysentery (Summers, 1999). Prior to viral infection, bacterial 
cells are involved in replicating their own DNA, as well as transcribing and translating its 
genetic information in order to perform biosynthesis, growth and cell division. After 
infection, the viral DNA takes over the molecular machinery of the host cell in order to 
synthesize the nucleic acids and proteins required for the production of new virions. The 
viral DNA replaces the host bacterium’s DNA as the template for both replication and 
transcription to respectively generate more viral DNA and mRNA. The viral mRNAs are 
then translated by using the bacterial ribosomes, tRNAs and amino acids to produce the 
various viral proteins.  
Bacterial infections caused by phage can either be lysogenic (temperate) or lytic 
(virulent). For the double-stranded DNA (dsDNA) phage lytic cycle, the host cell 
infection process consists of four primary steps. The first step involves an initial weak 





recognizing and reversibly adhering to a specific epitope that is displayed on the surface 
of the target bacterium. Next, one or more components of the base plate of the phage 
irreversibly bind to bacterial cell surface. The sheath of the phage then contracts and 
allows the core to mechanically or enzymatically penetrate the bacterial envelope. 
Nucleic acid from the phage head passes through the core structure and into the periplasm 
of the bacterium. The irreversibly surface-bound phage remains on the outside of the 
bacterium as “ghost”.  
The subsequent steps of the lytic replication cycle involve synthesis of phage 
components, assembly, maturation and virion release. Early dsDNA lytic phage genes are 
transcribed and translated to produce a set of proteins primarily needed for phage DNA 
replication. Some examples of early proteins include a viral DNA-dependent DNA 
polymerase, a DNAse enzyme that targets and degrades host DNA, and peptidoglycan 
cell wall hydrolases (i.e. endolysins). Expression of late genes commences after a 
sufficient number of phage genomes have been replicated. These late phage genes mainly 
encode the structural proteins that make up the capsomeres and the various components 
of the tail assembly. The capsomeres assemble to form the capsid structure of the phage 
and are spontaneously packaged with a copy of the phage genome. The tail and accessory 
structures assemble and complex with the capsid to form the mature infective virion. The 
exact moment of host cell lysis is regulated by a small membrane protein called a holin, 
which, in combination with the endolysin, constitutes the lytic system of dsDNA lytic 
phage (Wang et al., 2000). Holins, which are expressed late in the lytic phage replication 
cycle, oligomerize on the inner membrane to generate pore-forming complexes that 





endolysins access to the periplasmic peptidoglycan (Wang et al., 2003; Young, 1992). 
Peptidoglycan functions as the major structural unit of the bacterial cell, supporting an 
internal osmotic pressure of 20-50 atmospheres in the case of Gram-positive 
microorganisms (Arnoldi et al., 2000; Doyle and Marquis, 1994; Whatmore and Reed, 
1990). The endolysin subsequently degrades the bacterial cell wall to incite hypotonic 
lysis and progeny virion liberation.  
Several characteristics of lytic phage that makes them potentially attractive 
therapeutic agents include their antibacterial efficacy against pathogenic bacteria, safety 
due to their high specificity, low dosage requirements to achieve optimal therapeutic 
effects because of their self-replicating and self-limiting nature, and rapid engineering 
potential to combat newly emerging bacterial threats (Sulakvelidze et al., 2001). In 
addition to d’Herelle’s laboratory in Paris, which later became the large French company 
L’Oréal, the United States began producing therapeutic phages for commercial use. In the 
1940s, the Eli Lilly Company from Indianapolis produced seven phage human 
therapeutic products that targeted pathogenic microbes such as staphylococci, 
streptococci and E. coli. These preparations consisted of sterile broth from phage-lysed 
cultures of the targeted bacteria (e.g. Colo-lysate, Ento-lysate, Neiso-lysate and Staphylo-
lysate) or the same preparations in a water-soluble jelly base (e.g. Colo-jel, Ento-jel and 
Staphylo-jel). They were used to treat an assortment of infections with varying degrees of 
success, including abscesses, suppurating wounds, vaginitis, acute and chronic infections 
of the upper respiratory tract, and mastoid infections (Sulakvelidze et al., 2001). 
Although issues with efficacy and the eventual discovery of antibiotics caused phage 





without antibiotics continued in Eastern Europe and in the former Soviet Union. There 
are currently over a hundred phage therapy publications available in the Georgian, 
Russian and English literature, including Ph.D. theses and meeting presentations from the 
former Soviet Union, that report the successful exploitation of phage therapy for 
prophylaxis and treatment of bacterial infections in humans. Some of the major human 
phage therapy studies performed in Poland and the former Soviet Union that were 
published in peer-reviewed journals are depicted in Table 1-2.  
 
Bacteriophage-Derived Peptidoglycan Hydrolases 
A promising alternative antimicrobial approach to conventional antibiotics 
involves the use of bactericidal enzymes derived from lytic phage, termed endolysins. 
Endolysins are peptidoglycan cell wall hydrolases that act on the host bacterium cell wall 
late in the phage replication cycle. These enzymes hydrolyze critical covalent bonds 
essential for maintaining cell wall structural integrity. As a result, the intense intracellular 
turgor pressure ruptures the cell to cause hypotonic lysis and progeny virion release. 
 Due to the absence of an outer membrane, extrinsically applied recombinant 
endolysins have direct access to the bacterial cell wall to lyse susceptible Gram-positive 
pathogens, thereby highlighting its therapeutic potential. The efficacy of endolysins have 
been validated in vitro and/or in vivo against a variety of Gram-positive pathogens, 
including Listeria monocytogenes (Gaeng et al., 2000; Loessner et al., 2002), S. 
pneumoniae (Entenza et al., 2005; Jado et al., 2003; Loeffler et al., 2003; Loeffler et al., 
2001; McCullers et al., 2007), Streptococcus pyogenes (Hoopes et al., 2009; Nelson et al., 





Table 1-2. Some of the major human phage therapy studies performed in Poland 
and the former Soviet Union. (Adapted from Sulakvelidze et al., 2001) 
Reference(s) Infection(s) Etiologic agent(s) Comments 
(Babalova et 
al., 1968) 
Bacterial dysentery Shigella Shigella phages were successfully used 
for prophylaxis of bacterial dysentery. 
(Bogovazova 
et al., 1992) 
Infections of skin and 
nasal mucosa 
K. ozaenae, K. 
rhinoscleromatis, K. 
pneumoniae 
Adapted phages were reported to be 
effective in treating Klebsiella infections 
in all of the 109 patients. 








Thirty-one patients having chronically 
infected skin ulcers were treated orally 
and locally with phages. The success 
rate was 74%. 
(Ioseliani et 
al., 1980) 





Phages were successfully used together 
with antibiotics to treat lung and pleural 
infections in 45 patients. 
(Kochetkova 
et al., 1989) 
Postoperative would 




A total of 131 cancer patients having 
postsurgical would infections 
participated in the study. Of these, 65 
patients received phages and the rest 
received antibiotics. Phage treatment 
was successful in 82% of the cases, and 
antibiotic treatment was successful in 





Various infections Staphylococcus, 
Klebsiella, E. coli, 
Pseudomonas, 
Proteus 
Immunogenicity of therapeutic phages 
was analyzed in 57 patients. The authors 
concluded that the phages’ 





E. coli Recurrent subphrenic abscess (after 
stomach resection) caused by an 
antibiotic-resistant strain of E. coli was 





E. coli, Proteus Phages were successfully used together 
with bifidobacteria to treat antibiotic-




Lung and pleural 
infections 
Staphylococcus Phages were used to treat 223 patients 
having lung and pleural infections, and 
the results were compared to 117 cases 
where antibiotics were used. Full 
recovery was observed in 82% of the 
patients in the phage-treated group, as 







Shigella, Salmonella The effectiveness of treating 
salmonellosis using phages and a 
combination of phages and antibiotics 
was examined. The combination of 
phages and antibiotics was reported to be 
effective in treating cases where 
antibiotics alone were ineffective. 











Adapted phages were used to treat acute 
and chronic urogenital inflammation in 
46 patients. The efficacy of phage 
treatment was 92% (marked clinical 














Phages administered subcutaneously or 
through surgical drains in 236 patients 
having antibiotic-resistant infections 













A total of 1,380 patients having 
infectious allergoses were treated with 
phages (360 patients), antibiotics (404 
patients), or a combination of phages 
and antibiotics (576 patients). Clinical 
improvement was observed in 86, 48 and 
83% of the cases, respectively. 
(Slopek et al., 
1984; Slopek 
et al., 1983a, 
b; Slopek et 
al., 1985a, b, 
c; Slopek et 
al., 1987) 
Gastrointestinal tract, 






A total of 550 patients were treated with 
phages. The overall success rate of 
phage treatment was 92%. 




K. pneumoniae Orally administered phages were used 
successfully to treat meningitis in a 
newborn (after antibiotic therapy failed). 
(Tolkacheva 
et al., 1981) 
Bacterial dysentery E. coli, Proteus Phages were used together with 
bifidobacteria to treat bacterial dysentery 
in 59 immunosuppressed leukemia 
patients. The superiority of treatment 
with phage-bifidobacteria over 









Orally administered phages were used to 
successfully treat 56 patients, and the 
phages were found to reach the patients’ 
blood and urine. 
(Zhukov-
Verezhnikov 






The superiority of adapted phages 
(phages selected against bacterial strains 
isolated from individual patients) over 
commercial phage preparations was 










 Pritchard et al., 2007), Streptococcus uberis (Celia et al., 2008), Streptococcus suis 
(Wang et al., 2009), B. anthracis (Porter et al., 2007; Schuch et al., 2002; Yoong et al., 
2006), S. aureus (Donovan et al., 2006b; O'Flaherty et al., 2005; Obeso et al., 2008; 
Rashel et al., 2007; Sass and Bierbaum, 2007; Takac et al., 2005), Clostridium 
perfringens (Zimmer et al., 2002) and E. faecalis (Yoong et al., 2004). After only 13 
years since their first documented use an antimicrobial in 2001 (Nelson et al., 2001), 
endolysins are now being pre-clinically developed and subjected to clinical trials as a 
human therapeutic. For example, the ContraFect endolysin CF-301 (Gilmer et al., 2013), 
which has specificity for all forms of S. aureus, including MRSA and vancomycin-
intermediate (VISA) and -resistant (VRSA) isolates, as well as S. pyogenes and S. 
agalactiae, is currently in phase 1 clinical trials for treating staphylococcal bacteremia 
infections. 
Endolysins are emerging antimicrobial option because of the several favorable traits 
associated with these enzymes, including: 
 Well-established efficacy against drug-resistant microorganisms 
 Broad application range (humans, animals, food, environment) 
 Nonexistent resistance formation observed to date 
 Low toxicity due to the high specificity of the enzyme 
 Vast availability of endolysin candidates as a result of bacteriophage ubiquity   
 Extensive bioengineering potential prompted by the modular architecture of the 







Lysis From Without 
Contrary to Gram-negative bacteria species, the absence of a protective outer 
membrane for Gram-positive bacteria makes their cell wall structures externally 
accessible to peptidoglycan-acting antimicrobial agents. While endolysins require a 
phage particle for DNA delivery as well as holins for substrate accessibility to achieve 
lysis from within the host bacterium, the extrinsic application of an endolysin to a Gram-
positive organism would remove those two restrictions. Accordingly, endolysins have 
been expressed and purified as recombinant proteins, and then extraneously applied to 
susceptible Gram-positive pathogens to induce lysis upon direct contact with the cell 
wall.  
 
Structure of Gram-positive and Gram-negative Endolysins 
The protein structure of Gram-positive and Gram-negative endolysins varies due 
to differences in cell wall architecture between these major bacterial groups. Endolysins 
that target Gram-positive bacterial species are typically 25-40 kDa and employ a modular 
structure, with an N-terminal enzymatically active domain (EAD) linked to a C-terminal 
cell wall binding domain (CBD) (Borysowski et al., 2006; Fischetti, 2010; Loessner, 
2005; Loessner et al., 1995; Lopez and Garcia, 2004). The EAD structure is 
evolutionarily conserved and responsible for the hydrolytic activity of the enzyme (i.e. 
cleaving particular covalent bonds within the bacterial peptidoglycan). The CBD 
structure is evolutionarily variable and accountable for guiding the endolysin to its 
substrate through the reversible binding of a highly specific cell wall associated epitope, 





wall ligand, thereby conferring species, strain or serotype endolysin specificity (Fischetti, 
2010). For some endolysins, it has been shown that the CBD bound tightly to the cell 
wall debris after cell lysis in order to prevent the possibility of the enzyme diffusing to 
and killing other uninfected bacterial cells (Loessner et al., 2002). There is structural 
evidence that the N-terminal EAD and C-terminal CBD of Gram-positive endolysins 
interact with each other prior to the CBD binding to the bacterial cell wall to render the 
EAD inactive. Along these lines, when the CBD binds to its cell wall epitope, there is a 
structural alteration that activates the EAD. To illustrate this phenomena, the 
pneumococcal endolysin Cpl-1 was crystallized in free and choline-bound states 
(Hermoso et al., 2003). In the absence of choline, the tertiary structure of Cpl-1 was 
oriented into a hairpin conformation with the two domains directly interacting. 
Conversely, choline recognition by the CBD altered the structure of Cpl-1 to allow the 
EAD to be properly oriented for hydrolysis of the bacterial cell wall. 
Gram-negative endolysins are generally 15-20 kDa and comprised of a single 
globular EAD. These endolysins lack a CBD because the moderately thin peptidoglycan 
(5-10 nm) of Gram-negative bacteria, which lies adjacent to the outer membrane, lacks 
surface proteins and carbohydrates (Stark et al., 2010). Two exceptions can be observed 
from endolysins encoded by the P. aeruginosa phages φKZ and EL (Briers et al., 2009; 
Briers et al., 2007). These endolysins, KZ144 and EL188, consists of an N-terminal CBD 
and a C-terminal EAD. The KZ144 endolysin binds to P. aeruginosa with high affinity 







Bacteriolytic Mechanism of Endolysins 
Peptidoglycan hydrolases, including endolysins, autolysins and exolysins, cleave 
critical covalent bonds in the cell wall structure to induce lysis or cell wall remodeling. 
Peptidoglycan is essential for maintaining cell shape and counteracting the high 
intracellular osmotic pressure (Royet and Dziarski, 2007). Its structure consists of a linear 
polysaccharide backbone of alternating units of β-1,4-linked N-acetylglucosamine 
(GlcNAc) and N-acteylmuramic acid (MurNAc). The lactyl group of every MurNAc unit 
is substituted with stem peptides, typically consisting of four alternating L- and D-amino 
acids. For Gram-negative bacteria and Gram-positive bacilli, the four amino acids in 
order starting closest to MurNAc are L-alanine, D-iso-glutamic acid, meso-
diaminopimelic acid (mDAP) and D-alanine (i.e. DAP-type peptidoglycan) (Fig. 1-1a). 
For Gram-positive bacteria, the stem peptide moiety is identical to that of Gram-negative 
bacteria with the exception of the third amino acid position, for which mDAP is replaced 
by L-lysine (i.e. Lys-type peptidoglycan) (Fig. 1-1b). Adjacent stem peptides are then 
cross-linked, either directly by an mDAP to D-alanine interpeptide bond (Gram-negative 
and Gram-positive bacilli) or through an interpeptide bridge of amino acids (Gram-
positive). The composition of the interpeptide bridge varies. For example, the cell wall of 
S. aureus contains a pentaglycine interpeptide bridge, whereas the stem peptides in the 
cell wall of S. pyogenes are interconnected by a dialanine interpeptide bridge. 
Depending on the particular bond that is cleaved within the cell wall structure, 
endolysins can be organized into at least five different groups: N-acetylmuramidases, 
lytic transglycosylases, N-acetyl-β-D-glucosaminidases, N-acetylmuramoyl-L-alanine 







Figure 1-1. DAP-type and Lys-type peptidoglycan structure. Bacterial peptidoglycan 
can be classified into one of two types: (a) DAP-type or (b) Lys-type. DAP-type is 
specific to Gram-negative and Gram-positive bacilli species, whereas Lys-type is found 















that of N-acetylmuramidases (i.e. lysozymes) and lytic transglycosylases. They both 
cleave the N-acetylmuramoyl-β-1,4-N-acetylgluocosamine bond, which is one of the two 
alternating glycosidic bonds of the glycan moiety (Fig. 1-2, label 1). The other glycosidic 
bond in the glycan strand is cut by N-acetyl-β-D-glucosaminidases, which cleaves the 
linkage between N-acetylglucosaminyl-β-1,4-N-acetylmuramine (Fig. 1-2, label 2). N-
acetylmuramoyl-L-alanine amidases, the most commonly observed lytic activity of 
endolysins, hydrolytically process the amide bond formed between MurNAc and L-
alanine, which is the linkage responsible for conjoining the sugar and stem peptide 
moieties of peptidoglycan (Fig. 1-2, label 3). The last group of endolysins, 
endopeptidases, cleaves between two amino acids that constitute either the stem peptide 
(Fig. 1-2, label 4) or interpeptide bridge (Fig. 1-2, label 5). 
 According to the International Union of Biochemistry and Molecular Biology 
(IUBMB) enzyme nomenclature, glucosaminidases, muramidases, L-alanine-amidases 
and endopeptidases are classified as hydrolases. Additionally, glucosaminidases and 
muramidases are further termed glycosidases or glycosol hydrolases. Lytic 
transglycosylases are not hydrolases and instead use an intramolecular interaction to 
break the glycosidic bond between N-acetylmuramoyl-β-1,4-N-acetylgluocosamine by 
promoting the formation of a concomitant 1,6-anhydromuramoyl product (Holtje et al., 
1975; Thunnissen et al., 1994). Due to the conservation in the EAD sequence and 
structure of endolysins, databases have grouped these domains into specific families. 
These subgroups relate to the hydrolytic mechanism for which the cleavage occurs rather 
than the specific bond cleaved. For example, cysteine, histidine-dependent 







Figure 1-2. Cleavage site specificity by the major classes of endolysins. Depending on 
the particular covalent bond that is disrupted in the cell wall structure, endolysins can be 
organized into one of five groups: (1) N-acetylmuramidases (i.e. lysozymes) and lytic 
transglycosylases; (2) N-acetyl-β-D-glucosaminidases; (3) N-acetylmuramoyl-L-alanine 











that utilizes a cleavage mechanism where a cysteine is deprotonated by a nearby histidine 
to promote a nucleophilic attack by the cysteine on the scissile bond. Some CHAP 
domains have been reported to display amidase activity (Nelson et al., 2006a), whereas 
others have shown endopeptidase specificity, cleaving between the terminal D-alanine of 
the stem peptide and the adjacent amino acid of the interpeptide bridge (Becker et al., 
2009; Pritchard et al., 2004).  
 
Antimicrobial Potential (Resistance, Toxicity, Immunogenicity, Synergy) 
One major concern with the application of an antibacterial agent is the eventual 
development of resistance by the bacterial microorganism targeted. With respect to the 
modern-day global health and economic implications of antibiotic resistance, there is an 
urgent need for novel antimicrobials that are immalleable to resistance evolution. The 
misuse and overuse of broad-range antibiotics has accelerated the development and 
dissemination of antibiotic-resistant genes among the bacterial community by placing 
selective pressure not only on the targeted pathogen, but also on nearby susceptible 
commensal bacteria (Nelson et al., 2012). In this regard, the high specificity of most 
endolysins is advantageous over classic broad-range antibiotics. Additionally, the 
coevolution of phage and their explicit bacterial host over millions of years has resulted 
in Gram-positive endolysins binding to and cleaving conserved cell wall targets that are 
required for bacterial viability and hence these targets are immutable due to bactericidal 
ramifications (Fischetti, 2008; Loessner, 2005). This is exemplified by the receptor 
epitopes targeted by pneumococcal and streptococcal endolysins. Pneumococcal 





viability (Garcia et al., 1983; Lopez and Garcia, 2004). Similarly, streptococcal 
endolysins have been shown to interact with polyrhamnose of S. pyogenes, which has 
been shown to be important for cell survival (Fischetti, 2003; Yamashita et al., 1999). By 
virtue of the cell wall of Gram-positive bacteria being the outermost structure, the 
extrinsic application of endolysins can avoid common resistance mechanisms exploited 
by bacteria, including neutralization or degradation by antimicrobial-specific intracellular 
proteins and enzymes, expulsion by efflux pumps and decreased membrane permeability. 
 Several endolysin resistance studies have been performed by the Fischetti 
laboratory using both native and engineered endolysins. The pneumococcal endolysin Pal 
was repeatedly added to actively growing S. pneumoniae either in low concentrations on 
agar plates or using increasing concentrations in liquid culture. In both scenarios, no 
resistant pneumococcal strains were encountered (Loeffler et al., 2001). In a related 
study, the B. anthracis endolysin PlyG was repeatedly added to Bacillus cells in the 
presence of the mutagenic chemical methane-sulphonic acid ethyl ester in an effort to 
expedite the evolution of resistant strains to the endolysin (Schuch et al., 2002). Similar 
to the Pal resistance studies, there were no PlyG-resistant strains of Bacillus recovered, 
whereas the same experimental method generated 1,000-10,000 fold increases in 
novobiocin and streptomycin resistance. Engineered endolysins efficacious towards 
antibiotic-resistant bacteria were also used in resistance studies. Increasing concentrations 
of the chimeric S. aureus endolysin ClyS was added to MRSA cells in parallel with the 
antibiotic mupirocin over a total of eight days (Pastagia et al., 2011). At the conclusion of 
the experiment, the minimum inhibitory concentration (MIC) for ClyS remained 





although there have been no documented cases of endolysin resistance to date, resistance 
to other peptidoglycan cell wall hydrolases has been observed. For example, bacterial 
strains have become resistant to human lysozyme by various secondary cell wall 
modifications, such as O-acetylation and N-deacetylation of the peptidoglycan and D-
alanylation of teichoic acids (Guariglia-Oropeza and Helmann, 2011; Vollmer, 2008). 
Likewise, certain S. aureus strains have developed resistance against the Staphylococcus 
simulans bacteriocin lysostaphin, which targets pentaglycine interpeptide bridge of S. 
aureus as a glycyl-glycine endopeptidase (DeHart et al., 1995; Grundling et al., 2006; 
Sugai et al., 1997). S. aureus accomplishes this by altering the length (e.g. downsizing 
from pentaglycine to a single glycine (Sugai et al., 1997)) or amino acid composition 
(e.g. incorporating serine residues (DeHart et al., 1995)) of its peptidoglycan interpeptide 
bridge. 
The high degree of selectivity by an endolysin CBD is not only advantageous for 
impeding resistance development, but this property also reduces their inherent toxicity as 
an antimicrobial. Endolysins have the innate ability to search out and destroy pathogenic 
bacterial species while evading the desirable commensal microflora that are often harmed 
by antibiotics or chemical preservatives. Adverse to topical application, one safety 
concern with endolysin therapy involves the release of proinflammatory cellular 
components during the treatment of systemic infections. Due to the bacteriolytic 
mechanism exploited by these enzymes, the continuous systemic administration of 
endolysins in humans or animals would result in the release of proinflammatory bacterial 
cell components, such as teichoic acids, lipotechoic acids and peptidoglycan that could 





(Nau and Eiffert, 2002). There is in vivo evidence that suggests this concern could be 
alleviated by varying the endolysin concentration during treatment. While one murine 
sepsis study showed that the continuous intravenous application of the pneumococcal 
Cpl-1 endolysin enhanced the concentration of proinflammatory cytokines (Entenza et 
al., 2005), results from a similar study showed that using lower concentrations of Cpl-1 
actually reduced cytokine concentrations relative to untreated infected mice (Witzenrath 
et al., 2009). To explain this observation, it was hypothesized that using higher 
concentrations of endolysin stimulates a more complete digestion of the bacterial cell 
wall, thereby generating higher levels of proinflammatory cell wall fragments that 
continuously circulate in the serum. In addition to altering endolysin concentration, the 
congruent use of anti-inflammatory agents, including steroids and non-steroidal anti-
inflammatory drugs (NSAIDs), can help combat inflammation. Besides their high 
specificity, endolysins are biodegradable because of their proteinacious nature, which 
further limits the possibility of toxic side effects.   
Seeing as endolysins are proteinacious and genetically encoded by phage, 
immunogenicity studies relating to the systemic and mucosal therapeutic application of 
these antimicrobials in animals and humans have been conducted in vitro and in vivo. 
When rabbit hyperimmune serum was raised against the Cpl-1 endolysin, it was found 
that the in vitro activity of Cpl-1 against pneumococcal cells was slightly decreased but 
never fully inactivated (Loeffler et al., 2003). In the same study, it was elucidated that 
mouse IgG antibodies were raised against Cpl-1 when several doses of the endolysin 
were administered intravenously. Endolysin efficacy was also investigated in vivo using 





infected with S. pneumoniae, it was determined that there was no significant difference 
between the two groups regarding the reduction in pneumococcal cells by the enzyme, 
suggesting that the antibodies raised against Cpl-1 were unable to inhibit the enzyme in 
vivo. Similar results were obtained when using different endolysins and pathogens (S. 
pyogenes, B. anthracis and S. aureus). In each of these experiments, antibodies were 
successfully developed against these various endolysins (Fischetti, 2010) but the 
antibodies were incapable of neutralizing their bacteriolytic efficacy (Jado et al., 2003; 
Rashel et al., 2007). In an attempt to explain how endolysins are able to avoid antibody 
inactivation, it has been theorized that the reported high binding affinity (e.g. L. 
monocytogenes endolysins Ply118 and Ply500 have nanomolar binding affinities) 
(Loessner et al., 2002; Schmelcher et al., 2010) and rapid kinetics of endolysins are able 
to outcompete the immune system of the host. 
Results from additional immunogenicity studies using the Cpl-1 endolysin in the 
treatment of systemic infections demonstrated that antimicrobial had a half-life of 
approximately 20 minutes, which is comparable to other foreign proteins like 
streptokinase, a thrombolytic enzyme used for treatment of acute myocardial infarction 
(Brucato and Pizzo, 1990; Loeffler et al., 2003). Beyond delivering endolysins repeatedly 
or by intravenous diffusion to achieve systemic concentrations during treatment, 
chemically modifying or bioengineering endolysins have proven to prolong half-life. 
PEGylation is a commonly used chemical modification for successfully slowing the 
systemic clearance rate of molecules by reducing antibody binding affinity (Kim et al., 
2008; Ramon et al., 2005; Walsh et al., 2003). Unfortunately, it has been reported that the 





2011a). However, PEGylating other peptidoglycan hydrolases, such as the bacteriocin 
lysostaphin, significantly improved the pharmacokinetics while rendering the enzyme 
still bacteriolytically active (Walsh et al., 2003). Bioengineering improved endolysin 
pharmacokinetic properties has proven to be more successful than introducing chemical 
modifications. For example, dimerization of Cpl-1 by engineering a C-terminal 
intermolecular disulfide bond increased activity and promoted a tenfold deceleration of 
plasma clearance (Resch et al., 2011b). Seeing as several endolysins have been 
implicated to undergo dimerization, an engineering strategy of constructing stable 
disulfide-based endolysin dimers may be successful at expanding systemic half-life.   
In combination with other peptidoglycan hydrolases or antibiotics, endolysins 
have demonstrated synergistic therapeutic efficacy when analyzed in vitro and in vivo. 
Achieving synergism between two or more antimicrobials translates to lower dosage 
requirements and improved efficacy while reducing the chances of resistance formation 
by concurrently acting on multiple unique targets. Synergy between two endolysins has 
been observed when using enzymes with different peptidoglycan cut sites, as the 
simultaneous cleavage of two distinct bonds in the cell wall would conceivably have 
enhanced destabilizing effects (Schmelcher et al., 2012a). Improved lytic activity could 
also be due to the cleavage of a particular site by the first catalytic domain improving 
substrate accessibility for the catalytic domain of the second endolysin (Loeffler and 
Fischetti, 2003; Schmelcher et al., 2012b). An example of endolysin synergism was 
exemplified by the pneumococcal endolysins Cpl-1 and Pal. The combinational use of 
Cpl-1 (muramidase) and Pal (L-alanine amidase) provoked in vitro and in vivo synergistic 





two pneumococcal endolysins were used together in a murine sepsis challenge was 
reduced to a greater extent compared to when either endolysin was used alone. 
Synergistic effects were also observed in vitro when using the S. aureus endolysin LysK 
(L-alanine amidase/D-alanyl-glycine endopeptidase) with lysostaphin (glycyl-glycine 
endopeptidase) (Becker et al., 2008). Similarly, combining lysostaphin with either of the 
chimeric streptococcal/staphylococcal endolysins λSA2-E-Lyso-SH3b and λSA2-E-Lyso-
SH3b resulted in synergistic ramifications in vitro and in vivo using a mouse model of 
bovine mastitis (Schmelcher et al., 2012b). Synergy has also been validated when 
combining endolysins with antibiotics. For example, anti-pneumococcal synergy was 
established when combining Cpl-1 with penicillin or gentamicin (Djurkovic et al., 2005). 
Synergistic efficacy was also seen either in vitro when the staphylococcal MV-L 
endolysin was added to either glycopeptide antibiotics vancomycin or teicoplanin to kill 
VISA (Rashel et al., 2007), or in vivo when the chimeric staphylococcal ClyS endolysin 
was combined with oxacillin to cure mice from MRSA-induced septicemia (Daniel et al., 
2010).  
 
Engineering Endolysin Properties 
The coevolution of phage and bacteria over millions of years has resulted in the 
extensive optimization of endolysins that efficiently and rapidly induce bacterial lysis in 
an intracellular environment. Considering there was no evolutionary pressure to perfect 
these enzymes for exogenous application, there is engineering potential for endolysins to 
alter their functionality in and tolerance of complex extracellular environments, including 





Several endolysin engineering strategies have been utilized, including chimeragenesis 
(i.e. domain swapping), directed evolution and peptide/protein fusions. 
The modular protein architecture of Gram-positive endolysins makes them ideal 
candidates for constructing chimeras with modified catalytic and binding properties. This 
engineering approach has been successfully exploited by nature itself, where several 
chimeric phage endolysins have been identified as a result of horizontal gene transfer 
(Hendrix, 2002), such as the L. monocytogenes endolysin PlyPSA (Zimmer et al., 2003) 
and the pneumococcal endolysin Pal (Sheehan et al., 1997). The structure of PlyPSA 
consists of a CBD that resembles that of other Listeria endolysins but consists of an 
evolutionary divergent EAD that is homologous to amidase domains from Bacillus and 
Clostridium phages. Crystal structures of endolysins as well as detailed bioinformatic 
analysis of their protein sequences have provided the necessary framework to devise and 
construct functional chimeras consisting of domains from different origins. The earliest 
studies involving domain shuffling of peptidoglycan hydrolases were conducted in the 
1990s. Swapping domains between the pneumococcal autolysin LytA (amidase) and 
endolysin Cpl-1 (muramidase) culminated in chimeric enzymes with exchanged lytic 
activities and regulatory properties (Diaz et al., 1990). Furthermore, cell wall specificity 
was altered by interchanging the choline-dependent CBD from LytA with the choline-
independent CBD from the pneumococcal Cpl-7 endolysin (Diaz et al., 1991). While the 
previous two examples proved exchanging modules between peptidoglycan hydrolases 
that target the same bacterial species can result in a functional chimeric enzyme with 
unique properties, it was still unknown if it was feasible to synthesize chimeras using two 





was answered in 1993, when the EAD of the Clostridium acetobutylicum autolysin Lyc 
was fused to the choline-dependent CBD of Cpl-1. The resulting chimeric enzyme 
displayed lytic activity against choline-containing pneumococcal cell walls but was 
devoid of activity against C. acetobutylicum cell walls (Croux et al., 1993a). In an 
independent study, fusing the CBD of Lyc to the EAD of LytA improved activity against 
C. acetobutylicum 250-fold (Croux et al., 1993b). Constructing chimeras has also been 
shown to be useful for broadening specificity. For example, fusing the full-length or 
truncated S. agalactiae B30 endolysin to lysostaphin produced chimeric enzymes that 
displayed antibacterial efficacy towards both streptococcal and staphylococcal cells 
(Donovan et al., 2006a). In experiments where Listeria endolysin CBDs were labeled 
with GFP and consequently added to cells for bacterial diagnostic purposes, fusing the 
Ply500 CBD, which is specific for serovar 4, 5 and 6 L. monocytogenes strains, to the 
PlyP35 CBD, which targets the majority of serovar 1/2 and 3 strains, produced 
heterologous GFP constructs that had broad binding specificity for Listeria cells from all 
species and serovars (Schmelcher et al., 2011). It was also shown that combining two 
Ply500 CBDs together resulted in a 50-fold increase in affinity to the cell wall when 
compared to a construct consisting of a single Ply500 CBD. 
Random mutagenesis and site-directed mutagenesis (SDM) studies have been 
performed with endolysins to enhance desirable properties. Directed evolution, which 
cultivates Darwinian evolution in a laboratory setting to engineer desirable 
macromolecular properties, was applied to the S. agalactiae endolysin PlyGBS, also 
known in the literature as B30, to improve its bacteriolytic activity (Cheng and Fischetti, 





or error-prone polymerase chain reaction (epPCR) and consequently screened for 
improved lytic potency using soft agar overlay assays. These assays consist of first 
replica plating the original transformation plate containing PlyGBS mutant colonies while 
simultaneously inducing protein expression, followed by exposing the plate to 
chloroform vapors to liberate the overexpressed endolysins and then finally overlaying 
the plate with soft agar containing S. agalactiae target cells. Activity was assessed based 
on the qualitative evaluation of lytic clearing zones. After multiple rounds of random 
mutagenesis and screening, the lead PlyGBS mutant candidate exhibited a 28-fold 
increase in bacteriolytic activity compared to wild-type. This evolved construct consisted 
of a frameshift mutation that resulted in the deletion of the C-terminal CBD, leaving only 
the N-terminal endopeptidase EAD as well as 13 out-of-frame amino acids at the C-
terminus. Aside from improving the EAD activity, directed evolution can be used for 
increasing CBD binding affinity, augmenting thermal stability or modifying pH and salt 
dependence for activity. 
Structure-guided SDM has also been effectively harnessed for modifying 
endolysin properties (Diez-Martinez et al., 2013; Low et al., 2011). Taking into 
consideration the cell wall surface of Gram-positive bacterial species is generally 
negative charged, a 2011 study showed the activity of an endolysin EAD correlated with 
its net (positive) charge in the absence of the CBD (Low et al., 2011). This conceptual 
understanding was then incorporated into endolysin bioengineering studies for increasing 
EAD activity and CBD-independence. For example, the endogenous XlyA EAD, which 
is an amidase derived from a B. subtilis prophage and consists of a net charge of Z = -3 at 





cationic surface residues to lysines to shift the net charge from Z = -3 to Z = +3, the 
resulting XlyA EAD mutant lysed B. subtilis cells at a rate nearly identical to that of full-
length XlyA. A reverse loss-of-function engineering approach was then conducted using 
the PlyBa04 EAD, which is a muramidase derived from the B. anthracis Ba04 phage and 
carries a net charge of Z = +1 at pH 7.5. The native PlyBa04 EAD was able to lyse B. 
cereus cells as efficiently as the full-length endolysin. However, when four neutral 
residues on the surface of the PlyBa04 EAD were mutated to aspartic acid to change the 
net charge from Z = +1 to Z = -3, the resulting PlyBa04 mutant showed little or no lytic 
activity towards Bacillus. The same negatively charged EAD mutant was made in the 
context of the full-length protein, and it was uncovered that a significant fraction of wild-
type activity was preserved. Therefore, changing the net charge of the PlyBa04 EAD 
from positive to negative correspondingly transitioned the lytic activity of the module 
from a CBD-independent to a CBD-dependent state. An alternative study established a 
direct correlation between the net charge of the CBD of an endolysin and its bacteriolytic 
activity (Diez-Martinez et al., 2013). Introducing 15 amino acid substitutions to reverse 
the charge of the CBD belonging to the pneumococcal endolysin Cpl-7 from Z = -14.93 
to Z = +3.0 at neutral pH significantly increased the activity of the endolysin against S. 
pneumoniae (including MDR strains), S. pyogenes and other pathogens.  
The current therapeutic strategy involving the exogenous application of 
endolysins has been limited to Gram-positive pathogens due to the existence of the outer 
membrane structure of Gram-negative bacteria. To overcome this, engineering strategies 
are being explored in an attempt to allow endolysins to penetrate this protective barrier in 





strategy involves fusing peptidoglycan hydrolases to various cationic, polycationic and 
other membrane-disrupting peptides. Human lysozyme was fused to cecropin, which is 
an antimicrobial peptide that forms pores in the outer membrane, and the resulting 
construct had considerable antimicrobial efficacy against several Gram-negative bacterial 
species (Lu et al., 2010). A subset of endolysins reportedly encompasses intrinsic charge 
and/or hydrophobic motifs that interact with the outer membrane to increase 
permeability. For example, the extrinsic application of the Bacillus amyloliquefaciens 
endolysin Lys1521 established antibacterial efficacy towards not only Gram-positive 
bacteria, but E. coli and P. aeruginosa as well (Morita et al., 2001a; Morita et al., 2001b; 
Orito et al., 2004). Likewise, in addition to Gram-positive species, the Acinetobacter 
baumannii endolysin LysAB2 displays activity against a variety of Gram-negative 
bacteria, including A. baumannii, E. coli, Citrobacter freundii, Salmonella enterica and 
Enterobacter aerogenes (Lai et al., 2011). While the use of an endolysin that possesses 
the ability to permeabilize or disrupt outer membrane structures of Gram-negative 
bacteria is desirable in vitro, their therapeutic use in vivo may be limited due to toxicity 
issues stemming from interactions with eukaryotic cell membranes.   
Intracellular pathogens are problematic because they are able to evade the host 
immune system as well as antimicrobials that cannot penetrate the eukaryotic cell 
surface. To address this concern, peptidoglycan hydrolases are being fused to cationic or 
amphipathic peptides, termed protein transduction domains (PTDs) (i.e. cell-penetrating 
peptides, membrane-permeable peptides or Trojan horse peptides), that naturally interact 
with the eukaryotic membrane to promote internalization (Dietz, 2010; Dietz and Bahr, 





extracellular to intracellular environment of eukaryotic cells has been successfully 
accomplished through PTD fusions. Therefore, fusing peptidoglycan hydrolases to PTDs 
could be an effective antimicrobial strategy for targeting and killing Gram-positive 
pathogens that invade, persist and replicate within eukaryotic cells, such as S. aureus, L. 
monocytogenes, S. pyogenes and B. anthracis (Borysowski and Gorski, 2010). 
Preliminary studies using lysostaphin or staphylococcal endolysins fused to PTDs have 
generated promising results (Schmelcher et al., 2012a). Both constructs were capable of 
reducing intracellular drug-sensitive or -resistant S. aureus cells in bovine mammary 






Although the molecular cloning, protein purification and subsequent biochemical 
characterization of endolysins has been a research concentration in laboratories for 
decades, the medicinal application of these enzymes was not formulated until 2001. It 
was this year in which the first in vivo endolysin study was performed by Fischetti’s 
group to validate the therapeutic potential of these enzymes to prevent and treat bacterial 
infections (Nelson et al., 2001). Fischetti’s group, which termed endolysins as 
“enzybiotics” in order to describe their antimicrobial potential, first pretreated mice with 
a single 250 U dose of the streptococcal PlyC endolysin in the oral cavity and then 
subsequently added 10
7 
colony forming units (CFU)
 





mice were protected from bacterial colonization (28.5% infected, n = 21) compared to the 
untreated control mice (70.5% infected, n = 17). In the same study, S. pyogenes was 
introduced to the oral cavity of nine mice and were found to be heavily colonized for four 
consecutive days by oral swabs. On day 4, the infected mice were then orally treated with 
500 U of PlyC. Two hours post-endolysin treatment, the nasopharyngeal cavity of all 
nine mice was found to be sterilized.  
Among the most studied endolysins in vivo are Pal and Cpl-1, both of which are 
derived from phage that infect S. pneumoniae. The in vitro application of Pal at 100 U/ml 
was able to induce a ~4-log decrease in viability after 30 seconds when applied to 15 
different clinical strains of S. pneumoniae, including several strains that were penicillin-
resistant (Loeffler et al., 2001). In an in vivo murine model for nasopharyngeal S. 
pneumoniae colonization, 18 mice were first colonized intranasally with 10
8
 CFU of S. 
pneumoniae. 42 hours post-infection, half of the mice (n = 9) were then treated with 1400 
U of Pal. This single dose of Pal was able to eliminate S. pneumoniae nasopharyngeal 
colonization within 5 hours. Another study involved using a murine bacteremia model, 
where 20 mice were intravenously infected with 3 x 10
8 
CFU of S. pneumoniae (Loeffler 
et al., 2003). One hour later, 10 mice were intravenously treated with a single bolus 
containing 2,000 µg of Cpl-1. All endolysin-treated mice survived throughout the 
duration of the 48 hour experiment, whereas only 20% of the untreated mice survived, 
with a median survival time of 25.56 hours. Both Cpl-1 and Pal were also shown to 
protect mice from pneumococcal bacteremia induced by intraperitoneal (ip.) injection in a 
synergistic manner in vivo (Jado et al., 2003). While intraperitoneally administering 200 





protect mice intraperitoneally infected with 5 x 10
7
 CFU of S. pneumoniae, only 2.5 µg 
of each endolysin was required to achieve the same effect when both Cpl-1 and Pal were 
used simultaneously. More recent in vivo studies using Cpl-1 include: continuous 250 
mg/kg endolysin infusion treatment of S. pneumoniae-induced endocarditis in rats, 
resulting in sterilizing 10
5
 CFU/ml pneumococci in the blood after 30 minutes and a > 4-
log CFU/g  reduction in bacterial titers on heart valve vegetations (Entenza et al., 2005); 
prevention of otitis media secondary problems as a result of primary influenza infections 
through Cpl-1 stimulated pneumococcal decolonization (McCullers et al., 2007); 
treatment of pneumococcal meningitis in rats by either intracisternal (20 mg/kg) or ip. 
(200 mg/mkg) injection of Cpl-1 decreased pneumococcal titers in cerebrospinal fluid 
(CSF) by 3 or 2 logs, respectively (Grandgirard et al., 2008); and treatment of severe 
pneumonia in mice (Witzenrath et al., 2009). In the latter study, the survival rate of mice 
treated with Cpl-1 or amoxicillin 24 hours after infection was 100% and 86%, 
respectively. When treatment started after the onset of bacteremia at 48 hours post 
infection, Cpl-1 or amoxicillin treatment led to the respective mouse survival rates of 
42% and 71%.  
Another streptococcal species that has been subjected to in vivo endolysin 
treatment is S. agalactiae (Group B Streptococcus, GBS), the most common causative 
agent of neonatal sepsis and meningitis, using murine vaginal and oropharynx infection 
models (Cheng et al., 2005). Thirty mice were initially inoculated vaginally with 10
6
 
streptomycin-resistant GBS. Twenty-four hours later, the vaginal cavities were swabbed 
to determine the initial colonization rate of GBS. The mice were then treated with 10 U 





cavities were swabbed at 2 and 4 hour time points post-treatment to determine bacterial 
titers. Mice treated with PlyGBS displayed a significant ~3-log decrease in GBS CFU at 
the 2 and 4 hour time points when compared to the buffer only controls. To determine if 
PlyGBS could be used for postpartum treatment in newborns, 38 mice were inoculated 
with 10
8
 CFU of streptomycin-resistant GBS in the oropharynx. The next morning, mice 
were oropharyngeally swabbed in order to calculate baseline GBS colonization. Mice 
were then treated orally and nasally with 10 U of PlyGBS (n = 20) or enzyme buffer only 
(n = 18). GBS titers elucidated by oropharyngeal swabs at 2 and 24 hour time points 
showed the endolysin-treated mice had a significant reduction in GBS colonization at 
both time points compared to the bacterial levels in the buffer control group.  
Besides the treatment of streptococcal infections, the therapeutic efficacy of 
endolysins has been validated against B. anthracis, an infectious agent commonly 
associated with biowarfare. PlyG, an endolysin from the B. anthracis γ phage, displayed 
the ability to kill both vegetative cells and germinating spores (Schuch et al., 2002). Mice 
ip. infected with 10
6
 CFU of Bacillus cells died within 5 hours when treated with enzyme 
buffer only. Mice ip. treated with 50 U of PlyG 15 minutes post-infection led to 13 of the 
19 mice (68.4%) surviving the duration of the 72 hour experiment and extended the life 
of the remaining mice several fold over the untreated controls. Furthermore, a 5 minute 
treatment with 10 U of PlyG was able to generate a 7,500-fold reduction in heat-activated 
Bacillus spores viability. Another Bacillus endolysin, PlyPH, was biochemically 
characterized to display lytic activity over a broad pH range of 4.0-10.5 and exhibited the 
ability to rescue mice from ip. challenge of Bacillus (Yoong et al., 2006). Mice (n = 26) 
were injected with 2.5 x 10
6





treated 10 minutes later with approximately 1,200 µg of PlyPH (n = 13) or enzyme buffer 
only (n = 13). At the conclusion of the 38 hour study, ~40% of the PlyPH-treated mice 
survived, whereas 100% of the buffer-treated mice were unable to be rescued. 
There are several studies that report the ability to control S. aureus infections in 
animal models through the use of endolysin therapy. The MV-L endolysin, encoded by 
the S. aureus phage ΦMR11, displayed in vitro and in vivo bacteriolytic activity against 
multidrug-resistant S. aureus strains, including MRSA and VISA clinical isolates. In a 





MRSA cells, followed by treatment at 0, 30 or 60 minute time points post-infection 
with 500 U of MV-L or enzyme buffer only. Endolysin treatment at 0, 30 and 60 minutes 
post-infection resulted in respective mouse survival rates of 100%, 100% and 60% at the 
conclusion of the 60 day study. Conversely, 100% of the mice were killed within 24 
hours post-infection when treated with enzyme buffer only at each time point. In another 
study, the chimeric staphylococcal endolysin ClyS was shown to be more effective than 
the standard topical antimicrobial mupirocin for treating murine epidermal infections 
caused by methicillin-susceptible S. aureus (MSSA) and MRSA (Pastagia et al., 2011). 
At 24 hours postcolonization with MSSA or MRSA, the infected epidermal tissue of mice 
was treated with either 10% (wt/wt) of ClyS in Aquaphor or 2% mupirocin. With respect 
to the untreated controls, ClyS treatment caused a 3-log reduction in bacterial 
colonization while mupirocin achieved a 2-log decrease.  
In a mouse nasal decolonization model, a 2-log reduction in MRSA viability was 
observed 1 hour after nasal and oral treatment with 960 µg of ClyS (n = 20) when 





course of a 10 day experiment, a single ip. injection of 1,000 µg of ClyS promoted the 
survival of 14 out of 16 mice (87.5%) that were subjected to a murine septicemia model 
for MRSA infection. As a basis of comparison, mice treated with enzyme buffer (n = 14) 
were dead from bacterial sepsis within 24 hours. Using the aforementioned murine 
septicemia model, therapeutic synergism was attained when using ClyS in combination 
with oxacillin. Mice were intraperitoneally injected with ~5 x 10
5
 CFU of MRSA and 
then treated intraperitoneally 3 hours post-infection with 166 µg ClyS, 100 µg oxacillin 
or 166  g Clys combined with 50 or 100 µg of oxacillin. At the conclusion of the 10-day 
study, mice treated with ClyS or oxacillin individually resulted in 30% (n = 20) and 35% 
(n = 23) survival rates, respectively. Contrarily, ClyS simultaneously applied with 50 or 
100 µg of oxacillin significantly increased mouse survival to a respective 80% (n = 10) 
and 82% (n = 22). A successful 2-log decrease in S. aureus colonization was reported 
when applying the isolated CHAP domain (CHAPk) of the staphylococcal endolysin 
LysK in a murine intranasal infection model (Fenton et al., 2010). S. aureus endolysins 
LysGH15 (50 µg per mouse, n = 3) and P-27/HP (250 µg per mouse, n = 15) were able to 
induce a respective ~7- and 2-log decrease in staphylococcal colonization in murine 
spleens and subsequently prevent bacteremia lethality (Gu et al., 2011a; Gu et al., 2011b; 
Gupta and Prasad, 2011).  
 
Food Safety 
Foodborne illness is a costly public health problem that is both prevalent and 
preventable. The CDC estimates 1 in 6 people (or 48 million people) domestically each 





beverages, resulting in over 120,000 hospitalizations and 3,000 deaths. There have been 
over 250 different foodborne diseases elucidated, many of which the causative agent is a 
particular bacterial species. The Food and Drug Administration’s Center for Food Safety 
and Applied Nutrition (CFSAN) has constructed a list of foodborne pathogenic 
microorganisms that cause human disease in the United States. Some examples of Gram-
positive pathogens on this list include L. monocytogenes, C. perfringens, Clostridium 
botulinum, B. cereus and S. aureus. Significantly, lytic phages have been identified for 
each of the aforementioned bacterial pathogens and, in many cases, the endolysins they 
encode have been cloned, biochemically characterized to various extents and 
experimentally validated to be effective for both detecting and eradicating foodborne 
pathogens. 
Considering many foodborne illnesses caused by Gram-positive pathogens 
develop rapidly and often require supportive care for treatment, preventing the initial 
infection is critical. Current bacterial diagnostic techniques, such as immunoassays and 
DNA-based methods, require up to 10
7
 cells in order to accurately identify the causative 
bacterial pathogen. However, the infectious dose of many foodborne bacterial pathogens 
is often orders of magnitude less. Additionally, these methodologies often take several 
days to complete. To this end, the development of new rapid diagnostics with increased 
sensitivity is required for effectively lowering the number of foodborne illnesses. 
Endolysin CBDs have high specificity and nanomolar equilibrium association 
constants for their particular cell wall receptor (Loessner et al., 2002) and remain 
functional without the presence of the N-terminal EAD.  This mechanistic understanding 





alternative diagnostic tool for foodborne bacterial pathogens. CBDs can be chemically 
crosslinked with an organic dye or genetically fused to a reporter protein (e.g. GFP, CFP, 
DsRed) for fluorescent detection by spectrophotometric or microscopic analysis. 
Furthermore, CBDs can be conjugated to magnetic nanoparticles for selective enrichment 
of target bacteria to a detectable level for diagnostics. 
Listeriosis is an infection caused by the major foodborne pathogen L. 
monocytogenes that can cause meningitis, meningoencephalitis, septicemia and 
generalized infection of the fetus and abortion (Vazquez-Boland et al., 2001). Depending 
on the risk group studied, the fatality rate associated with listeriosis can be as high as 
50% for newborns and 20% for the elderly (Bortolussi, 2008). The CDC estimates that 
approximately 1,600 illnesses and 260 deaths are due to listeriosis in the United States 
annually. L. monocytogenes present in contaminated food products is often difficult to 
detect due to the typically small L. monocytogenes cell populations coupled with the low 
sensitivity of current listerial diagnostics.  
Presently, growing Listeria from contaminated food products in selective 
enrichment media is an absolute requirement in order to increase the number of total 
viable Listeria cells to detectable levels. The efficiency of the standard selective 
enrichment protocol is hindered by the total length of the 96 hour protocol. As an 
alternative detection methodology, paramagnetic beads coated with purified recombinant 
Listeria-specific endolysin CBDs were used for the detection of Listeria in food samples, 
a diagnostic approach known as CBD-based magnetic separation (CBD-MS). Detections 
rates for a variety of Listeria species and serovars (L. monocytogenes, L. ivanovii and L. 





communities (Kretzer et al., 2007). A total of 275 potentially naturally contaminated food 
samples were tested for Listeria contamination using either standard selective enrichment 
media or CBD-MS. In totality, Listeria was detected in 42 samples using standard 
selective enrichment media, compared to the 45 samples that were found to be Listeria-
positive using CBD-MS. Besides the enhancement in sensitivity, the CBD-MS method is 
more rapid and only requires half the time (48 hours) compared to the standard selective 
enrichment media method.  The CBD-MS method was also shown to be applicable to 
other bacterial species, such as B. cereus and C. perfringens. In addition, the CBD-MS 
separation method was combined with real-time quantitative PCR to yield a highly 





CFU/ml (Walcher et al., 2010). Another endolysin-related methodology being utilized for 
the detection of bacteria involves fusing phage endolysin CBDs to various fluorescent 
markers. The fluorescent CBDs can then be used for the detection and differentiation of 
bacterial species and strains. For example, eight different Listeria CBDs, each of which 
had unique cell wall specificity, were fused to a collection of differently colored reporter 
proteins (Schmelcher et al., 2010). When added to a mixed population of L. 
monocytogenes, the fluorescent CBDs made it possible to rapidly detect and distinguish 
individual cells with serovar to strain specificity using fluorescence microscopy. This 
technique was further used in combination with CBD-MS for the recovery and 
identification of different Listeria serovars and strains from artificially contaminated milk 
or cheese. CBD-based detection methods have also been described for B. anthracis 





bioengineered CBD derived from the PlyG endolysin that was coupled to fluorescent 
Qdot® nanocrystals for strain-specific detection of B. anthracis. 
Supplementary to using isolated CBDs for bacterial diagnostics, the antimicrobial 
efficacy of full-length endolysins has been validated as a means to control a series of 
food-borne pathogens, including S. aureus, S. agalactiae, S. uberis, L. monocytogenes, 
Clostridium butyricum and Erwinia amylovora. Purified endolysins were shown to 
successfully control food-borne pathogens when utilized as biopreservatives for food 
products. For example, the S. aureus ΦH5 phage endolysin LysH5 rapidly reduced 
staphylococcal cell populations growing in pasteurized milk to undetectable levels after 4 
hour incubation at 37°C (Obeso et al., 2008). A number of other endolysins, including the 
streptococcal endolysins B30 (Donovan et al., 2006a) and Ply700 (Celia et al., 2008), as 
well as the chimeric streptococcal-staphylococcal constructs λSA2E-Lyso-SH3b and 
λSA2E-LysK-SH3b (Schmelcher et al., 2012b), have been shown to display bacteriolytic 
activity in milk or milk products. With the ability to retain significant lytic activity after 
incubating at 90°C for 30 minutes, the kinetically stable L. monocytogenes endolysins 
Ply511, Ply118 and Ply500 could be applicable as a disinfectant for food products that 
undergo elevated heat treatment, such as pasteurized milk (Schmelcher et al., 2012c). 
These three Listeria endolysins were also effective for decreasing L. monocytogenes 
viability on iceberg lettuce by up to 2.4-log units after storage for 6 days. Another 
example of using phage endolysins to prevent the growth of food-borne pathogens 
involved pre-treating pear slices with E. coli lysates containing overexpressed E. 





incubating the samples at 26°C for 5 days, lysate pre-treatment was able prevent E. 
amylovora colonization on the surface of the pear slices (Kim et al., 2004).  
Endolysins can also be alternatively exploited by starter microorganisms, such as 
Lactococccus lactis, used for fermentation processes in order to prevent contamination 
and consequent economic loss for manufacturers. Contamination during fermentation can 
decrease food quality as well as possibly presenting future health risks if no further 
pasteurization occurs. Whereas broad spectrum antimicrobials cannot be used due to the 
nonspecific killing of the starter microorganisms, the high specificity of endolysins 
makes them ideal antimicrobial candidates for controlling contamination. One validated 
strategy involves genetically inserting endolysin genes into starter microorganisms, 
followed by the expression and secretion of the enzyme into the environment for the 
eventual eradication of unwanted bacteria. Genetically modifying fermentation bacteria 
for the expression and secretion of endolysins derived from both Listeria (Gaeng et al., 
2000; Stentz et al., 2010; Turner et al., 2007) and Clostridium phages (Mayer et al., 
2010), as well as the exolysin lysostaphin (Turner et al., 2007), has been reported, 
although the application of these microorganisms to food products has yet to be shown.   
 
Agriculture 
Several agricultural applications for phage endolysins have been explored. For 
instance, endolysin-producing transgenic plants were able to avoid phytopathogenic 
bacterial infections. Transgenic potatoes producing T4 lysozyme were resistant against 
Erwinia carotovora, a plant pathogen known to cause black leg and soft rot (de vries et 





transgenic plant tissue, is simultaneously released as a result of plant cell damage caused 
by E. carotovora pectinases. As a result, the intracellular lysozyme is liberated and has 
the ability to lyse the phytopathogens upon direct contact. Besides the implications 
affiliated with phytopathogen resistance, transgenic plants programmed to express 
endolysins can serve as bioreactors capable of large-scale production of translational 
antimicrobials in an inexpensive manner. To illustrate this point, the S. pneumoniae 
endolysins Cpl-1 and Pal (Oey et al., 2009b) and the S. agalactiae endolysin PlyGBS 
(Oey et al., 2009a) were integrated into the plastid genome of the tobacco plant Nicotiana 
tabacum. The total protein expression of Cpl-1 and Pal was respectively estimated to 
represent ~10% (i.e. 0.5 g protein per kg of fresh weight) and ~30% (i.e. 2 g protein per 
kg of fresh weight) of the total soluble protein levels of the plant, while expression of 
PlyGBS was calculated to reach more than 70% of the total plant soluble protein. These 
immense protein expression yields were rationalized to be caused by the highly stable 
intracellular environment provided by the chloroplasts, as indicated by the absence of 
endolysin turnover during plant development. 
In the case of animal agriculture, endolysins have been investigated as a 
disinfectant, prophylactic and therapeutic antimicrobial agent as an alternative means for 
preventing or combating animal disease. Equine strangles is a highly contagious infection 
of the lymph nodes of horses caused by Streptococcus equi. This disease is characterized 
by the expeditious onset of fever followed by upper respiratory tract catarrh, causing 
nasal discharge and acute swelling with subsequent abscess formation in the throat area 
(Sweeney et al., 2005). If left untreated, infected horses can suffocate due to enlarged 





strangles occur in approximately 20% of infected horses, resulting in mortality rates as 
high as 8% on farms where the infection is endemic (Sweeney et al., 1987). The efficacy 
of the streptococcal endolysin PlyC was benchmarked as a narrow-spectrum disinfectant 
for eliminating S. equi on horse stable surfaces and equipment (Hoopes et al., 2009). 
PlyC was shown to be 1,000 more active per weight than Virkon-S, a common 
disinfecting agent, with 1 µg of endolysin possessing the ability to sterilize a 10
8
 CFU/ml 
culture of S. equi in 30 minutes. Furthermore, PlyC was efficacious when applied as an 
aerosol to common stable and horse-related equipment contaminated with S. equi and 
capable of retaining lytic activity in conditions that mimic a horse stable, including the 
presence of nonionic detergents, hard water or organic materials. 
Use of peptidoglycan hydrolases for prophylactic and therapeutic applications 
specific to animal disease have also been tested and validated. Bovine mastitis, a 
microbial intramammary infection that induces inflammation of the mammary gland in 
cattle, affects one third of all dairy cows (Sordillo and Streicher, 2002). This specific 
disease causes reduced milk production in addition to increased replacement costs, 
discarded milk, treatment costs, veterinary fees and labor costs. The National Mastitis 
Council estimates economic losses are approximately $200 per cow annually in the 
United States, equating to a total exceeding $2 billion. Treatment of bovine mastitis with 
classical antibiotics is frequently ineffective and thus alternative antimicrobial 
approaches are needed (Brouillette and Malouin, 2005). While an assortment of bacteria 
cause bovine mastitis (e.g. P. aeruginosa, S. agalactiae, E. coli, Mycoplasma, K. 
pneumoniae), staphylococci are the most prevalent pathogen associated with the disease 





prevent or treat infection. Lysostaphin at a concentration of 10 µg/ml in milk was able to 
generate a 5 to 6 log reduction in S. aureus (Bramley and Foster, 1990). After a 10
8
 CFU 
inoculation of S. aureus, infusion of the lactating murine mammary gland with 10 µg of 
enzyme stimulated a 2 to 3 log reduction in bacteria within 30 minutes. Pre-treating the 
murine mammary gland with 10 µg of lysostaphin either immediately before or 1 hour 
prior to staphylococcal challenge caused a 6 log decrease in S. aureus viability. In an 
independent study, S. aureus was introduced to the teat cistem of cattle and infections 
were established for a minimum of 3 weeks (Oldham and Daley, 1991). A bactericidal 
concentration of lysostaphin was maintained in the milk extracted from the mammary 
gland of infected cows for up to 36 to 48 hours following treatment with a single 100 mg 
teat infusion of enzyme. The cure rate of infected cows administered 100 mg of 
lysostaphin over three consecutive p.m. milkings was 20%, which is comparable to the 
29% cure rate obtained using the antibiotic sodium cephapirin. Moreover, transgenic 
mice (Kerr et al., 2001) and cows (Wall et al., 2005) producing lysostaphin in the 
mammary glands were resistant to S. aureus-induced mastitis. Considering the 
application of a single antimicrobial may ultimately promote resistance formation, using 
chemotherapeutic agents in combination may prove to be a more efficient strategy. To 
this end, using lysostaphin together with the chimeric endolysin λSA2E-LysK-SH3b 
prompted the synergistic killing of S. aureus both in vitro and in a murine model of 
bovine mastitis (Schmelcher et al., 2012b).  
 
PlyC, a Thermolabile Streptococcal Endolysin with Unique Characteristics 





specific endolysin PlyC is an evolutionary outlier when compared to all other 
characterized endolysins to date. PlyC, derived from the streptococcal C1 phage (Nelson 
et al., 2003), was first described in 1957, when C1 phage lysates were shown to possess 
the ability to cause rapid lysis of groups A (GAS) and C (GCS) streptococci (Krause, 
1957). This observation prompted the eventual use of this phage enzyme as a tool for 
isolating peptidoglycan-associated proteins and extracting DNA from group A 
streptococci (Fischetti et al., 1985; Wheeler et al., 1980). Over the past 13 years, PlyC 
has been validated both in vitro and in vivo for its anti-streptococcal efficacy (Nelson et 
al., 2001). Unlike other monomeric Gram-positive endolysins, PlyC consists of a novel 
multimeric structure that deploys a catalytic mechanism several orders of magnitude 
more bacteriolytically active when compared to other endolysins (McGowan et al., 2012; 
Nelson et al., 2006a). Similar to other mesophilic phage-derived endolysins, PlyC 
displays poor thermal stability, thereby limiting the feasibility of developing the enzyme 
as an antimicrobial for industrial application due to short shelf life expectancy. 
Bioengineering strategies directed towards the catalytic subunit of PlyC can be utilized to 
increase the stability of the structure and consequently progress the shelf life of the 
translational antimicrobial. 
 
In vitro and in vivo Validation of Antimicrobial Efficacy 
 The use of a phage endolysin as a therapeutic alternative to classical antibiotics 
was first documented in 2001, when PlyC was shown to both prevent and eradicate S. 
pyogenes infection in a murine sepsis model for oral and nasal mucosal infection (Nelson 





streptococcal and non-streptococcal bacterial species. Initially, the lytic activity of PlyC 
against the major human pathogen, group A streptococci (i.e. S. pyogenes), was assessed. 
The endolysin was diluted to three different concentrations and added to ~10
7
 group A 
streptococci. An aliquot of each sample was removed, diluted and plated on agar plates at 
5, 30 and 60 seconds and 5 and 10 minutes to calculate total viable cell counts. Exposing 
the streptococci to 1,000 U of PlyC completely killed all the cells in the first 5 seconds, 
whereas 100 U of the endolysin was capable of decreasing streptococcal viability by an 
order of 3 logs in 5 seconds, 4 logs in 1 minute and 5 logs in 10 minutes. Lysis of 
endolysin-treated group A streptococci could be visualized by thin-section electron 
microscopy (Fig. 1-3). The lytic activity displayed by PlyC towards group A streptococci 
is ~100-200 fold higher than any other presently characterized endolysin.  
 To elucidate the antimicrobial spectrum of PlyC, a total of 250 U of PlyC was 
added to a collection of streptococcal (GAS, GBS, GCS, group D streptococcus (GDS), 
group E streptococcus (GES), group F streptococcus (GFS), group G streptococcus 
(GGS), group L streptococcus (GLS), group N streptococcus (GNS), Streptococcus 
crista, Streptococcus intermedius, Streptococcus gordonii, Streptococcus mitis, 
Streptococcus mutans, Streptococcus oralis, Streptococcus parasanguis, Streptococcus 
salivarius) and non-streptococcal (Bacillus pumulis, S. aureus, S. epidermidis, E. coli, 
Neisseria lactamicus, Porphyromonas gingivalis, P. aeruginosa) bacteria and the enzyme 
kinetics were monitored for a total of 8 hours. PlyC exhibited lytic activity against all 
GAS strains tested, including the serological grouping strain, an M protein-negative 
strain, 8 unique M protein types  and an A variant strain. The enzyme also showed 







Figure 1-3. Thin-section electron micrograph of PlyC-treated group A streptococci 
treated. Group A streptococci were treated with the endolysin PlyC for 15 seconds and 
then visualized for lysis by thin-section electron microscopy (50,000x). (a) The 
streptococcal cell wall is first weakened, (b) thereby allowing the membrane to extrude 













PlyC to prevent or eliminate upper respiratory colonization by group A streptococci in 
vivo was tested. In the first set of experiments, group A streptococci was pre-mixed with 
either 1,000 U of PlyC or buffer in vitro and then was simultaneously applied orally and 
nasally to mice. After 24 hours post-infection, none of the endolysin-treated mice (n = 5) 
were colonized with group A streptococci, while all of the buffer-treated mice (n = 5) 
were colonized (P < 0.01). At the conclusion of the 7 day experiment, daily swabs of 
each mouse resulted in the detection of only a single colony from the endolysin-treated 
mice. In a second set of mouse experiments, animals were orally pre-treated with 250 U 
of either crude (n = 10) or purified (n = 11) PlyC prior to challenge with ~10
7
 group A 
streptococci. The prophylactic application of PlyC was able to reduce streptococcal 
colonization from 70.5% (n = 17) in endolysin-treated mice to 28.5% (n = 21) in control 
animals after 24 hours (P < 0.03). The protection offered by the crude (3/10 infected) and 
purified (3/11 infected) endolysin treatment were similar and, with the exception of one 
mouse, all of the colonized endolysin-treated mice displayed low CFU counts (1-11 
colonies). The CFU counts for the infected endolysin-treated animals either remained low 
or bacterial colonization was eliminated after 48 hours, whereas all of CFU counts for the 
buffer-treated mice increased at 48 hours. In the third mouse experiment, mice (n = 9) 
were first heavily colonized by group A streptococci (> 300 CFU per swab) for a total of 
four days. The infected animals were then orally treated with either a single 500 U dose 
of PlyC and then monitored for the next 48 hours for bacterial reduction. Swabs taken 2 
hours post-treatment indicated that streptococci were completely eliminated from the 
mucosa of all nine mice. However, swabs taken 24 and 48 hours post-treatment revealed 





Molecular, Biochemical and Structural Characterization of PlyC  
Prior to 2006, not much was known about the biochemical and structural 
properties of the endolysin derived from the C1 phage. Purifying PlyC from phage lysates 
followed by native polyacrylamide gel electrophoresis (PAGE) analysis showed the 
enzyme behaves as a single homogenous protein (Nelson et al., 2006a). However, when 
viewed by sodium dodecyl sulfate PAGE (SDS-PAGE), the purified PlyC sample was 
shown to consist of two protein products, a ~50 kDa heavy chain, termed PlyCA, and an 
8 kDa light chain, termed PlyCB. N-terminal sequencing results dictated that both PlyCA 
(SKKYTQQQYE) and PlyCB (SKINVNVENV) polypeptides have unique sequences. 
 To identify the gene(s) encoding PlyC, a genetic screen was implemented. The C1 
phage genome was partially digested with the Tsp509I restriction endonuclease and the 
DNA fragments were then cloned into the pBAD24 expression vector. Screening the 
resulting E. coli expression library allowed for the identification of a single clone, labeled 
as pBAD24: plyC, that exhibited lytic activity towards group A streptococci. Expression 
and purification of PlyC from this construct yielded a bacteriolytically-active enzyme 
with identical properties to PlyC purified form phage lysates when analyzed by means of 
column chromatography as well as native and SDS-PAGE. The plyC clone was 
comprised of a 2.2 kb insert with putative operon encoding three ORFs, with ~100 bp of 
noncoding sequence flanking the 5’ and 3’ ends of the insert. The first predicted gene in 
the operon, plyCB, consists of a translated 72 amino acid (7.858 kDa predicted mass) 
polypeptide that matches the before mentioned N-terminal sequencing results for PlyCB. 
The second putative gene in the plyC operon is predicted to encode a 105 amino acid 





homology to 31 endonucleases, many of which belong to the homing HNH endonuclease 
family. The genes encoding HNH endonucleases are known to exist within group I 
introns and confer mobility to their host intervening sequence by catalyzing a precise 
double-strand break in the cognate allele deficient of the intervening sequence (Chevalier 
and Stoddard, 2001). Due to the position of the putative endonuclease gene between 
plyCB and ORF3, this region of the operon was named lil, for lysin intergenic locus.  The 
third ORF of the plyC operon, plyCA, comprises a 465 amino acid (50.366 kDa) 
polypeptide that corresponds to the size and N-terminal sequence of PlyCA.  
 Various plyC-related constructs were synthesized, cloned and expressed to 
understand what genetic elements are required for PlyC activity. When expressing plyCB, 
lil and plyCA individually, all of the translated products were devoid of lytic activity. 
PlyC expressed in a Δlil background retained activity, although the residual activity was 
less than a third of the full-length plyC clone. Co-expressing plyCA (pBAD24: plyCA) 
and plyCB (pBAD33: plyCB) on separate expression plasmids yielded a functional PlyC 
holoenzyme. While the activity of PlyC clearly requires both plyCB and plyCA, the 
presence of lil is not imperative for producing an active endolysin. RT-PCR and Northern 
blot analysis both suggest that intron splicing does not take place in the plyC operon. As a 
result, the molecular functionality of lil is currently still not understood.  
Gel filtration and sedimentation analysis of purified PlyC in 1971 suggested that 
the mass of the endolysin was 101-105 kDa (Fischetti et al., 1971), which was then 
further confirmed in 2001 (Nelson et al., 2001). To determine the stoichiometry of 
PlyCB:PlyCA subunits, PlyC was subjected to size-exclusion chromatography (SEC) 





measurements (Nelson et al., 2006a). Results from a total of 20 independent SEC 
experiments using purified PlyC at various concentrations (100-300 µg total) confirmed 
the endolysin holoenzyme structure is 114.0 kDa with a standard deviation of ± 0.4 kDa. 
Considering PlyCB and PlyCA have predicted masses of 7.858 and 50.366 kDa, 
respectively, the SEC-LS/UV/RI data predicted an 8.0 ± 0.005 PlyCB to 1.0 PlyCA 
model for the holoenzyme structure.  
Proteomic analysis of the PlyCA polypeptide using the Pfam database 
(www.pfam.xfam.org) disclosed the presence of a putative C-terminal CHAP domain. 
One of the two hydrolytic activities displayed by CHAP domains of peptidoglycan 
hydrolases is that of an N-acetylmuramoyl-L-alanine amidase. Significantly, prior 
experiments, which entailed using thin layer chromatography to analyze S. pyogenes cell 
wall fragments digested by PlyC, revealed the endolysin exhibited amidase activity 
(Fischetti et al., 1972a). Seeing as cysteine is the one of two active-site residues 
conserved in CHAP domains, several thiol-reactive inhibitors were added to PlyC to 
observe whether or not these chemicals had an effect on enzyme activity.  An oxidizing 
compound, dithiodipyridine, in addition to two sulfhydryl alkylating reagents, 
ethylmaleimide and iodoacetamide, significantly reduced the enzymatic activity of PlyC. 
When an excess of reducing agent was subsequently added to each PlyC sample, activity 
was partially rescued for the oxidized PlyC but not the alkylated samples. It was 
concluded from these biochemical experiments that PlyC consists of an active-site 
cysteine. Performing a sequence alignment of PlyCA against other known members of 
the CHAP domain family indicated that the most likely active-site residues were C333 





was used. The mutants PlyC (PlyCA) C333S and PlyC (PlyCA) H420A each displayed 
less than 1% activity compared to wild-type PlyC, thereby confirming C333 and H420 
are indeed the active-site residues. As a control, independently mutating three additional 
cysteine residues to serine (C268S, C345S and C404S) in PlyCA resulted in a PlyC 
mutant that displayed activity that resembled that of wild-type. Therefore, these results 
confirm the presence of a CHAP domain within PlyCA.  
 PlyCA alone lacks the ability to lyse streptococcal cells and thus requires the 
presence of the eight PlyCB subunits. With this understanding, PlyCB was hypothesized 
to serve as the CBD of the holoenzyme that directs PlyCA to the streptococcal cell wall 
for peptidoglycan hydrolysis. To test this, PlyC, PlyC (PlyCA) C333S and PlyCB were 
each purified and fluorescently labeled, added to bacteria and visualized for cell binding 
via fluorescence microscopy. Notably, PlyCB eluted from gel filtration at ~60 kDa, 
suggesting that it forms a self-assembled octomer. When gel filtration was repeated in the 
presence of 0.1% SDS, PlyCB eluted as an ~8 kDa monomer. Labeled wild-type PlyC 
not only retained its binding properties, but the sample was still catalytically active and 
therefore lysed all of the streptococcal cells before they could be mounted on a 
microscope. PlyC (PlyCA) C333S (Fig. 1-4a) and PlyCB (Fig. 1-4b) were both able to 
successfully fluorescently label S. pyogenes cells, but not other bacterial species tested 
(e.g. S. agalactiae, S. mutans and S. aureus) (Fig. 1-4c), indicating that PlyCB acts as the 
CBD of the PlyC holoenzyme.  
Recently, a 3.3-Å X-ray crystal structure of the PlyC holoenzyme was published 
(Fig. 1-5) (McGowan et al., 2012). As suggested by previous structural studies, the 







Figure 1-4. PlyCB acts as the cell wall binding domain of PlyC. Fifty micrograms of 
labeled protein was added to 1 ml of various bacterial cells, washed two times and 
viewed under both phase-contrast and fluorescent light sources. (a) PlyC (PlyCA) C333S 
cross-linked with Alexa Fluor 568 specifically labels S. pyogenes. (b) PlyCB labeled with 
Alexa Fluor 488 specifically labels S. pyogenes; thus PlyCB directs cell wall binding for 
PlyC. (c) Bacterial species insensitive to PlyC (S. agalactiae (shown), S. mutans and S. 
aureus (not shown)) are resistant to labeling by PlyCB-Alex Fluor 488. All panels were 
viewed through a 100x magnification oil-immersion objective lens with a 2x magnifier 
(200x total). Additionally, B was digitally zoomed 2x, for a final magnification of 400x. 
















Figure 1-5. X-ray crystal structure of PlyC. (a) The 3.3-Å X-ray crystal structure of 
PlyC whereby PlyCB monomers are colored alternatively with magenta/cyan and labeled 
monomers A-H. The PlyCA subunit is colored by domain as indicated. The Cα atoms of 
the model show the N-terminal residues 1-205 in light blue, the disordered linker 1 
(residues 206-227) in red, the helical structure (residues 226-288) that docks PlyCA to 
PlyCB in yellow, the second disordered linker 2 (residues 289-308) in a dashed red line, 
and the CHAP domain (residues 309-465) in green. Regions of disordered/absent density 
are depicted by dashed lines. (b) The PlyCB CBD alone colored alternatively in 





monomers interact through protein-protein interactions to form a symmetrical octomeric 
complex, which serves as the CBD of the holoenzyme (Fig. 1-5, magenta and cyan). The 
ninth subunit, PlyCA, consists of a previously unknown N-terminal glycosol hydrolase 
(GyH) domain (Fig. 1-5a, light blue) linked via linker 1 to a central helical docking 
domain (Fig. 1-5a, yellow). This centralized domain is responsible for interacting with 
the PlyCB CBD to form the holoenzyme structure. The carboxyl end of the helical 
docking domain of PlyCA is then linked via linker 2 to the C-terminal CHAP domain 
(Fig. 1-5a, green).  
 Stimulated by the unexpected finding of an N-terminal GyH in PlyCA, a series of 
biochemical assays were performed to determine whether or not the GyH domain is 
functional and, if so, elucidate if this domain displays synergism with the C-terminal  
CHAP domain and consequently identify the active-site residues and hydrolytic 
mechanism (amidase or glycosidase) of the domain. To first assess if the GyH domain is 
enzymatically active and synergistic with the CHAP domain, a PlyCΔCHAP (i.e. PlyC 
holoenzyme with CHAP domain deletion) construct was synthesized, expressed, purified 
to homogeneity and assayed for lytic activity against S. pyogenes using turbidity 
reduction assays. Additionally, other PlyC constructs were expressed, purified and 
assayed for activity, including PlyC, PlyCA alone, CHAP alone and PlyCΔGyH (i.e. 
PlyC holoenzyme with GyH domain deletion). In these particular experiments, 44 nM of 
each protein was added to S. pyogenes in an individual well of a 96-well microtiter plate 
and the OD600 was monitored at 37°C every 6 seconds for 10 minutes, with a loss in OD 
correlating to enzyme-specific lytic activity. PlyCΔGyH and PlyCΔCHAP each displayed 





restore wild-type activity. PlyC at a 1 nM concentration was still considerably more 
active than 44 nM PlyCΔCHAP complimented with 44 nM CHAP. Altogether, these 
kinetic results show that, in the context of the holoenzyme, the GyH and CHAP domains 
are both hydrolytically active and act together cooperatively to generate the robust lytic 
mechanism of PlyC.  
 VAST and DALI searches showed that the enzymatically-active N-terminal GyH 
domain of PlyCA is homologous to class IV family 19 chitinases, which cleave β-1,4 
glycosidic bonds of unbranched chains of N-acetylglucosamine polymers. To determine 
the lytic mechanism of this domain and to confirm the amidase activity affiliated with the 
C-terminal CHAP domain of PlyCA, two separate biochemical assays were used to 
analyze free sugar (glycosidase activity) (Spiro, 1966) and amine (amidase activity) 
(Snyder and Sobocinski, 1975) release that occurs as a result of PlyC hydrolysis of 
purified streptococcal peptidoglycan. PlyC, PlyCA only and PlyCB octomer only were 
used as controls and purified streptococcal peptidoglycan was used as a substrate. To 
assess the contribution of the CHAP domain, an active-site mutant, PlyC (PlyCA) C333S, 
was used. To analyze the contribution of the GyH domain, four putative catalytic center 
mutants, PlyC (PlyCA) E78A, N87A, H88A and N104A, were used. Results showed that 
PlyC exhibits elevated glycosidase activity and mutating any of the putative GyH domain 
catalytic residues or surrounding residues reduced activity ~85%. Additionally, the 
CHAP domain active-site knockout, PlyC (PlyCA) C333S, also displayed a dramatic 
reduction in glycosidase activity, further supporting the idea that the CHAP domain and 
GyH domain work together synergistically. Combining the CHAP domain active-site 





the GyH domain consequently eradicated all glycosidase activity associated with PlyC. 
Similar biochemical assays were then used to quantitate amidase activity. As expected, 
PlyC (PlyCA) C333S provoked a complete loss in amidase activity. Mutations to the 
putative catalytic residues of the GyH also promoted significant losses in amidase 
activity, although the reduction was not as severe as the CHAP active-site mutant. 
Combining the PlyCA (C333S) mutation with each of the GyH putative catalytic residue 
mutations yielded a PlyC construct devoid of all amidase activity. Conjointly, the results 
of these two biochemical experiments suggest that PlyCA exhibits both amidase and 
glycosidase activity, and additionally provide further evidence that both the GyH and 
CHAP domains act together cooperatively. 
  
Transient Shelf Life of PlyC Caused by the Thermolability of PlyCA  
There are several characteristics associated with PlyC that makes this particular 
translational antimicrobial a potentially valuable alternative to classical antibiotics. First, 
the immense bacteriolytic activity unique to PlyC allows this enzyme to rapidly clear 
streptococcal colonization when utilized as a disinfectant, prophylactic and therapeutic. 
Secondly, as is the case with most Gram-positive endolysins, the high selectivity of these 
enzymes inhibits the non-specific killing of commensal bacteria. This reduction in 
chemotherapeutic toxicity helps prevent harmful side effects from occurring. However, 
contrary to other endolysins, PlyC can target and lyse a variety of streptococcal species 
that cause both human (e.g. S. pyogenes) and animal (e.g. S. equi, S. uberis and 
Streptococcus porcinus) health complications. Group A streptococcus, S. pyogenes, is the 





pharyngitis, scarlet fever, impetigo and cellulitis) and invasive (e.g. necrotizing fasciitis, 
myositis and toxic shock syndrome) suppurative infections. S. equi, S. uberis and S. 
porcinus are causative agents for equine strangles, bovine mastitis and swine 
lymphadenitis, respectively. An antimicrobial, like PlyC, that encompasses the ability to 
target and expeditiously eliminate both human and animal pathogens is vastly desirable 
for commercialization, especially as an alternative therapy for treating MDR infections. 
A critical property of any chemotherapeutic agent relates to its intrinsic thermal 
stability. In congruence with the Arrhenius equation, which relates the rate of a chemical 
reaction to the temperature present in the system, the structural stability of a 
macromolecule directly correlates with its shelf life expectancy (Anderson and Scott, 
1991). The Arrhenius equation is as followed: 
k = Aexp (-EA/RT) 
where k is the rate constant, A is the frequency factor, EA is activation energy, R is the 
universal gas constant and T is the temperature. As defined by the equation, high 
temperatures and low activation energy values favor larger rate constants, thus speeding 
up a chemical reaction. Considering both variables consist in an exponent, the effects of 
each on the reaction rate is substantial. Simplistically applying this equation to 
macromolecules, like proteins, for shelf life calculations elucidates two important trends. 
First, the shelf life of a chemotherapeutic is progressively shortened as the storage 
temperature increases. Secondly, chemotherapeutic shelf life continuously increases as 
the activation energy of kinetic inactivation or unfolding is elevated.  
Heating experiments in 2004 involving PlyC demonstrated that the endolysin 





experiments, PlyC was incubated at temperatures ranging from 37°C-100°C for one hour 
in phosphate buffered saline (PBS). At the conclusion of the incubation, the structural 
integrity of the holoenzyme was visualized by both native and SDS-PAGE and the 
residual lytic activity was assayed by means of turbidity reduction assays. At 
temperatures exceeding 42°C, PlyC irreversibly precipitates to form high molecular 
weight complexes incapable of penetrating the native PAGE gel, rendering the enzyme 
inactivate.  
 Unpublished thermodynamic characterization of PlyC in 2008 by differential 
scanning calorimetry (DSC) revealed the endolysin has transient shelf life expectancy 
due to the thermolabile nature of the catalytic subunit, PlyCA (Fred Schwarz, personal 
communication). Altogether, the complete unfolding of the PlyC holoenzyme fulfills a 
five-state thermal transition model. The unfolding of PlyCA consists of an irreversible 
three-state thermal transition, with an initial unfolding event occurring at 46.2°C. PlyCA 
was further dissected to determine the thermodynamics of the N-terminal GyH and C-
terminal CHAP domain. The catalytic subunit in a PlyCΔCHAP (PlyC holoenzyme with 
a PlyCA CHAP domain deletion) background exhibited a thermal transition temperature 
(TG) 46.0°C, whereas the isolated CHAP domain had a TG of 39.1°C. This suggests that 
the CHAP domain of PlyCA is the most heat-susceptible structural element in the EAD. 
Conversely to PlyCA, the octomeric PlyCB CBD is endogenously thermostable, 
displaying a three-state transition model with a TG of 75.0°C. When the CBD unfolds, the 
PlyCB octomer first reversibly dissociates into individual monomers, followed by the 





 The inferior inherent thermal stability of PlyCA and hence limited antimicrobial 
potential of PlyC makes the feasibility of developing the endolysin as a translational 
chemotherapeutic for industrial application challenging. While the database of thermally 
characterized endolysins is sparse, there are several examples of Gram-positive 
endolysins derived from mesophilic phages that display similar thermolability to that of 
PlyC. For example, heating the staphylococcal endolysin LysK to 42°C caused a 1,000 
fold reduction in lytic activity against S. aureus (Filatova et al., 2010). Results from 
circular dichroism (CD) far-UV spectroscopy signified that the loss in enzymatic activity 
was accompanied by significant changes in the secondary structure of the protein. In 
addition to LysK, the thermal properties of the pneumococcal endolysins Cpl-1, Pal and 
Cpl-7 were investigated by DSC. Deconvolution of the excess heat capacity data for Cpl-
1 and Pal showed both endolysins manifested three-state thermal transition models, with 
Cpl-1 (Sanz et al., 1993) and Pal (Varea et al., 2004) exhibiting respective TG values of 
43.5°C and 50.2°C. Analyzing the DSC-derived heat capacity thermogram of Cpl-7 
revealed the unfolding of the enzyme consists of a four-state thermal transition, 
displaying a TG of 50.4°C at the optimum pH for stability (Bustamante et al., 2012). 
 
Protein Engineering Methodologies 
Protein engineering constitutes a powerful tool for designing new enzymes or 
proteins with novel or desirable properties. At the beginning of the 1980s, the inability to 
alter macromolecular chemistry was viewed as a significant hindrance in the field of 
biochemistry. Without the capability of modifying macromolecular surface chemistries, 





especially in the field of enzymology. The principles that govern enzyme catalysis were 
well understood (Knowles and Albery, 1977) and the quantity of solved enzyme X-ray 
crystal structures was continually expanding (Campbell, 2002). Together, this 
information provided the framework hypothesizing enzymatic mechanisms of action in 
which particular roles could be assigned to functional groups that were identified in the 
active sites. In order to test these hypotheses, scientists would attempt to chemically 
modify these functional groups of interest using laborious techniques with limited range 
and poor specificity. However, the development of SDM changed everything in the field 
of biochemistry. The first reported use of this technology, for the purpose of mutating a 
gene encoding an enzyme with a known mechanism to yield a final protein product with 
a defined amino acid substitution, was documented in 1982 for a tyrosyl-transfer RNA 
synthetase (TyrRS) (Winter et al., 1982) and β-lactamase (Dalbadie-McFarland et al., 
1982; Sigal et al., 1982). Mutating one or two amino acids eventually expanded to 
changing entire loops and even entire domains. This production of modified proteins to 
study their corresponding properties fueled the formation of a new field, termed protein 
engineering. 
Currently, a variety of protein engineering approaches can be exploited to protein 
catalysis, specificity, folding and stability. Bioengineering methodologies tailored 
towards increasing protein thermal stability can be employed to address the innate 
instability of Gram-positive endolysins. Although there are no documented examples of 
thermostabilizing endolysins to date, there are numerous examples where the stability of 
other enzymes was significantly augmented. Engineering desirable properties to enzymes 





SDM or in silico computational modeling) or random techniques (e.g. random 
mutagenesis, gene shuffling or directed evolution).  
 
Rationale-based Methods for Protein Thermostabilization 
Protein stability is dependent on a multitude of both local and distant 
intermolecular and intramolecular interactions. Engineering enhanced stability to proteins 
generally requires combining multiple thermostabilizing amino acid mutations that 
individually have a small effect on stability. In many cases, the mechanism of stability for 
each residue mutation is unique and therefore combining numerous advantageous 
mutations can be additive to induce pronounced enhancements in protein stability 
(Akasako et al., 1995; Ohage and Steipe, 1999; Pantoliano et al., 1989; Serrano et al., 
1993; Shih and Kirsch, 1995; von der Osten et al., 1993).  
Rational protein engineering methods collectively involve replacing amino acids 
at specific sites of the protein that are selected based on prior mechanistic or structural 
knowledge. One distinct advantage of rationale-based methodologies relative to random 
techniques is that only a small number of protein variants must be examined.  A number 
of rational methods have been validated to improve protein stability, including sequence 
and structure comparisons between related mesophilic and thermophilic proteins, 
structure-guided SDM and in silico computational modeling. 
Comparing amino acid sequences or three-dimensional structures between related 
mesophilic and thermophilic proteins can allow for the identification of critical residues 
or regions that enhance thermal stability. One systematic study compared the translated 





subtilis and the thermophile Bacillus caldolyticus (Perl et al., 2000). Despite only 12 of 
the 67 residues differ between the two protein sequences, the difference in structural 
stability is significant (15.8 kJ/mol at 70°C). Systematically introducing all 12 of the 
varying residues from the B. caldolyticus enzyme into the B. subtilis enzyme by SDM 
revealed that the difference in thermal stability between the two enzymes can be 
assimilated to just two amino acid mutations (E3R, E66L) located on the surface of the 
enzyme. The respective electrostatic and hydrophobic interaction contributions of E3R 
and E66L were able to convert the mesophilic enzyme into a modified highly 
thermostable form. In another study, the structures of the closely related mesophilic 
Clostridium beijerinckii alcohol dehydrogenase (CBADH) and the hyperthermophilic 
Thermoanaerobacter brockii alcohol dehydrogenase (TBADH) were directly compared 
in an attempt to identify structural differences that may contribute to the disparity in 
thermal stability (Bogin et al., 1998). While these two enzymes have 75% sequence 
identity, TBADH and CBADH differ greatly in stability, with TBADH and CBADH 
losing 50% activity at 93.8°C and 63.8°C, respectively. Analysis of the two protein 
structures suggested that the eight extra proline residues of TBADH, some of which are 
in apparent critical sites, could be potential thermostability factors. Due to the rigidity 
and hence low intrinsic entropy, proline is a common amino acid residue found in 
thermophilic proteins, especially in loop and turn structures. Using SDM, proline residues 
were individually substituted in place of the eight residues in CBADH that were spatially 
analogous to their endogenous location in TBADH. Of the eight individual proline 





with the most significant increase in melting temperature (Tm) observed with the S24P 
(ΔTm = +3.9°C) and L316P (ΔTm = +10.8°C) mutations.  
An alternative rationale-based protein engineering strategy consists of using 
previously solved protein structures as a platform to incorporate modifications that are 
hypothesized to be stabilizing. There are several general strategies for stabilizing proteins 
that have been validated, including “entropic stabilization” (i.e. rigidification) by glycine 
→ alanine or Xxx → proline mutations or the insertion of disulfide bridges (Clarke and 
Fersht, 1993; Mansfeld et al., 1997; Matsumura et al., 1989; Matthews et al., 1987), 
“helix capping” by introducing residues that interact with the alpha-helix dipole 
(Marshall et al., 2002; Nicholson et al., 1991; Nicholson et al., 1988; Sali et al., 1988; 
Serrano and Fersht, 1989), other types of helix optimization (e.g. replacing residues in 
left-handed helical structures with glycine or asparagines) (Blaber et al., 1993; Serrano et 
al., 1992), formation of additional salt-bridge interactions (Makhatadze et al., 2003; Pace 
et al., 2000; Schwehm et al., 2003; Serrano et al., 1990; Strop and Mayo, 2000; Sun et al., 
1991; Waldburger et al., 1995), and the introduction of clusters of aromatic-aromatic 
interactions (Anderson et al., 1993; Burley and Petsko, 1985; Puchkaev et al., 2003; 
Serrano et al., 1991).  Furthermore, conserved characteristics of proteins encoded by 
thermophiles and hyperthermophiles have provided insight into how these 
macromolecules adapt to the stressful elevated temperature environments they are 
exposed to. Thermophilic proteins typically consist of (Renugopalakrishnan et al., 2005): 






 Arginine and tyrosine are more frequent while cysteine and serine are less 
frequent, longer α-helices with lower proline composition (Cooper et al., 1992) 
 Polar residues form extra hydrogen bonds with each subunit (Dalhus et al., 2002) 
 Charged residues form extra ionic interactions between dimer-dimer interface 
(Facchiano et al., 1998; Vieille and Zeikus, 2001)  
 Higher number of alanine and aromatic residues (Hakulinen et al., 2003) 
 Decrease in β branched residues (valine, isoleucine, threonine) (Facchiano et al., 
1998) 
 Larger threonine:serine ratio in β-strands (Hakulinen et al., 2003) 
 Increase of charged residues on the protein surface, especially arginine  
Proteins derived from hyperthermophiles typically consist of: 
 Reduced glutamine and increased glutamic acid levels (Tekaia et al., 2002) 
 Salt bridges that rigidify the protein structure (Kumar et al., 2000a) 
 Larger number of isoleucine (Facchiano et al., 1998) 
 Decrease in glycine residues in α-helices (Hakulinen et al., 2003) 
Comparing mesophilic proteins to their homologous thermophilic counterparts have 
revealed that nature has employed several structural strategies for achieving high 
stability. The high conservation of the hydrophobic core of mesophilic and thermophilic 
protein homologs has led to the realization that the surface and surface electrostatics of a 
protein are more important for thermal stability than originally thought (Eijsink et al., 
1995; Hoseki et al., 1999; Machius et al., 2003; Martin et al., 2002; Martin et al., 2001; 
Perl et al., 2000; Perl and Schmid, 2001; Vieille and Zeikus, 2001). Also, large 





for thermostabilization (Clantin et al., 2001; Maeda et al., 2002; Thoma et al., 2000; 
Vetriani et al., 1998; Vieille and Zeikus, 2001; Walden et al., 2001; Xiao and Honig, 
1999). Collectively, unique compositional and structural characteristics of proteins 
originating from thermophiles and hyperthermophiles can be incorporated into 
mesophilic homologues for the purpose of engineering progressed stability.  
Computational screening methods have been developed to measure the effect that 
amino acid mutations have on protein stability through the estimation of Gibbs free 
energy (ΔΔG) values. These algorithms use either biophysical models of amino acid 
interactions (Kellogg et al., 2011; Seeliger and de Groot, 2010; Worth et al., 2011; Yin et 
al., 2007), statistical analyses of available proteins and corresponding thermodynamic 
properties (Dehouck et al., 2011; Guerois et al., 2002; Johnston et al., 2011), machine 
learning methods (Capriotti et al., 2008; Tian et al., 2010), or a combination thereof (Li et 
al., 2012; Masso and Vaisman, 2010) to estimate the effect a mutation has on stability. 
Some examples of algorithms that have been successfully exploited to increase protein 
stability are CC/PBSA (Benedix et al., 2009), EGAD (Pokala and Handel, 2005), I-
mutant 2.0 (Capriotti et al., 2005), Rosetta (Dantas et al., 2007; Kellogg et al., 2011; 
Leaver-Fay et al., 2011) and FoldX (Guerois et al., 2002). Independent evaluation of 
these computational methods suggested that they are highly efficient and display 
moderate accuracy (Potapov et al., 2009).  
Results from third-party testing showed the FoldX protein folding algorithm 
performed with useful accuracy across all protein types, with a correlation coefficient r of 
0.5 between estimated and experimental ΔΔG values (Khan and Vihinen, 2010; Potapov 





energy terms (e.g. van der Waals interactions, hydrogen bonding, electrostatics and 
solvation), statistical energy terms and structural descriptors (Guerois et al., 2002; 
Schymkowitz et al., 2005b). The parameters used in the potential were determined by 
fitting experimental ΔΔG values for 339 point mutants from a total of nine different 
proteins, resulting in a respective correlation coefficient and standard deviation between 
the predicted and experimental data of 0.8 and 0.75 kcal/mol (Guerois et al., 2002). 
FoldX was applied to the structure of Cel7A chimeric fungal cellobiohydrolase I 
(CBH I), as well as 39 different fungal CBH I crystal structures, in order to identify 
mutations that are predicted to be stabilizing for the majority of the CBH I structures 
(Komor et al., 2012). The in silico screening combined with a consensus sequence 
analysis using a total of 41 CBH I sequences ultimately generated a final combined 
mutant with a T50 (i.e. temperature at which the enzyme loses 50% activity after a 10 
minute incubation) increase of 4.7°C. The stabilized chimeric Cel7A mutant comprised 
an overall T50 of 72.1°C, which is 9.2°C higher than that of the most stable native CBH I. 
This improvement in stability also increased the optimal temperature for activity from 
50°C to 60°C. In an independent study, the automated computer algorithm PERLA and 
the FoldX empirical force field were used to improve the thermal stability of a multimeric 
tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) (van der Sloot et 
al., 2004). Stabilization of the TRAIL trimer was accomplished by two mutations the 
caused both intra- and inter-subunit modifications, resulting in a Tm increase of 8°C. 
Consequently, the thermostabilized TRAIL protein was shown to be biologically active 






Random Methods for Protein Thermostabilization 
The use of rational protein engineering methods for improving stability are often 
limited because structural and mechanistic understanding of the protein is often required, 
the library size tested is limited and there is inherent difficulty in predicting distinct 
amino acid mutations that are thermally advantageous, even if the crystal structure is 
known. Moreover, although extensive proteomic and structural studies have yielded 
protein properties that are believed to enhance thermal stability, findings from 
independent studies tend to be contradictory, making it difficult, if not impossible, to 
identify universal thermostabilization strategies. For example, Jaenicke and Bohm state 
that the optimization of atomic packing contributes to protein thermostability whereas 
Karshikoff and Ladenstein indicate that there is little disparity between the atomic 
packing of mesophilic and thermophilic proteins (Jaenicke and Bohm, 1998; Karshikoff 
and Ladenstein, 1998). After performing a systematic analysis of the structural 
distribution of amino acids between 20 families of homologous mesophilic and 
thermophilic proteins, Pack and Yoo state there is no difference in the occurrence of the 
amino acid cysteine between the samples, which contradicts the findings of Kumar et al. 
who observed a significant decrease in cysteine residues in thermophilic proteins when 
performing a statistical analysis between 18 families of homologous mesophilic and 
thermophilic proteins (Kumar et al., 2000b; Pack and Yoo, 2004). While analyzing the 
difference between 16 different families of homologous mesophilic and thermophilic 
proteins, the Argos group found that hydrogen bonding was the most important 
stabilizing factor for thermophilic proteins (Vogt and Argos, 1997; Vogt et al., 1997). 





homologous mesophilic and thermophilic proteins and found no significant difference in 
hydrogen bonding (Szilagyi and Zavodszky, 2000).  
Accordingly, alternative methods have been designed that involve randomly 
mutating individual amino acids to each of the other 19 naturally occurring amino acids. 
The resulting mutant library is then screened in order to identify mutations that are 
beneficial to the stability of the protein. Random methods are often preferred to rational 
methods due to two reasons. First, the size and genetic diversity of the libraries produced 
when using random methods are significantly greater than that of the SDM mutant pool 
produced for rationale-based methodologies. Larger and more diverse libraries allow for 
the possibility of identifying stabilizing mutations that would have been otherwise 
overlooked if using structure-guided rational methods. Secondly, random bioengineering 
methodologies require minimal understanding of the structure and function of the protein 
of interest. Along these lines and contrary to most rational methods, an understanding of 
the mechanism of stabilization is not required when a stabilizing mutation is identified 
during the screening process. In general, stabilizing mutations selected by random 
mutagenesis approaches are scattered throughout the entire protein (typically near the 
surface) and their effects are not always understood on the basis of generally accepted 
principles of protein stability (van den Burg and Eijsink, 2002).  
Random mutagenesis strategies involve methods for generating diversity either 
throughout an entire DNA sequence or to explicit regions along the sequence (e.g. 
saturation or localized/region-specific mutagenesis) (Neylon, 2004). These strategies can 
generally be classified into groups of enzymatic and chemistry- or cell-based approaches, 





modifying enzymes, such as DNA polymerase. For example, natural or engineered 
defective DNA polymerase enzymes with low fidelity are often used in a random 
mutagenesis technique known as epPCR. The error rates for these enzymes can be 
modulated by unbalancing nucleotide concentrations, altering pH, changing the divalent 
cation(s) used in the reaction  and/or varying the number of heating cycles (Cadwell and 
Joyce, 1992; Shafikhani et al., 1997). Chemical methods can either directly or indirectly 
(e.g. oligonucleotide synthesis) modify DNA to provoke nucleotide mutations. 
Traditionally, chemical DNA-modifying strategies have been employed for in vivo 
mutagenesis of plasmids and genomes of bacteria and eukaryotes, using chemicals such 
as ethyl methane sulfonate (EMS), methylnitronitrosoguanidine (MNNG) and 
ethylnitrosourea (ENU) (Rasila et al., 2009). Conversely, only few chemicals have been 
validated to successfully modify DNA in vitro (Smith, 1985), including EMS (Lai et al., 
2004) and hydroxylamine hydrochloride (Kaur and Sharma, 2006; Stellwagen and Craig, 
1997; Wong et al., 2006b). Cell-based mutagenesis strategies are based on the increased 
rate of DNA replication errors. These elevated mutation rates observed in these methods 
are caused by either environmental/physiological stress (e.g. exposure to ionizing 
radiation or ultraviolet light) or defective replication/repair functions in cells (e.g. 
bacterial mutator strains with deficient DNA repair pathway genes). Using this strategy, 
mutations are randomly introduced during in vivo replication of the gene of interest that is 
comprised within an appropriate replicative vector. The E. coli strain XL1-Red, which 
lacks the three primary DNA repair pathways mutS, mutT and mutD (Greener et al., 
1996), is an example of a validated cell-based system that is commercially available for 





2007; Henke and Bornscheuer, 1999; Lu et al., 2001). Alternatively, homology-
dependent and -independent in vitro genetic shuffling methods have proven to be an 
effective approach for randomly mutagenizing proteins (Brakmann, 2001). 
Firefly luciferase, which catalyzes the oxidation of a benzothiazole substrate (e.g. 
beetle luciferin) in the presence of magnesium ions, adenosine triphosphate (ATP) and 
oxygen, is an extremely sensitive genetic reporter widely used in molecular biology 
(Deluca, 1976; Gould and Subramani, 1988). Besides being utilized as a genetic reporter, 
the North American firefly luciferase is used extensively for measuring microbial 
contamination as well as bioluminescence-based technologies as an alternative to more 
conventional screening methods. Unfortunately, the applicability of the enzyme was 
limited due to its native in vitro and in vivo instability. To address this concern, the North 
American firefly luciferase gene, luc, was subjected to random mutagenesis in hopes of 
identifying potential thermostabilizing mutations (White et al., 1996). The gene was first 
cloned into an expression vector and then chemically-treated with hydroxylamine, 
transformed into E. coli and plated. After overnight incubation at 37°C, the bacterial 
colonies were transferred to a new agar plate by nylon filters, followed by incubation at 
37°C for 2-4 hours. The nylon filters were removed and soaked in D-luciferin to assay for 
residual luciferase activity. One particular clone was identified that displayed a 
substantial increase in kinetic stability. This mutant, encoding a single glutamate to lysine 
mutation at position 354, allowed the luciferase enzyme to retain 80% activity after the 
37°C incubation, whereas the wild-type enzyme was devoid of activity. Saturation 
mutagenesis was then performed on residue position 354 to investigate whether any of 





40°C confirmed the most stabilizing mutations at 354 were E354K and E354R, each of 
which exhibited a 12 fold increase in kinetic stability over wild-type. This prompted the 
authors to hypothesize that the side-chain size, hydrophobicity and charge characteristics 
are all important contributors to the overall stability of the enzyme at position 354. 
The laboratory approach to Darwinian evolution of biological macromolecules, 
often referred to as directed evolution, is the most commonly exploited protein 
engineering method for augmenting enzyme stability (Lutz and Patrick, 2004). 
Evolutionary methods used for protein engineering require generating extensively diverse 
and voluminous variant libraries of an initial lead candidate enzyme by in vitro random 
mutagenesis and recombination (Fig. 1-6) (Arnold et al., 2001; Love, 2008). From this 
immense mutant pool, a highly selective screening process is required for identifying 
variants with improved thermal properties. Multiple iterations of this two-step process are 
often required for the biosynthesis of enzyme mutants with significantly progressed 
structural stability (Brakmann, 2001). While the number of thermostabilized enzymes 
using directed evolution methods is vast, some notable studies using this approach 
include the construction of subtilisin variants with an up to 1,200 fold increase in kinetic 
stability at 60°C as well as a ~23°C improvement in thermal stability (Wintrode et al., 
2001; Zhao and Arnold, 1999), an esterase depicting a 14°C increase in Tm (Giver et al., 
1998), a galactose oxidase with a 4°C increase in thermal stability (Sun et al., 2001) and a 
cold-shock protein with a 28°C augmentation in Tm (Martin et al., 2001). 
 
Purpose of Research 







Figure 1-6. Directed evolution methodology overview. The two essential steps for 
directed evolution protein engineering approaches are: (1) generating an extensive mutant 
library by in vitro random mutagenesis and recombination that is exceedingly diverse, 
and (2) utilizing a stringent screening process in order to select enzyme variants that 
display desired properties. This two-step process is repeated multiple times followed by 














positive endolysins derived from mesophilic phage revealed these enzymes generally lack 
intrinsic thermal stability. With a long-term goal of developing endolysins as novel 
alternative translational antimicrobials to classical antibiotics, their unstable nature limits 
their antimicrobial potential and subsequently makes the feasibility of developing these 
enzymes for industrial application challenging due to transient shelf life expectancy. This 
dissertation focuses on using rational and/or random bioengineering methods for 
increasing the kinetic, structural and thermodynamic stability of the streptococcal-
specific endolysin PlyC. By doing so, one would generate an antimicrobial with an 
elongated shelf life that would increase the prospect of commercialization, as well as 
providing validated thermostabilizing engineering strategies that can then be further 
applied to other heat-labile endolysins. A rationale-based computational screening 
analysis is first described in this dissertation that involves using the protein folding 
algorithms FoldX and Rosetta for the purpose of identifying thermostabilizing mutations 
specific to the thermolabile CHAP domain of PlyC (Chapter II). Next, the development 
of a novel directed evolution methodology is discussed that is comprised of an epPCR 
step followed by an extensively optimized screening process to ultimately elucidate 
amino acid mutations that improve the kinetic stability of any bacteriolytic enzyme 
(Chapter III). Finally, this directed evolution protocol was then applied to PlyC with a 
goal of further validating the methodology by significantly improving the structural 









Increasing the Stability of the Bacteriophage Endolysin PlyC Using 
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Endolysins are bacteriophage-derived peptidoglycan hydrolases that induce host 
cell lysis and progeny virion release late in the lytic bacteriophage infection cycle. When 
expressed and purified as a recombinant protein, endolysins extrinsically lyse susceptible 
Gram-positive pathogens, thus representing a novel alternative antimicrobial approach to 
antibiotics. While the streptococcal endolysin PlyC has been validated in vitro and in vivo 
for its therapeutic efficacy, the inherent thermosusceptible structure of the enzyme 
correlates to transient shelf life expectancy, thereby hindering the feasibility of 
developing the enzyme as an antimicrobial. Here we thermostabilized the CHAP domain 
of the PlyCA catalytic subunit of PlyC using a FoldX-driven computational protein 
engineering approach. Ten mutants were selected as potentially increasing 
thermodynamic stability using a combination of FoldX, Rosetta and visual inspection. 
One of these mutants, PlyC (PlyCA) T406R, predicted by FoldX and Rosetta to produce 
stabilizing ΔΔG values of -1.05 and -1.29 kcal/mol, respectively, was shown 
experimentally to significantly increase the stability of the PlyC endolysin. This mutant is 
expected to introduce a new hydrogen bond between the C-terminal CHAP domain R406 
and the Q106 side-chain of the N-terminal GyH domain, likely stabilizing the PlyCA 
subunit to account for the observed increase in melting temperature of ≥ 2.2°C and the 16 
fold improved kinetic fitness at 45°C due to the 11 kcal/mol enhancement in the 









Endolysins, also termed phage lysins or enzybiotics, are bacteriophage-encoded 
peptidoglycan hydrolases (Nelson et al., 2006a). During a lytic phage replication cycle 
within the host bacterium, endolysins are expressed and accumulate in the cytosol in a 
fully folded and active conformation. The exact moment of cell lysis is then highly 
regulated by holins, hydrophobic membrane proteins that generate pore-forming 
complexes on the cytoplasmic membrane, providing cytosolic endolysins access to their 
peptidoglycan substrate (Wang et al., 2000; Young, 1992). The endolysin then degrades 
the peptidoglycan upon direct contact due to the hydrolysis of key covalent bonds within 
the cell wall structure, resulting in osmotic lysis and liberation of intracellular progeny 
virions. With this mechanistic understanding, the exogenous application of a purified 
recombinant endolysin to susceptible Gram-positive bacteria produces the same 
bacteriolytic phenotype without the presence of the bacteriophage or holins and thus 
represents an alternative antimicrobial to treat antibiotic resistant bacterial infections 
(Fischetti et al., 2006).  
PlyC is an endolysin derived from the streptococcal C1 lytic bacteriophage that 
has been validated in vitro for its bacteriolytic efficacy against groups A (GAS), C (GCS) 
and E (GES) streptococci and in vivo for its ability to protect mice from streptococcal 
challenge (Krause, 1957; Nelson et al., 2001). When added to GAS (Streptococcus 
pyogenes) in vitro, 10 ng of PlyC was able to cause a 7 log decrease in colony forming 
units in 5 s, making this endolysin ~100 fold more active than any other characterized 
endolysin to date (Nelson et al., 2001). Unlike other endolysins, which are single gene 





binding domain (CBD), PlyC consists of a novel multimeric structure with nine distinct 
subunits (McGowan et al., 2012; Nelson et al., 2006a). Eight identical PlyCB monomers 
interact to form a symmetrical octomeric ring structure that serves as the CBD of the 
holoenzyme. The ninth subunit, PlyCA, functions as the EAD of the endolysin and 
consists of an active N-terminal glycosol hydrolase (GyH) domain that is linked to a 
central helical docking domain. The helical docking domain is responsible for interacting 
with the PlyCB octomer to form the holoenzyme structure. The carboxyl end of the 
helical docking domain is linked to an active C-terminal cysteine, histidine-dependent 
amidohydrolase/peptidase (CHAP) domain that functions as an N-acetylmuramoyl-L-
alanine amidase (Fischetti et al., 1972b; Nelson et al., 2006a). The PlyCA N-terminal 
GyH domain acts synergistically with the C-terminal CHAP domain to generate the 
robust bacteriolytic mechanism of the enzyme (McGowan et al., 2012). 
Thermodynamic characterization of PlyC by means of differential scanning 
calorimetry (DSC) showed that the PlyCB octomer is endogenously thermostable, 
displaying a thermal transition temperature (TG) of 75.0°C, whereas the PlyCA EAD is 
thermosusceptible, with an TG of 46.2°C (F. Schwarz, personal communication). While 
the dissociation of the PlyCB octomer into isolated monomers is a reversible 
thermodynamic process, the unfolding of the individual PlyCA and PlyCB monomers is 
an irreversible event, which is supported by their inability to refold after being heat-
denatured. The C-terminal CHAP domain of PlyCA was shown to have a TG of 39.1°C 
when isolated, compared to a TG of 46.0°C associated with PlyCAΔCHAP in a 
PlyCΔCHAP background (i.e. PlyC holoenzyme with a PlyCA C-terminal CHAP domain 





component of the PlyC holoenzyme.  
Although the number of thermodynamically characterized endolysins is limited, 
there are examples of endolysins that display similar structural instability to that of PlyC. 
For example, the Staphylococcus aureus endolysin LysK as well as the Streptococcus 
pneumoniae endolysins Cpl-1, Pal and Cpl-7 are devoid of activity or unfold at 42.0°C, 
43.5°C, 50.2°C and 50.4°C, respectively (Bustamante et al., 2012; Filatova et al., 2010; 
Sanz et al., 1993; Varea et al., 2004).  In congruence to the Arrhenius equation, the 
thermolability of PlyC and other endolysins correlates to a short-term therapeutic shelf 
life expectancy (Anderson and Scott, 1991).  
A number of computational methods have proven partially effective at identifying 
single amino acid substitutions that result in increased thermodynamic stability of a 
protein (Cheng et al., 2006; Gilis and Rooman, 2000; Guerois et al., 2002; Parthiban et 
al., 2007; Parthiban et al., 2006; Schymkowitz et al., 2005a; Zhou and Zhou, 2002). One 
example is FoldX (Guerois et al., 2002; Schymkowitz et al., 2005a; Schymkowitz et al., 
2005b), which uses an empirical potential derived from a weighted combination of 
physical energy terms (e.g. van der Waals interactions, hydrogen bonding, electrostatics 
and solvation), statistical energy terms and structural descriptors. Parameters in the 
potential were obtained by fitting to experimental ΔΔG values for 339 point mutants in 
nine different proteins  (Guerois et al., 2002), yielding a correlation coefficient and 
standard deviation between the predicted and experimental data of 0.8 and 0.75 kcal/mol, 
respectively. The resulting potential gave similar agreement against a further set of 625 
point mutants in 27 proteins not used in training, with a respective correlation coefficient 





calculated ΔΔG values. In third-party testing, FoldX has been shown to perform with 
useful accuracy across all protein structure types, yielding a correlation coefficient of 0.5 
between estimated and experimental ΔΔG (Khan and Vihinen, 2010; Potapov et al., 
2009). Rosetta was developed primarily for designing proteins with desirable properties, 
including new protein folds (Kuhlman et al., 2003), novel enzymatic activity (Jiang et al., 
2008; Rothlisberger et al., 2008) and modified substrate specificity (Ashworth et al., 
2006). The ddG module also provides a means of estimating ΔΔG for point mutations 
(Kellogg et al., 2011).  
Here we aim to engineer enhanced stability of a thermolabile bacteriolytic 
enzyme using computational modeling. Using the PlyC holoenzyme structure as the 
template, our engineering strategy was to apply the FoldX and Rosetta algorithms 
together, in addition to subsequent visual inspection, to the C-terminal CHAP domain of 
PlyCA. By doing so, we were able to identify one point mutant, PlyC (PlyCA) T406R, 
which was shown experimentally to thermostabilize the PlyC holoenzyme structure and 
thereby improve the shelf life expectancy and feasibility of developing the endolysin as a 
translational antimicrobial. 
 
Materials and Methods 
 
Computational Modeling of PlyC Mutants 
Initial atomic co-ordinates were taken from the PlyC holoenzyme X-ray crystal 
structure (Protein Data Bank ID 4F88). Due to the relatively low (3.30 Å) resolution of 





(Raman et al., 2009), followed by another round of side-chain orientation optimization 
using the FoldX3.0 RepairPDB command (Guerois et al., 2002; Schymkowitz et al., 
2005b). The resulting co-ordinates were then processed with FoldX3.0 PositionScan to 
obtain estimated changes in folding free energy (ΔΔGFoldX) for all of the 2945 possible 
CHAP domain point mutants (155 total CHAP domain residues multiplied by the 19 
alternative natural amino acids).. The structural environments of those mutations with a 
predicted ΔΔGFoldX ≤ -1 kcal/mol were then manually inspected to remove those judged 
likely to introduce unfavorable structural alterations. Finally, the remaining mutants were 
processed through the Rosetta ddg_monomer application (Kellogg et al., 2011) to yield 
the PlyC candidate mutant list for experimental study.   
 
Bacterial Strains and Culture Conditions 
S. pyogenes D471 (group A streptococcus) was maintained and grown in Todd 
Hewitt broth supplemented with 1% yeast extract as previously described (Nelson et al., 
2001; Nelson et al., 2003). E. coli strains DH5α and BL21(DE3)pLysS (Novagen) were 
grown in Luria-Bertani (LB) broth at 37°C in a shaking incubator unless otherwise stated. 
When needed, ampicillin (100 μg/ml) was added to the media. 
 
Cloning and Site-directed Mutagenesis 
The plyC operon was cloned into pBAD24 as previously described (Nelson et al., 
2006a). Site-directed mutagenesis was performed using the Phusion Site-Directed 
Mutagenesis Kit (Thermo Scientific). Mutations were introduced into the middle of the 





reverse primer being complimentary to the next 30 nucleotides upstream (Eurofins 
Scientific). The standard 50 µl PCR reaction mixture consisted of 1 ng of pBAD24:plyC, 
1x Phusion HF Buffer, 0.2 mM dNTP, 0.5 μM of each primer and 1 U of Phusion DNA 
polymerase. The thermocycler heating conditions consisted of 98°C for 30 s, 25x (98°C 
for 10 s; 65°C for 30 s; 72°C for 4 min) and 72°C for 5 min. The resulting PCR products 
were then ligated and transformed into E. coli DH5α. Mutations were confirmed by 
nucleotide sequencing (Macrogen USA).  
 
Protein Expression and Purification 
E. coli BL21(DE3)pLysS harboring the wild-type and mutant pBAD24:plyC 
expression constructs were grown to mid-log phase in 1.5L LB supplemented with 
ampicillin in a 4L baffled Erlenmeyer flask. Protein expression was induced with 0.25% 
L-arabinose at 37°C overnight. The cells were harvested the following morning at 7,000 
RPM, resuspended in PBS, pH 7.25, supplemented with 1 mM phenylmethanesulfonyl 
fluoride (Sigma-Aldrich) and sonicated on ice for 15 min. The insoluble cell debris from 
the cell lysate was pelleted at 13,000 RPM for 1 h at 4°C. The soluble endolysins were 
then purified as previously described (Nelson et al., 2001). Protein solubility and purity 
was assessed on a 4-15% gradient sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) gel (Laemmli, 1970).  
 
In vitro Endolysin Activity on S. pyogenes 
Spectrophotometric-based turbidity reduction assays were performed to determine 





pyogenes D471 was harvested at 4,000 RPM for 15 min, washed once with PBS, pH 7.2, 
and resuspended to an OD600 = 2.0. In a flat-bottomed 96-well plate, the purified 
endolysin at an initial concentration of 8.84 µM (1 µg/µl) was serial diluted in 100 μl of 
PBS buffer. An equal volume of bacteria was then mixed with the different enzyme 
concentrations and the OD600 was monitored kinetically on a SpectraMax 190 microplate 
spectrophotometer (Molecular Devices) every 6 s for 30 min at 37°C. The amount of time 
(s) to decrease the initial OD600 by 50% was then plotted against the enzyme molar 
concentration and fit with a one-phase exponential decay curve. 1 U of enzyme activity 
was equated to the amount of endolysin (μg) required to decrease the ODmax by 50% in 15 
min. Each independent turbidity reduction assay was performed in triplicate. 
 
Circular Dichroism (CD) Spectroscopy 
A Chirascan CD spectrometer (Applied Photophysics) equipped with a 
thermoelectrically controlled cell holder was used for all CD experiments. For secondary 
structure far-UV analysis, the endolysins were at a 0.1 mg/ml concentration in 20 mM 
sodium phosphate buffer, pH 7.0. CD spectra were obtained in the far-UV range (190-
260 nm) in a 1 mm path length quartz cuvette at 1 nm steps with 5 second signal 
averaging per data point. Spectra were collected in triplicate, followed by averaging, 
baseline subtraction, smoothing and conversion to mean residue ellipticity (MRE) by the 
Pro-Data software (Applied Photophysics). Secondary structure prediction was 
performed using the Provencher and Glockner method provided by DICHROWEB 
(Provencher and Glockner, 1981; Whitmore and Wallace, 2004). Melting experiments 





phosphate buffer, pH 7.0, from 20°C to 95°C at 1°C/min. MRE was monitored at 222 nm 
in a 1 mm path length quartz cuvette at 0.5°C steps with 5 second signal averaging per 
data point. The melting data was smoothed, normalized and fit with a Boltzmann 
sigmoidal curve. The first derivative of the melting curve was then taken to determine the 
temperature (T1/2) at which the folded and unfolded state of the PlyCA subunit was at 
equilibrium. This temperature was defined as the minimum in the first derivative graph 
(Fallas and Hartgerink, 2012). 
 
Differential Scanning Calorimetry 
DSC experiments were performed on a Nano DSC differential scanning 
calorimeter (TA Instruments) at a constant pressure of 3 atm.  All samples were degassed 
for at least 15 minutes prior to the experiment. The sample and reference cells consist of 
an optimal operational volume of 0.3 ml and were calibrated with equal volumes of 20 
mM sodium phosphate buffer, pH 7.0, by means of three consecutive heating/cooling 
cycles from 15°C to 105°C and 105°C to 15°C at 1°C/min. The endolysins were then 
heated from 15°C to 105°C at a 1°C/min heating rate in 20 mM sodium phosphate buffer, 
pH 7.0, using a final protein concentration of 1 mg/ml followed by immediate cooling 
from 105° to 15°C at 1°C/min. Data analysis by means of baseline subtraction and curve 
fitting was performed by the NanoAnalyze software (TA Instruments).  
 
Calculating the Activation Energy of PlyCA Unfolding 
The rate constant k for PlyCA unfolding was derived from the corresponding DSC 





k = vCp/(Qt-Q) 
where v (K/min) is the scan rate, Cp the excess heat capacity, Qt  the total heat of the 
process and Q the heat evolved at a given temperature, T. The activation energy, EA, is 
determined by measuring the value of k at several temperatures and then using the 
Arrhenius equation k = Aexp (-EA/RT). That is, the corresponding Arrhenius plot, ln k 
versus 1/T, is used to calculate EA by using the equation 
m = -EA/R 
where m stands for the slope of the Arrhenius plot and R stands for the gas constant.  
 
45°C Kinetic Stability Assay 
The various endolysins investigated were incubated in a 45°C hot plate in PBS, 
pH 7.2, at a 44 nM (5 μg/ml) concentration for a total of 3 hours. At 20 minute 
increments, a 400 μl aliquot of the heated enzyme was removed and incubated on ice for 
5 minutes. Three adjacent wells of a 96-well plate were then filled with 100 μl of the 
cooled enzyme, followed by the addition of an equal volume of S. pyogenes D471 (see In 
Vitro Endolysin Activity on S. pyogenes for cell preparation). The residual lytic activity 
of the endolysin was analyzed via turbidity reduction assay by monitoring the OD600 
every 6 s for 20 min. The activity of the endolysin was equated to the Vmax (milli-OD 
units per min) corresponding to the linear portion of the resulting killing curve. Residual 










Prediction of Stabilizing Mutations of the PlyCA CHAP Domain 
FoldX was applied to the C-terminal CHAP domain of PlyCA (CHAP is 
comprised of PlyCA amino acids 309-465; however, atomic co-ordinates were only 
available for residues 310-464), substituting each of the possible 19 alternative natural 
amino acids at each residue position, so generating a library of 2945 PlyC mutants. Most 
of the mutations analyzed (n = 2453) were predicted by FoldX to have either 
destabilizing or neutral effects on stability, resulting in a ΔΔGFoldX ≥ 0 kcal/mol 
(ΔΔGFoldX = ΔGmut – ΔGwt) (Fig. 2-1). All of the mutants (n = 92) that had a ΔΔGFoldX ≤ -
1 kcal/mol were visually inspected, resulting in the elimination of another 61 mutants that 
appear to modify the PlyC structure in an unfavorable manner. Examples of these 
disadvantageous structure changes are disruption of salt-bridge and dipole interactions, 
replacement of salt-bridge interactions with weaker dipole interactions, generation of 
cavities in the hydrophobic core by the introduction of an amino acid with a smaller side-
chain, exposure of hydrophobic side-chains at the surface and disruption of the active 
site. 
The impact of the mutations encoded by the remaining 31 mutants was analyzed 
by the Rosetta ddg monomer algorithm (Kellogg et al., 2011) to further evaluate likely 
stabilizing potential (Fig. 2-2). Rosetta predicted 12 of the 31 mutants to be destabilizing 
(ΔΔGRosetta > 0.01 kcal/mol) and these were eliminated from further consideration (Fig. 2-
2, triangles). An additional mutant, PlyC (PlyCA) Q332H, has a predicted mildly 







Figure 2-1. Log distribution of the predicted change in folding free energy 
(ΔΔGFoldX) for all 2945 possible PlyCA CHAP domain point mutants calculated with 
FoldX 3.0 PositionScan. Mutations with ΔΔGFoldX < 0 are expected to increase protein 

















Figure 2-2. Comparison between the ΔΔGFoldX and ΔΔGRosetta values of the final 31 
mutant candidates retained after manual curation. 12 of these remaining mutants 
displayed a ΔΔGRosetta > 0.01 kcal/mol and were not further considered (triangles).  Of the 
remaining 19 mutants (circles and diamonds), 10 were selected for experimentally 
characterization (diamonds). All of the final candidates had predicted ΔΔG ≤ 0.01 












location, adjacent to the active site cysteine of the CHAP domain, C333. Although 
mutations near the active site generally induce activity defects, there are several 
documented instances where such mutations improve overall thermal stability (Daude et 
al., 2013; Kanaya et al., 1996; Zhi et al., 1991). In addition to Q332H, the PlyC (PlyCA) 
mutants D330Y, Q332V, C345T, D375Y, T381Y, V384Y, C404I, T406R and T421I 
were also selected as candidates for experimental study, on the basis of predicted ΔΔG < 
0 kcal/mol by both of FoldX and Rosetta (Fig. 2-2, diamonds, Table 2-1). These final 10 
candidates consisted of mutations located either near the CHAP domain active site 
(D330Y, Q332H, Q332V), in the hydrophobic core (C404I and T421I), at the surface and 
predicted to form an intra-domain hydrogen bond (V384Y) and at the surface, predicted 
to form  an inter-domain interaction with the N-terminal GyH domain (C345T, D375Y, 
T381Y, T406R). The other nine mutants with FoldX and Rosetta ΔΔG < 0 kcal/mol 
values were omitted from further characterization (Fig. 2-2, circles). These had similar 
structural locations to those selected, and were hypothesized to employ analogous 
stabilizing mechanisms so that inclusion would not improve the diversity of the candidate 
pool.  
 
Protein Solubility, Purity and Secondary Structure Determination  
PlyC (PlyCA) mutants Q332H, Q332V, C345T, D375Y, V384Y, C404I and 
T406R all expressed as soluble holoenzymes and were purified to homogeneity based on 
SDS-PAGE analysis (Fig. 2-3). PlyC (PlyCA) D330Y and T381Y did not express and 
therefore were excluded from further characterization (data not shown). SDS-PAGE and 





Table 2-1. List of the final 10 FoldX PlyC mutant candidates, including the specific 
mutation within the PlyCA CHAP domain (column 1), the location of the mutation 
(column 2) and the calculated ΔΔG (kcal/mol) values by the FoldX (column 3) or 











Wild-type -------- -------- -------- 
D330Y Near the active site -1.09 -2.51 
Q332H Near the active site -2.19 0.01 
Q332V Near the active site -1.79 -1.29 
C345T Surface with potential domain-domain interaction -1.20 -2.70 
D375Y Surface with potential domain-domain interaction -2.49 -1.53 
T381Y Surface with potential domain-domain interaction -1.32 -2.65 
V384Y Surface with potential intra-domain hydrogen bond -1.04 -5.57 
C404I Hydrophobic core -2.17 -5.44 
T406R Surface with potential domain-domain interaction -1.05 -1.29 















Figure 2-3. SDS-PAGE analysis of the FoldX PlyC mutants. The solubility and purity 
of each of the mutants was analyzed on a 4-15% gradient SDS-PAGE gel. The various 
lanes correlate to: (M) Molecular weight standard, (1) Wild-type, (2) Q332H, (3) Q332V, 
(4) C345T, (5) D375Y, (6) V384Y, (7) C404I, (8) T406R and (9) T421I. Protein 
expression was not observed for D330Y and T381Y and therefore both were excluded 












population of holoenzyme and uncomplexed PlyCB octomer structures (data not shown). 
To overcome this issue, a C-terminal 6x His-tag was added to PlyCA T421I. This mutant 
was expressed and purified in the same way as the other PlyC mutants, with two 
alterations; protein expression was induced at 18°C instead of 37°C, and there was an 
addition of a final immobilized metal affinity chromatography (IMAC) step using a 5 ml 
Bio-Scale Mini Profinity IMAC Cartridge (Bio-Rad) to remove uncomplexed PlyCB 
octomers.  
Protein secondary structure analysis was performed using far-UV CD. The CD 
spectra for all of the proteins analyzed were represented in terms of mean residue 
ellipticity (MRE) as a function of wavelength (Fig. 2-4a). All eight of the purified PlyC 
mutants displayed no deviation in secondary structure when compared to that of wild-
type. The far-UV spectra resembles that of an α/β folded protein, displaying ellipticity 
minima at 208 nm and 220 nm, and ellipticity maxima at 195 nm (Greenfield and 
Fasman, 1969; Kelly et al., 2005). Secondary structure composition analysis results 
depict highly homologous regular α-helical (±1.1%), distorted α-helical (±1.2%), regular 
β-sheet (±1.0%), distorted β-sheet (±0.5%), turn (±0.7%) and unordered (±0.7%) 
structures when comparing wild-type to the eight FoldX mutants (Table 2-2).  The 
normalized root mean square deviation (NRMSD) measures the goodness-of-fit between 
back-calculated spectra (spectra extrapolated using the CONTIN method for soluble 
proteins with known crystal structures) and experimental spectra. All of the NRMSD 
values are < 0.1, suggesting that the back-calculated and experimental spectra are in close 
agreement. Thus, none of the point mutations introduced significantly affected the 






    
 
Figure 2-4. Secondary structure and thermal stability determination. (a) The 
secondary structure of each of the FoldX PlyC mutant was analyzed by far-UV CD 





) was plotted against wavelength (nm) for each mutant, with all of the 
resulting spectra being overlaid for comparative purposes. The thermal stability of each 
mutant was then analyzed by means of (b) CD and (c) DSC in 20 mM phosphate buffer 
pH 7.0 at a protein concentration of 1 mg/ml using a heating rate of 1°C/min. Using the 
calorimetric data, the rate constant (k) for each FoldX PlyC mutant was calculated and 




) in order to determine the EA 







Table 2-2.  Far-UV CD protein secondary structure estimation using the CONTIN 
deconvolution method. Calculations were made for regular α-helix (αR), distorted α-

































Kinetic Analysis of Bacteriolytic Activity against S. pyogenes 
To assess the bacteriolytic activity of each PlyC mutant, the purified enzymes 
were incubated with S. pyogenes D471 at different molar concentrations and the resulting 
activity was elucidated by turbidity reduction assays. There were no activity defects 
observed with the PlyC (PlyCA) C345T, D375Y and V384Y mutants, displaying 1.13, 
1.03 and 1.23 fold increases in activity when compared to wild-type, respectively (Table 
2-3).  PlyC (PlyCA) mutants C404I and T406R exhibited a moderate loss in activity, 
exhibiting a respective 2.2 and 2.1 fold decrease in activity.  Significant activity 
deficiencies were observed with the PlyC (PlyCA) Q332H, Q332V and T421I mutants, of 
3.6, 9.1 and 16.7 fold reduction in activity, respectively. 
 
Circular Dichroism Thermal Stability Analysis 
Equal molar concentrations of the PlyC mutant enzymes were subjected to CD 
melting experiments to determine the temperature (T1/2) at which the apparent folded and 
unfolded fractions of the mutagenized PlyCA subunits in the context of the holoenzyme 
structure were in equilibrium (Fig. 2-4b). When monitoring the loss of α-helical 
secondary structure, PlyCA qualitatively exhibits a single, cooperative structural 
transition that is not reversed on cooling. PlyC (PlyCA) mutations Q332V, C345T, 
D375Y, C404I and T421I were destabilizing, decreasing the T1/2 of the catalytic subunit 
by 1.98°C, 0.07°C, 2.45°C, 0.99°C and 10.41°C, respectively, compared to wild-type 
(T1/2 = 50.09°C) (Table 2-4). The PlyC (PlyCA) mutants Q332H and V384Y slightly 
stabilized PlyCA by 0.08°C and 0.39°C, respectively. PlyC (PlyCA) T406R was 





Table 2-3. Bacteriolytic activity quantitation by means of S. pyogenes turbidity 
reduction assay.  
 
PlyC Construct Lytic Activity (U/ml) Relative Lytic Activity 
Wild-type 45350 1.00 
Q332H 12730 0.28 
Q332V 4950 0.11 
C345T 51180 1.13 
D375Y 46550 1.03 
V384Y 55560 1.23 
C404I 16000 0.45 
T406R 21550 0.48 




















Table 2-4. Comparison of T1/2 values derived from the CD melting experiments.  
 
PlyC Construct T1/2 (°C) ΔT1/2 (°C) 
Wild-type 50.09 - 
Q332H 50.17 +0.08 
Q332V 48.11 -1.98 
C345T 50.02 -0.07 
D375Y 47.64 -2.45 
V384Y 50.48 +0.39 
C404I 49.10 -0.99 
T406R 52.36 +2.27 





















PlyCA by 2.27°C. 
 
Differential Scanning Calorimetry  
To validate the CD stability analysis, the thermodynamic stability of each PlyC 
mutant was investigated by DSC at equal molar concentrations (Fig. 2-4c). Contrary to 
the CD thermal analysis of PlyCA, which qualitatively suggests PlyCA irreversibly 
unfolds in a cooperative manner, DSC analysis of the FoldX mutants depicts PlyCA 
unfolding non-cooperatively in a three-state, and in some cases, four-state, thermal 
transition model. Heating the protein samples from 15°C to 105°C followed by 
immediate cooling from 105°C to 15°C did not result in the refolding of the PlyCA 
subunit for each PlyC construct investigated.  
Consistent with CD results, PlyC (PlyCA) mutants Q332V, C345T, D375Y, 
C404I and T421I were less thermostable than wild-type (TG = 48.27°C, ΔHVH = 171.23 
kcal/mol) when analyzed by DSC, encompassing a 1.33°C, 0.27°C, 2.01°C, 0.52°C and 
9.03°C decrease in PlyCA TG and a 20.73 kcal/mol, 12.84 kcal/mol, 15.22 kcal/mol, 
17.47 kcal/mol and 49.86 kcal/mol reduction in ΔHVH, respectively (Table 2-5). PlyC 
(PlyCA) mutants Q332H and V384Y displayed marginable increases in thermodynamic 
stability, with an increase in PlyCA TG of 0.20°C and 0.23°C, and a 5.84 kcal/mol and 
2.73 kcal/mol gain in ΔHVH , respectively. The T406R mutation produces a more notable 
improvement in PlyCA, increasing TG and ΔHVH by 2.21°C and a 21.45 kcal/mol, 
respectively. 
Using the wild-type PlyC and mutant calorimetric traces, the PlyCA thermal 





Table 2-5. Calorimetric determination of PlyCA TG (columns 2-4) and the 
corresponding ΔHVH values (columns 5-7).  
 



















C345T 48.00 50.45 55.56 158.39 205.09 193.50 




V384Y 48.50 50.79 57.05 173.96 212.65 252.90 




























constants for at least nine different temperatures in order to derive EA values of unfolding 
(Fig. 2-4d). The calculated EA for PlyC (PlyCA) Q332V, C345T, D375Y, V384Y, C404I 
and T421I were lower than that of wild-type PlyC (178 kcal/mol) (Table 2-6). In contrast, 
PlyC (PlyCA) Q332H and T406R displayed a respective increase in EA of 7 kcal/mol and 
11 kcal/mol. 
 
45°C Kinetic Inactivation Analysis 
The rate of PlyCA kinetic inactivation was monitored for wild-type PlyC and the 
lead FoldX mutant candidate, PlyC (PlyCA) T406R, at 45°C for a total of 3 hours. For 
this particular assay, the unfolding of PlyCA is directly correlated with the loss of 
bacteriolytic activity as a function of temperature and time. The loss in activity is not 
associated with the unfolding of the PlyCB binding domain of PlyC due to the inherent 
thermal stability of the octomeric CBD complex of the CBD (F. Schwarz, personal 
communication). The heat-labile nature of wild-type PlyC promoted rapid PlyCA 
unfolding at 45°C, resulting in a half-life (t1/2) of 17.84 min (Fig. 2-5, squares). 
Conversely, PlyC (PlyCA) T406R mutant improved the kinetic fitness of PlyCA at 45°C 
16 fold when compared to wild-type, displaying an extrapolated t1/2 increase to 286.09 
minutes (Fig. 2-5, inverted triangles).  
 
Discussion 
The PlyC endolysin is the most active phage-derived peptidoglycan hydrolase 
characterized to date and has been validated in vitro and in vivo for its antimicrobial 





Table 2-6. Determination of the PlyCA EA (kcal/mol) of unfolding from applying a 






















PlyC Construct EA (kcal/mol) R
2
 
Wild-type 178 0.9982 
Q332H 185 0.9989 
Q332V 133 0.9982 
C345T 164 0.9956 
D375Y 152 0.9961 
V384Y 158 0.9963 
C404I 156 0.9960 
T406R 189 0.9992 







Figure 2-5. Kinetic stability of wild-type PlyC and PlyC (PlyCA) T406R at 45°C. 
Equal molar concentrations of wild-type PlyC and PlyC (PlyCA) T406R were incubated 
at 45°C for a total of 3 hours. At 20 minute increments, the residual lytic activity of each 
enzyme was monitored by means of turbidity reduction assay. The activity of each was 














and human health complications (Hoopes et al., 2009; Nelson et al., 2001; Nelson et al., 
2006a). With a long-term goal of developing PlyC as a novel antimicrobial disinfectant, 
prophylactic and therapeutic, the poor thermal stability, and hence transient shelf life, 
makes the feasibility of proceeding forward with the developmental process challenging. 
Here we show for the first time the ability to engineer increased stability in silico to a 
phage endolysin through the use of the FoldX algorithm. Considering the complexity of 
the novel nine subunit structure of PlyC in conjunction with the endogenous thermal 
stability of the PlyCB CBD, we decided to focus our engineering efforts on the most 
thermolabile structural component of the PlyCA EAD, which was previously shown to be 
the C-terminal CHAP domain.  
Although the structural integrity of all eight of the final CHAP domain mutant 
holoenzymes analyzed remained intact (Fig. 2-3 and Fig. 2-4a, Table 2-2), endolysin 
turbidity reduction activity titers showed that while the C404I and T406R mutations 
respectively caused considerable 2.2 and 2.1 fold decreases in activity, the Q332H, 
Q332V and T421I mutations to the CHAP domain generated significant activity defects 
that correlated to a >70% loss in activity (Table 2-3). Considering the PlyCA CHAP 
domain has active site residues at C333 and H420 (Nelson et al., 2006a), it was not 
surprising to observe major perturbations to the catalytic efficiency of the enzyme when 
introducing amino acid mutations adjacent to either of the two active site residues.  
After being subjected to CD and DSC thermal stability analysis, the lead FoldX 
mutant candidate was PlyC (PlyCA) T406R, which displayed a ≥ 2.2°C increase in 
PlyCA stability with a 21.45 kcal/mol gain in ΔHVH (Fig. 2-4b and c, Table 2-4 and 2-5). 





promote an inter-domain interaction between the C-terminal CHAP domain and the N-
terminal GyH domain of the PlyCA subunit. Modeling the T406R mutation into the 
CHAP domain shows how the longer arginine side-chain allows the formation of a 
stabilizing hydrogen bond with the polar Q106 side-chain located on the surface of the N-
terminal GyH domain of PlyCA (Fig. 2-6). The suspected PlyCA stabilizing inter-domain 
interaction engineered by the T406R mutation also resulted in an increase in kinetic 
fitness. This finding is consistent with a kinetic model based on the calorimetric traces 
provided by DSC. The resulting Arrhenius plots show the T406R mutation results in a 
PlyCA unfolding EA of 189 kcal/mol, an 11 kcal/mol increase in EA compared to wild-
type (Fig. 2-4d, Table 2-6).  Moreover, the T406R mutation promotes an extrapolated 16 
fold augmentation in PlyCA kinetic stability at 45°C (Fig. 2-5). Although PlyC (PlyCA) 
T406R had an overall reduction in bacteriolytic activity when compared to the 
endogenous activity of wild-type PlyC, a common observation when thermostabilizing 
biomolecules (Arnold et al., 2001; Beadle and Shoichet, 2002; Giver et al., 1998; 
Meiering et al., 1992; Mukaiyama et al., 2006; Shoichet et al., 1995; Yutani et al., 1987), 
the residual activity displayed by the mutant nonetheless remains more potent than that of 
any other characterized endolysin.  
Engineering inter-domain interactions is a commonly practiced strategy for 
thermostabilizing proteins (Choudhury et al., 2010; Wakabayashi and Fay, 2013; 
Wozniak-Knopp and Ruker, 2012). As suggested by the results from the thermal 
characterization and molecular modeling of PlyC (PlyCA) T406R, the hypothesized 
thermostabilizing inter-domain hydrogen bond would link the N-terminal GyH and C-







Figure 2-6. Local structure around wild-type PlyCA T406 with the proposed 
conformation of the mutant T406R superimposed. The crystal structure of the wild-
type PlyCA T406 residue (blue sticks) and the model of the PlyCA mutant residue T406R 
(green sticks) are shown together with the surrounding residues. The predicted additional 
hydrogen bond between Q106 of the N-terminal GyH domain and R406 of the C-terminal 
CHAP domain introduced by the T406R mutation is shown as orange dots. Parts of the 
polypeptide backbone of the PlyCA N-terminal GyH domain (magenta) and the C-










associated with the new hydrogen bond. 
With respect to the effectiveness of the FoldX algorithm for estimating CHAP 
domain mutant ΔΔG values, it should be born in mind that these calculations are based 
on a relatively low resolution 3.3-Å X-ray crystal structure. The ΔΔG estimates derived 
from FoldX did yield one very useful and non-obvious candidate that significantly 
increased the stability of PlyCA, at the expense of some extra experimental work on non-
useful ones.  There may of course be other potentially useful mutations that the procedure 
used here overlooked.  
While the increase in thermodynamic and kinetic stability are important findings 
from a computational-based engineering approach for improving the stability of phage 
endolysins, additional engineering efforts can be employed to the PlyC endolysin to 
further evolve the enzyme’s thermal fitness. For instance, instead of solely focusing on 
the C-terminal CHAP domain, FoldX modeling could be directed towards the N-terminal 
GyH domain. Despite the CHAP domain (TG = 39.1°C) being more thermosusceptible 
than the PlyCAΔCHAP subunit (TG = 46.0°C), this may not be the case when the 
thermodynamics of each are analyzed in the context of the holoenzyme.  Supplementary 
to rationale-based computational bioengineering methodologies, structure-guided site-
directed mutagenesis could be implemented to improve the thermal stability of PlyC. Due 
to the high conservation of the protein core when comparing a wide-range of homologous 
mesophilic and hyperthermophilic protein structures, various stabilization strategies that 
have been implemented typically focus on the polar surface areas of the protein (Vieille 
and Zeikus, 2001). Replacing residues in left-handed helical structures with glycine or 





formation of nonlocal surface ion pairs, and anchoring loop structures to the protein 
surface by the addition of a disulfide bridge are all strategies that have been successfully 
exploited for increasing the thermal stability of proteins (Kawamura et al., 1996; Kimura 
et al., 1992; Matthews et al., 1987; Sanz-Aparicio et al., 1998; Van den Burg et al., 
1998). Since protein stability can be increased through the sequential addition of 
individual adaptive mutations, advantageous mutations elucidated through different 
engineering strategies can be combined to further enhance the thermal stability of the 
endolysin in an additive nature.  
 
Acknowledgements 
We would like to respectively thank Amanda Altieri and Robert G. Brinson for 
their technical assistance when using the CD spectrometer and DSC. We are also thankful 
for the insight and advice provided by Philip N. Bryan regarding the thermodynamic and 
kinetic analysis experiments. Finally, we are grateful to the National Institute of 
Standards and Technology for access to DSC instrumentation. 
 
Author contributions: R.D.H, J.M.  and D.C.N. conceived the experiments; Y.Y. and 
J.M. performed the computational experiments and analyzed the data; R.D.H. performed 
the biological, biochemical and biophysical experiments and analyzed the data; J.M and 
D.C.N. planned and supervised the project. R.D.H. wrote the article. 
 
Funding: This work was supported by grants from the United States Department of 
















Institute for Bioscience and Biotechnology Research, 9600 Gudelsky Drive, Rockville, 
MD 20850, USA; 
2
Department of Veterinary Medicine, University of Maryland, 8075 
Greenmead Drive, College Park, MD 20742, USA 
 
This chapter has been published as follows: 
 
Heselpoth, R.D., Nelson, D.C. A New Screening Method for the Directed Evolution of 
Thermostable Bacteriolytic Enzymes. J. Vis. Exp. (69), e4216, doi:10.3791/4216 (2012). 
 













 Directed evolution is defined as a method to harness natural selection in order to 
engineer proteins to acquire particular properties that are not associated with the protein 
in nature. Literature has provided numerous examples regarding the implementation of 
directed evolution to successfully alter molecular specificity and catalysis (Jackel et al., 
2008). The primary advantage of utilizing directed evolution instead of more rational-
based approaches for molecular engineering relates to the volume and diversity of 
variants that can be screened (Liu et al., 2009). One possible application of directed 
evolution involves improving structural stability and the corresponding thermodynamic 
properties associated with bacteriolytic proteins, such as endolysins. Endolysins, often 
called enzybiotics for their therapeutic potential, are an emerging enzyme-based class of 
antimicrobials that hydrolyze critical covalent bonds in the peptidoglycan (i.e. cell wall) 
of susceptible Gram-positive bacteria species, resulting in cellular lysis (Fischetti, 2008; 
Fischetti et al., 2006; Loessner, 2005). The subject of our directed evolution study 
involves the PlyC endolysin, which is composed of PlyCA and PlyCB subunits (Nelson 
et al., 2006b). When purified and added extrinsically, the PlyC holoenzyme lyses group 
A streptococci (GAS) as well as other streptococcal groups in a matter of seconds and 
furthermore has been validated in vivo against GAS (Loeffler et al., 2001). Significantly, 
monitoring residual enzyme kinetics after elevated temperature incubation provides 
distinct evidence that PlyC loses lytic activity abruptly at 45°C, suggesting a short 
therapeutic shelf life, which may limit additional development of this enzyme. Further 
studies reveal the lack of thermal stability is only observed for the PlyCA subunit, 





the Arrhenius equation, which relates the rate of a chemical reaction to the temperature 
present in the particular system, an increase in thermostability will correlate with an 
increase in shelf life expectancy (Anderson and Scott, 1991).  Toward this end, directed 
evolution has been shown to be a useful tool for altering the thermodynamics of various 
molecules in nature but never has this particular technology been exploited successfully 
for the study of bacteriolytic proteins. In this video, we employ the use of an error-prone 
DNA polymerase followed by an optimized novel screening process using a 96-well 
microtiter plate format to identify mutations to the PlyCA subunit of the PlyC 
streptococcal endolysin that correlate to an increase in enzyme thermostability. Results 
after just one round of random mutagenesis suggest the methodology is generating 
thermodynamically advanced PlyC variants that retain more than twice the residual 


















1. Determining Optimal Heating Conditions 
 First, one must experimentally determine the optimal incubation temperature and 
time to use for the heating step in the assay. For our PlyC model, it is important to note 
that E. coli co-transformed with plyCA and plyCB genes on separate expression plasmids 
has been shown to form a fully functional PlyC holoenzyme (Nelson et al., 2006b). The 
96-well microtiter plate preparation as well as cell growth conditions and the subsequent 
replica plating technique were adapted from examples provided in the literature (Kim et 
al., 2000; Koutsioulis et al., 2008; McCarthy et al., 2004; Ren et al., 2009; Tsuzuki et al., 
2005). Using 30 minutes as the predetermined heat treatment time, the optimal incubation 
temperature for PlyC was elucidated by the following steps: 
1.1) Transform the expression construct pBAD24:plyCA (Amp
r
) into the 
competent E. coli strain DH5α pBAD33:plyCB (Cm
r
).  
1.2) Plate the transformants on a Luria-Bertani (LB) agar plate supplemented with 
ampicillin (100 μg/ml) and chloramphenicol (35 μg/ml). Incubate the plates 
overnight at 37°C. 
1.3) With a sterile toothpick, inoculate an individual colony into each row of wells 
(Fig. 3-1a) in a sterile, clear, flat-bottomed 96-well, lidded microtiter plate 
that contains 200 μl of LB supplemented with ampicillin and 
chloramphenicol. 
1.4) Securely place the 96-well microtiter plate on a 37°C shaking incubator and 
































Figure 3-1. 96-well microtiter plate templates for directed evolution assay. (a) The 
microtiter plate schematic during the determination of the optimal heating conditions 
consists of inoculating a single WT PlyC clone into each row of the microtiter plate. (b) 
The microtiter plate schematic during mutant screening consists of inoculating each well 
in column 1 with a unique WT PlyC clone as well as inoculating each well in columns 2-
12 with a distinct PlyC mutant clone. Wells A1-D1 are designated for the positive 
controls, which consist of WT PlyC constructs not exposed to non-permissible 
temperature incubation. Wells E1-H1 are designated for the negative controls, which 








1.5) Retrieve the 96-well microtiter plate from the 37°C shaking incubator and 
replica plate to a new 96-well microtiter plate as follows: 
a. Add 180 μl of LB supplemented with ampicillin and chloramphenicol to 
each well of the replica plate. 
b. Transfer 20 μl of bacteria from the original plate to the corresponding 
wells in the replica plate. This should result in an initial optical density 
between 0.3-0.5. 
1.6) Securely place the replica plate on the 37°C shaking incubator and incubate 
the plate for 1 hour at 300 RPM, then add the inductant. In the case of our 
pBAD expression systems, the inductant is 0.25% arabinose. Other expression 
systems may require different inductants. Place the plate back on the 37°C 
shaking incubator and shake at 300 RPM for an additional 4 hours to allow for 
protein expression.  
1.7) Once protein expression has concluded, retrieve the replica plate and pellet the 
bacteria by placing the 96-well microtiter plate in a refrigerated centrifuge that 
contains a swinging-bucket rotor which fits 96-well microtiter plates.  
Centrifuge at 3000 RPM for 10 minutes at room temperature.  
1.8) Remove the media supernatant with a vacuum apparatus being careful not to 
disturb the pelleted bacteria in order to minimize the chances of cross-
contamination or sample loss.  
1.9) Lyse the cells by adding 50 μl of B-PER II Bacterial Protein Extraction 





1.10) Increase the volume in each well to 120 μl by adding 70 μl of phosphate 
buffered saline (PBS) pH 7.2.  
1.11) Pellet the insoluble cellular debris by spinning the plate at 3000 RPM for 10 
minutes at 4°C in the refrigerated centrifuge. 
1.12) Transfer 110 μl of the soluble crude lysate to the corresponding wells of a 96-
well thermocycler plate.  
1.13) Using 30 minutes as the predetermined incubation time, expose the soluble 
lysates currently residing in the 96-well thermocycler plate to a broad gradient 
temperature range spanning 15°-20°C. Note, the goal is to determine what 
temperature your particular enzyme loses > 95% catalytic activity.  
1.14) After incubation, incubate the 96-well thermocycler plate at 4°C for 5 minutes 
and transfer 100 μl of the soluble lysates from the 96-well thermocycler plate 
to their corresponding well location in the final 96-well microtiter plate. 
1.15) With a 12-channel multipipettor, add 100 μl of GAS strain D471 to each well. 
Note, D471 cells are originally lyophilized from overnight cultures and 
resuspended with PBS pH 7.2 to obtain an OD600 of ~1.5.  
1.16) Immediately place the 96-well plate in the microplate spectrophotometer and 
monitor the enzyme kinetics by measuring the OD600 every 15 seconds for 20 
minutes. The lowest temperature incubation that corresponded to wells that 
lacked a change in optical density (ΔOD ≤ 0.1) is defined as the non-






After a broad temperature screen is performed to identify the non-permissive 
temperature, the above steps can be repeated over a more narrow range of temperatures 
(5°-10°C) to elucidate the precise non-permissive temperature for the enzyme of interest. 
Note, the non-permissive temperature identified in this assay may be different than the 
melting temperature elucidated by other means due to differences in volume, 
concentration, etc.  
 
2. Generating the Mutant Library 
 The creation of the mutant library to be screened involves randomly incorporating 
mutations with minimal nucleotide bias in the plyCA gene using the GeneMorph II 
Random Mutagenesis Kit as follows: 
2.1) Nucleotide primers with similar melting temperatures (Tm) between 55°-72°C 
were designed with the restriction sites of choice to the 5’ and 3’ ends of the 
plyCA gene.  
2.2) Since the desired mutation rate is 2-3 nucleotides per plyCA (1.4 kb), we 
utilized the PCR reaction component concentrations as well as the 
thermocycler conditions recommended by the manufacturer for low mutation 
frequencies (0-4.5 per kb). 
2.3) Clone the mutagenized plyCA genes into the expression vector pBAD24. 
2.4) Transform the constructs into a DH5α pBAD33:plyCB background and plate 
transformants on LB agar plates supplemented with ampicillin and 





2.5) Additionally, transform and plate DH5α pBAD33:plyCB with the expression 
vector pBAD24 containing the WT plyCA gene. Colonies from this plate will 
serve as the controls during thermostability screening. 
 
3. 96-Well Microtiter Plate Preparation and Cell Growth Conditions 
3.1) Fill each well of a 96-well microtiter plate with 200 μl of LB supplemented 
with ampicillin and chloramphenicol. 
3.2) Following the microtiter plate schematic (Fig. 3-1b), carefully select an 
individual colony from the overnight agar plates with a sterilized toothpick 
and inoculate the bacteria in the designated well of the 96-well microtiter 
plate. It is essential to ensure only one colony per well is inoculated. 
3.3) Shake the securely anchored 96-well microtiter plate at 300 RPM overnight at 
37°C.  
 
4. Replica Plating, Protein Expression Induction and Lysate Preparation 
4.1) Follow steps 1.5-1.11 from the section titled “Determining the optimal heating 
conditions” with one modification. Store the original plate at 4°C after the 
replica plating step has concluded.   
4.2) After step 1.11, transfer 110 μl of the soluble crude lysate to the 
corresponding wells of a 96-well thermocycler plate except for the positive 
control wells A1-D1. With regard to the positive control lysates (i.e. lysates 





a new 96-well microtiter plate that will serve as the final assay plate for the 
experiment.  
 
5. Soluble Lysate Heat Treatment 
5.1) Heat the negative control and mutant soluble lysates currently confined in the 
96-well thermocycler plate in the thermocycler for 30 minutes at the 
optimized non-permissive incubation temperature determined in step 1. 
5.2) After non-permissive temperature incubation, incubate the 96-well 
thermocycler plate at 4°C for 5 minutes.  
5.3) Transfer 100 μl of the soluble lysates from the 96-well thermocycler plate to 
their identical well locations in the final 96-well microtiter assay plate already 
containing the positive control soluble lysates. 
5.4) With a 12-channel multipipettor, add 100 μl of GAS strain D471 to each well. 
Immediately place the plate in the microplate spectrophotometer. 
5.5) Monitor the enzyme kinetics by measuring the OD600 every 15 seconds for 20 
minutes.  
a. We defined a thermostable PlyC variant as a construct that can decrease 
the original optical density by 50 percent in less than 900 seconds at the 
non-permissive temperature. Additionally, the positive controls (i.e. non-
heated, WT PlyC) need to display WT catalytic activity (t1/2 ≤ 100 
seconds) and the negative controls (i.e. heated, WT PlyC) should be 





5.6) Once a thermostable PlyC variant is identified, the original plate stored at 4°C 
is retrieved and bacteria from the individual well specific to the mutant of 
interest is inoculated into fresh LB media supplemented with ampicillin and 
chloramphenicol. The inoculum is then grown overnight at 37°C. 
5.7) Plasmid DNA was extracted and purified from the culture and submitted for 
sequencing to identify the nucleotide mutations that inferred enhanced 
thermodynamic properties to PlyCA. Additionally, a small aliquot from the 
overnight culture was supplemented with 10% glycerol and stored at -80°C 




 Over 6000 PlyC mutants were screened for increased thermodynamic properties. 
A total of 35 mutants with potentially increased thermostability were identified, selected 
and sequenced. Genomic analysis, summarized in Table 3-1, suggest that of the 35 
candidates, 7 of the constructs contained WT PlyCA sequences at the level of translation, 
corresponding to false positives identified by the assay. Of the remaining 28 candidates, 
the mutation range was from 1 to 6 nucleotide mutations with an average mutation rate of 
2.75 nucleotides per plyCA gene, which was in the 2-3 nucleotide mutation range we 
were targeting. At the translational level, this particular nucleotide mutation range and 
frequency yielded an amino acid mutation range of 1 to 5 amino acids, with an average 
mutation rate of 1.9 amino acid mutations per PlyCA polypeptide. Of the 28 candidates  
with at least one amino acid mutation, four of these mutant constructs were randomly 





Table 3-1.  Candidate Pool Genomic Analysis 
 
Total Round 1 Candidates 35 
Candidates with WT PlyCA Sequence 7 
Candidates with ≥1 Amino Acid Mutation 28 
     Average Nucleotide Mutation Rate (nt/plyCA) 2.75 
     Nucleotide Mutation Range (nt) 1-6 
     Average Amino Acid Mutation Rate (AA/PlyCA) 1.9 
























directed evolution methodology was indeed functioning properly. The mutant PlyC 
enzymes were purified to > 95% homogeneity based on SDS-PAGE analysis as 
previously described (Loeffler et al., 2001; Nelson et al., 2006b). Enzyme kinetics of WT 
PlyC and each of the four PlyC mutants were characterized at equal molar concentrations 
after incubating the purified enzymes at various elevated temperatures. Activity was 
monitored after the addition of D471 GAS by measuring the optical density at 600 nm 
every 15 seconds for 20 minutes. Activity was defined as the residual maximum velocity 
of the enzyme after heat incubation. Of the four candidates randomly selected for further 
characterization, mutant 29C3 showed the most enhanced thermodynamic properties 
(data not shown).  
 WT PlyC and 29C3 showed no significant difference in activity at room 
temperature (25°C) as depicted in the first set of bars in Fig. 3-2. However, after a short-
term incubation for 30 minutes from temperatures ranging from 45°-50°C, the activity of 
29C3 was substantially greater than the activity specific to the WT construct at each 
temperature point.  For example, after a 30 minute incubation at 45.2°C, WT PlyC lost 
50% of its activity whereas 29C3 showed no significant decrease in activity when 
compared to the activity displayed at room temperature.  
 Long-term incubation studies comparing the residual activity of both WT PlyC 
and 29C3 were additionally performed at 35°C and 40°C involving the measurement of 
residual activity at 24 and 48 hour time points. At 35°C, 29C3 displayed 41% and 176% 









Figure 3-2. Residual activity kinetic analysis comparing WT PlyC and 29C3. 
Enzymes were purified to homogeneity and incubated at equal molar concentrations at 
either room temperature or at a temperature gradient ranging from 45°-50°C. Enzymatic 


















































3-3a). At 40°C, 29C3 displayed 28% and 107% higher activity than WT PlyC at 24 and 
48 hour incubation time points, respectively (Fig. 3-3b). The residual activity of WT 
PlyC and 29C3 were also monitored every 20 minutes for a total of 3 hours at 45°C. WT 
PlyC was only able to retain 21% activity after a 3 hour incubation at this temperature 
whereas 29C3 was able to retain 46% activity, resulting in 29C3 displaying more than 
twice the thermostability when compared to WT PlyC (Fig. 3-4).  
 
Discussion 
 This protocol, outlined in Fig. 3-5, presents a 96-well microtiter plate 
methodology that allows one to utilize directed evolution to increase the thermodynamic 
properties of any bacteriolytic protein. Through the use of an error-prone DNA 
polymerase, one can introduce random mutations that increase the overall thermostability 
of the translated bacteriolytic molecule of interest, which is typically due to molecular 
reorganizations consisting of increasing electrostatic, disulfide bridge and hydrophobic 
interactions that generate improved molecular packing, enhanced modifications of 
surface charge networks or reinforcement of a higher oligomerization state (Eijsink et al., 
2005; Kumar and Nussinov, 2001). After the introduction of nucleotide mutations, an 
extensive screening procedure was then used to identify mutations that enhanced 
thermostability. The representative results presented here were based on one round of 
random mutagenesis.  In reality, it has been suggested that at least three successive 
rounds of random mutagenesis, each using the most robust mutant as the lead enzyme, 
followed by DNA shuffling is appropriate for these types of directed evolution 







Figure 3-3. Residual activity kinetic analysis comparing WT PlyC to 29C3 at 35°C 
and 40°C. Equal molar concentrations of purified WT PlyC and 29C3 were incubated at 
(a) 35°C or (b) 40°C. The residual enzyme activity was measured at 24 and 48 hour time 
points. The activity displayed by each construct was normalized to the maximum velocity 






































































Figure 3-4. Residual activity kinetic analysis comparing WT PlyC to 29C3 at 45°C. 
Equal molar concentrations of purified WT PlyC and 29C3 were incubated at 45°C and 
the residual enzyme activity was measured every 20 minutes for 3 hours. The activity 
displayed by each construct was normalized to the maximum velocity displayed at time 
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Figure 3-5. Directed evolution assay methodology. In random mutagenesis, one starts 
with the lead enzyme, which would be WT PlyC for the first round. A library of PlyC 
mutants containing random unbiased nucleotide mutations to the plyCA gene is then 
constructed, cloned into the expression vector pBAD24 and transformed into the E. coli 
strain DH5α already containing pBAD33:plyCB. Individual transformants are inoculated 
into their own specific well of a 96-well microtiter plate. Through an extensive screening 
process, individual PlyC mutants that are catalytically active after incubation at a non-
permissible temperature are classified as mutants with enhanced thermodynamic 
properties. After performing genomic analysis on the candidate pool, the chosen specific 
mutations are then incorporated into the plyCA gene by means of site-directed 





the next round of random mutagenesis. Overall, there are three complete rounds of 
random mutagenesis followed by DNA shuffling resulting in a thermodynamically 






 While the methodology presented here is specific to implementing increased 
thermostability to PlyC, this same methodology can additionally be employed to enhance 
thermostability to other bacteriolytic proteins with some minor alterations to variables 
such as buffers, mutation rates, heating conditions and expression systems. One critical 
variable associated with this assay relates to the nucleotide mutation rate of the error-
prone DNA polymerase. We chose to use the error-prone Mutazyme II DNA polymerase 
in our directed evolution assay due to experimental evidence suggesting this particular 
enzyme displays the least amount of bias with regards to which nucleotides are randomly 
incorporated into the gene of interest when compared to other random mutagenesis 
techniques such as use of hydroxylamine, mutator E. coli strains and other error-prone 
DNA polymerases (Rasila et al., 2009). In general, lower mutation rates tend to be more 
desirable for two reasons. First, engineering thermostability to proteins typically consist 
of relatively few amino acid substitutions. High mutation rates can cause dramatic 
structural alterations to particular molecules that can conclusively result in structural 
misfolding and functional discrepancies. For example, the incorporation of glycine and 
proline residues can disrupt alpha helical secondary structures (Wong et al., 2006a). 
Second, high nucleotide mutation rates increase the chances of incorporating premature 
stop codons, resulting in truncated molecules that are biologically inactive. In general, 
lower mutation rates are preferred because lower error rates result in the accumulation of 
adaptive mutations while higher mutation rates generate neutral or deleterious mutations 
(Arnold et al., 2001).  
 For each round of random mutagenesis, another critical variable that one must 





Selection of the experimental non-permissive temperature is relatively challenging. One 
needs to utilize an incubation temperature that is not too temperate (≤ 1°C higher than 
lowest non-permissive temperature) and conversely not too harsh (≥ 3°C higher than 
lowest non-permissive temperature). The ideal temperature we decided to use in this 
particular assay was a moderate 2°C higher than the experimentally determined non-
permissive temperature. Choosing a temperature that is too mild will result in a much 
higher false positive identification rate than the ~20% we observed (Table 3-1) when 
using a moderate incubation temperature. Furthermore, using an incubation temperature 
that is too harsh could ultimately result in the inability to identify mutants with 
significantly enhanced thermostability. For example, using an incubation temperature of 
≥ 3°C would have resulted in the inability to identify the thermodynamically promising 
29C3 mutant as well as the majority of the other candidates selected during the first 
round of screening.  In summation, we provide a protocol for engineering bacteriolytic 
proteins to acquire enhanced thermodynamic properties. Moreover, this same assay, 
without the heating steps, can be used to screen for mutations that increase catalytic 
activity.  Augmenting both catalytic activity and increased thermostability is an important 
developmental hurdle facing any therapeutic enzyme. While the details of this protocol 
are specific to the endolysin PlyC, the methodology can be adapted to any bacteriolytic 
protein with only a few alterations. We presented preliminary results from only the first 
round of mutagenesis which validates that this assay is indeed functional, resulting in the 
implementation and identification of mutations that generate an increase in molecular 
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 Bacteriophage-derived peptidoglycan hydrolases, termed endolysins, have been 
successfully exploited as an alternative antimicrobial to traditional antibiotics. One 
disconcerting property affiliated with many endolysins derived from mesophilic 
bacteriophage is the poor intrinsic thermal stability of their structures. The thermolability 
and subsequent abbreviated shelf life expectancy limits the antimicrobial potential of 
these enzymes. To overcome this challenge, directed evolution was applied to the heat-
sensitive catalytic subunit, PlyCA, of the streptococcal-specific PlyC endolysin to 
improve its structural stability. After screening a total of 18,000 mutants, the lead 
candidate was the mutant PlyC (PlyCA) N211H. This mutation, which is located in the 
linker structure that conjoins the N-terminal GyH domain with the central helical docking 
domain, appeared to thermostabilize PlyCA by forming electrostatic interactions with 
E113 and D150 of the GyH domain. These interactions improved the thermodynamic 
stability of PlyCA by respectively increasing the thermal transition temperature (TG) and 
van’t Hoff enthalpy (ΔHVH) of the subunit by 4.10°C and 19.97 kcal/mol. PlyCA was also 
kinetically stabilized, exhibiting an activation energy (EA) of PlyCA unfolding increase of 
17.52 kcal/mol. At pH 7.2-7.3, thermally-induced kinetic inactivation of PlyC (PlyCA) 
N211H decreased 18.8 fold at 45°C. When combining a previously identified stabilizing 
mutation, T406R, with N211H, the thermal stability augmentation was additive. PlyC 
(PlyCA) N211H T406R displayed a PlyCA ΔTG and Δ(ΔHVH) of +7.46°C and +22.60 
kcal/mol over wild-type PlyC, respectively, while also demonstrating a 28.72 kcal/mol 








 Antibiotic misuse and overuse has stimulated bacteria to rapidly develop 
resistance. In combination with the extensive dissemination of these antibiotic-resistant 
microorganisms, the loss in antimicrobial efficacy of antibiotics has subsequently caused 
health and economic implications globally, thus prompting a definitive need for 
alternative antimicrobial approaches. One such alternative is a class of translational 
antimicrobials known as endolysins. Endolysins, also termed phage lysins or enzybiotics, 
are bacteriophage-derived peptidoglycan hydrolases that coordinate host cell lysis at the 
completion of progeny virion assembly (Lopez et al., 1997; Nelson et al., 2006a; Wang et 
al., 2000). Late in the lytic phage infection cycle, the endolysin is translocated from the 
cytosol to the peptidoglycan structure of the host bacterium by holins, which are pore-
forming hydrophobic proteins encoded by the phage that oligomerize on the inner 
membrane of the host bacterium.  Upon direct contact with the peptidoglycan, the 
endolysin cleaves one or more essential covalent bonds in the cell wall structure, 
resulting in bactericidal osmotic lysis and progeny virion liberation. Due to the extrinsic 
accessibility to the peptidoglycan structure, purified recombinant endolysins have been 
validated both in vitro and in vivo for their antimicrobial efficacy against Gram-positive 
pathogens when extrinsically applied and thus serve as a novel alternative to classical 
antibiotics (Fischetti, 2005, 2008; Fischetti et al., 2006; Loessner, 2005).  
 PlyC is a streptococcal-specific endolysin that can lyse a range of bacterial 
species known to cause severe human (e.g. Streptococcus pyogenes) and animal (e.g. 
Streptococcus equi) health complications (Nelson et al., 2001). Unlike other endolysins, 





structure with nine distinct subunits (McGowan et al., 2012; Nelson et al., 2006a). Eight 
identical PlyCB monomers interact through protein-protein interactions to form the 
octomeric cell wall binding domain (CBD) of the holoenzyme. The CBD dictates the 
lytic specificity of an endolysin by binding to a species-specific cell wall-associated 
epitope. The ninth subunit, PlyCA, serves as the enzymatically active domain (EAD) of 
the endolysin responsible for peptidoglycan hydrolysis. PlyCA is comprised of a 
catalytically-active N-terminal glycosol hydrolase (GyH) domain that is linked to a 
central helical docking domain. The helical docking domain is responsible for interacting 
with the PlyCB octomer, thereby promoting the formation of the holoenzyme structure.  
The carboxyl end of the helical docking domain is linked to a catalytically-active C-
terminal cysteine, histidine-dependent amidohydrolase/peptidase (CHAP) domain that 
functions as an N-acetylmuramoyl-L-alanine amidase (Fischetti et al., 1972a). The GyH 
domain acts synergistically with the CHAP domain to generate the potent bacteriolytic 
mechanism of the enzyme. PlyC has been characterized in vitro to be several orders of 
magnitude more active than any other endolysin to date (McGowan et al., 2012; Nelson 
et al., 2001).  
 Despite the promising aforementioned antimicrobial characteristics of PlyC, one 
attribute that significantly hinders its antimicrobial potential relates to the inherent 
structural stability of the enzyme. Thermodynamic characterization of PlyC by 
differential scanning calorimetry (DSC) revealed the PlyCB octomer is endogenously 
thermostable, displaying a thermal transition temperature (TG) temperature of 75.85°C, 
whereas the PlyCA EAD conversely displayed a thermolabile TG of 48.27°C at pH 7.0 





dissociation of the PlyCB octomer is a reversible process, the unfolding of the individual 
PlyCA and PlyCB monomers is irreversible (F. Schwartz, personal communication). The 
thermolability associated with PlyC seems to be a common trend when compared to other 
thermally characterized Gram-positive endolysins derived from mesophilic 
bacteriophage. For example, the Staphylococcus aureus endolysin LysK and the 
Streptococcus pneumoniae  endolysins Cpl-1, Pal and Cpl-7, are kinetically inactivated 
and/or unfold at 42.0°C, 43.5°C, 50.2°C and 50.4°C, respectively (Bustamante et al., 
2012; Filatova et al., 2010; Sanz et al., 1993; Varea et al., 2004). The thermosusceptible 
nature of endolysins, such as PlyC, is problematic because, in congruence with the 
Arrhenius equation, poor structural stability directly correlates with abbreviated shelf life 
(Anderson and Scott, 1991).  
 There exists a wide-range of protein engineering methodologies that have been 
successfully exploited to alter the molecular properties of proteins, ranging from 
rationale-based techniques such as computational modeling, sequence homology 
comparisons and structure-guided site-directed mutagenesis, to random approaches such 
as directed evolution (Antikainen and Martin, 2005). Directed evolution is a laboratory-
based bioengineering approach that utilizes the concept of Darwinian evolution to alter 
various macromolecular properties (Lutz and Patrick, 2004). The two key steps of 
directed evolution are generating molecular diversity followed by the use of a screening 
process to identify variants that display progressed fitness.  After several iterations of 
mutagenesis, screening and amplification of selected mutants with enhanced properties, 
beneficial mutations can accumulate in true Darwinian evolution (Jackel et al., 2008). In 





techniques, directed evolution is commonly exploited for engineering increased protein 
stability. Directed evolution is often preferred to other engineering strategies due to the 
level of diversification and size of the mutant pool screened. Moreover, neither structural 
information nor an understanding of the molecular mechanism for increased fitness are 
required to design and implement directed evolution experiments (Arnold et al., 2001; 
Cherry and Fidantsef, 2003; Eijsink et al., 2004; Lutz and Patrick, 2004; Matthews, 1995; 
Robertson and Steer, 2004; Schiraldi and De Rosa, 2002; Turner, 2003; van den Burg, 
2003; Vieille and Zeikus, 2001; You and Arnold, 1994; Zhao et al., 2002).  
 Here we aim to increase the stability of PlyC by means of directed evolution in 
order to extend the shelf life and thus improve the antimicrobial potential of the enzyme. 
We previously developed and validated a novel directed evolution protocol that first 
utilizes the error-prone polymerase chain reaction (epPCR) to randomly incorporate 
mutations into a bacteriolytic enzyme. This step is followed by an extensive screening 
process that effectively identifies mutations that improve the kinetic stability of a 
bacteriolytic enzyme, such as an endolysin, without compromising its native catalytic 
efficiency (Heselpoth and Nelson, 2012).  At the time, we screened a total of 6,000 PlyC 
mutants and presented experimental results to validate the protocol. Here, we extend the 
screening to 18,000 PlyC variants, kinetically and biophysically characterize the lead 
enzyme candidate, perform site-directed mutagenesis to elucidate the stabilizing 
mechanism, and finally combine these results with a point mutant from rational design 








Materials and Methods 
 
Bacterial Strains and Culture Conditions 
 S. pyogenes D471 (group A streptococcus) was stored at -80°C and routinely 
grown in THY (Todd Hewitt broth, 1% wt/vol yeast extract) at 37°C. E. coli strains 
DH5α, DH5α pBAD33: plyCB and BL21(DE3)pLysS (Novagen) were grown in Luria-
Bertani (LB) broth at 37°C in a shaking incubator unless otherwise stated. When needed, 
ampicillin (100 μg/ml) and/or chloramphenicol (35 μg/ml) were added to the media. 
 
Molecular Cloning of PlyC Structural and Directed Evolution Constructs 
 The plyC operon is composed of the structural gene for PlyCB, a non-coding 
intergenic locus termed the lysin intergenic locus, or lil, and the structural gene for 
PlyCA. plyCB and plyCA were cloned into pBAD24 as previously described (Nelson et 
al., 2006a). gyh was amplified with the forward primer 5’-
CTTCTTCAATTGATTATGAGTAAGAAGTATACACAACAACAATACG and 
reverse primer 5’-
CCCTCTAGATTAATGGTGATGATGATGATGAATTGAACCACCTG. chap was 
amplified with the forward primer 5’-
CTTCTTCAATTGATTATGTCACCAGGTCAAAACGATTTAGGGTCG and reverse 
primer 5’-CCCTCTAGATTATTTAAATGTTATCAAACCAGTTAGTG. plyCΔgyh was 
constructed by overlap extension PCR with three sets of primers. The first gene construct, 
plyCB+lil, was amplified with the forward primer 5’-





5’-CTTCTCTCTGTTAGCTTCCATTAAATAAATTCTCCCTTTC. The second gene 
construct, plyCAΔgyh, was amplified with the forward primer 5’-
GAAAGGGAGAATTTATTTAATGGAAGCTAACAGAGAGAAG and reverse primer 
5’-CCCTCTAGATTATTTAAATGTTATCAAACCAGTTAGTGTTG. plyCB+lil and 
plyCAΔgyh were then fused together with the forward primer 5’-
CTTCTTCAATTGATTATGAGCAAGATTAATGTAAACGTAG and reverse primer 
5’-CCCTCTAGATTATTTAAATGTTATCAAACCAGTTAGTGTTG to generate the 
full-length plyCΔgyh construct. plyCΔchap was amplified with the forward primer 5’-
CTTCTTCAATTGATTATGAGCAAGATTAATGTAAACGTAG and reverse primer 
5’-GGGTCTAGATTA AACGGTCGGTTTGTCTGGG. plyCΔΔ was amplified with the 
forward primer 5’-CTTCTTCAATTGATTATGAGCAAGATTAATGTAAACGTAG 
and reverse primer 5’-CCCTCTAGA 
TTAGTGATGGTGATGGTGATGCGATCCCTGTAAGTTAACATCAGC. The 
standard 50 μl PCR reaction mixture consisted of 1 ng of template (pBAD24: plyC for all 
constructs except for plyCΔΔ, which required the use of pBAD24: plyCΔgyh), 1x Q5 
reaction buffer (New England Biolabs), 0.2 mM dNTP mix, 0.5 μM of each primer and 1 
U of Q5 DNA polymerase (New England Biolabs). The thermocycler heating conditions 
consisted of 98°C for 30 s, 35x (98°C for 10 s; 60°C for 30 s; 72°C for 30 s/kb) and 72°C 
for 2 min. The PCR products were then double digested with MfeI and XbaI restriction 
endonucleases and ligated into pBAD24 using the EcoRI and XbaI restriction sites of the 
vector. 
 Site-directed mutagenesis was performed using the Phusion Site-Directed 





30 nucleotide forward phosphorylated oligonucleotide primer for each mutant, with the 
reverse primer being complimentary to the next 30 nucleotides upstream. The standard 50 
μl PCR reaction mixture consisted of 1 ng of pBAD24:plyC , 1x Phusion HF buffer, 0.2 
mM dNTP, 0.5 μM of each primer and 1 U of Phusion DNA polymerase. The 
thermocycler heating conditions consisted of 98°C for 30 s, 25x (98°C for 10 s; 65°C for 
30 s; 72°C for 4 min) and 72°C for 5 min. The mutagenized PCR products were then 
ligated and transformed into E. coli DH5α. Mutations were confirmed by nucleotide 
sequencing (Macrogen USA). 
 Error-prone PCR (epPCR) using Mutazyme II (Agilent Technologies) was 
applied to plyCA at a low mutation rate of 2-3 nucleotides per plyCA gene. The standard 
50 μl epPCR reaction mixture consisted of 3 μg of pBAD24: plyCA (750 ng of target 
DNA), 1x Mutazyme II reaction buffer, 0.2 mM dNTP mix, 0.5 μM of each primer 
(forward primer 5’-
CTTCTTCAATTGATTATGAGTAAGAAGTATACACAACAACAATACG and 
reverse primer 5’-CCCTCTAGATTATTTAAATGTTATCAAACCAGTTAGTGTTG) 
and 0.05 U of Mutazyme II DNA polymerase. The thermocycler heating conditions 
consisted of 95°C for 2 min, 30x (95°C for 30 s; 60°C for 30 s; 72°C for 2 min) and 72°C 
for 10 min. The mutant plyCA library was then double digested with MfeI and XbaI 
restriction endonucleases and ligated into pBAD24 using the EcoRI and XbaI restriction 
sites of the vector. The resulting pBAD24: plyCA mutant constructs were then 
transformed into E. coli DH5α harboring pBAD33: plyCB and then plated on LB agar 






Protein Expression and Purification 
 With the exception of the protein expression during directed evolution screening, 
all of the endolysin constructs investigated were initially expressed in E. coli 
BL21(DE3)pLysS. Bacterial cells were grown in 1.5L LB supplemented with ampicillin 
(100 µg/ml) to mid-log phase in a 4L Erlenmeyer flask. Protein expression was induced 
using 0.25% L-arabinose at 37°C for 4 h. Cells were then harvested at 7,000 RPM for 15 
min at 25°C, resuspended in 75 ml of phosphate buffered saline (PBS), pH 7.2, 
supplemented with 1 mM phenylmethanesulfonyl fluoride (Sigma-Aldrich), and 
sonicated on ice for 15 min. The insoluble cellular debris was pelleted at 13,000 RPM for 
1 h at 4°C. The soluble endolysin constructs were purified as previously mentioned 
(Nelson et al., 2001). Protein solubility and purity was analyzed on a 4-15% gradient 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gel (Laemmli, 
1970).  
 
Directed Evolution Genetic Diversification and Screening Methodology 
 The directed evolution methodology was previously described (Heselpoth and 
Nelson, 2012). Briefly, epPCR was applied to the PlyCA subunit of PlyC at a low 
mutation rate. The resulting mutant library was cloned into pBAD24 and transformed 
into E. coli DH5α pBAD33: plyCB. Thermostabilized PlyC mutants encoded by the 
transformants were subsequently identified using a novel, optimized screening 







Thermal Inactivation Experiments 
 Wild-type PlyC and various PlyC mutants were incubated in a 45°C heat block in 
PBS, pH 7.2-7.3, at a 44 nM (5 μg/ml) concentration for a total of 3 hours. At 20 minute 
increments, a 400 μl aliquot of the heated enzyme was removed and immediately 
incubated on ice for 5 minutes. Three adjacent wells of a 96-well microtiter plate were 
then filled with 100 μl of the cooled enzyme, followed by the addition of an equal volume 
of S. pyogenes D471. Streptococcal cells used in this study were grown as previously 
described (see Bacterial Strains and Culture Conditions), then harvested at 4,000 RPM 
for 15 minutes, washed once with PBS, pH 7.2-7.3, and resuspended in PBS buffer to an 
OD600 = 2.0. The residual lytic activity of the endolysin was analyzed via turbidity 
reduction assay by monitoring the OD600 every 6 s for 20 min. The activity of the 
endolysin was equated to the Vmax corresponding to linear portion of the resulting killing 
curve. Residual lytic activity was normalized to the activity displayed in the absence of 
heat treatment.  
 
Circular Dichroism (CD) Spectroscopy  
 Far-UV and thermal denaturation CD experiments were conducted using a 
Chirascan CD spectrometer (Applied Photophysics). To determine protein secondary 
structure composition, the various PlyC constructs were analyzed at 0.1 mg/ml in 20 mM 
sodium phosphate buffer, pH 7.0. Using a 1 mm path length quartz cuvette, far-UV CD 
spectra (190-260 nm) were taken at 20°C using 1 nm steps with 5 second signal 
averaging per data point. Spectra were collected in triplicate, followed by averaging, 





Pro-Data software (Applied Photophysics). Thermal denaturation experiments consisted 
of monitoring the MRE at 222 nm for the protein samples as they were heated from 20°C 
to 95°C at 1°C/min. Samples were at a 1 mg/ml concentration in 20 mM sodium 
phosphate buffer, pH 6.0-8.0, and the MRE was measured at 0.5°C steps with 5 s signal 
averaging per data point. The data was smoothened, normalized and fit with a Boltzmann 
sigmoidal curve. The first derivative of the denaturation curve was then taken to 
determine the temperature (T1/2) at which the folded and unfolded PlyCA subunit 
population was at equilibrium (Fallas and Hartgerink, 2012). 
 
Differential Scanning Calorimetry  
 The thermally-induced unfolding thermodynamics of the protein samples were 
measured using a Nano DSC differential scanning calorimeter (TA Instruments).  All 
samples were degassed for at least 20 minutes prior to the experiment and maintained at 3 
atm during calorimetric analysis. The sample and reference cells were initially calibrated 
with equal volumes of 20 mM sodium phosphate buffer, pH 6.0-8.0, using three 
consecutive heating/cooling cycles at 1°C/min consisting of a temperature range of 15°C 
to 105°C. The protein samples at 8.84 μM were heated from 15°C to 105°C at a 1°C/min 
heating rate in 20 mM sodium phosphate buffer, pH 6.0-8.0, and immediately cooled 
over the same temperature range at 1°C/min. Baseline subtraction and curve fitting was 
performed by the NanoAnalyze software (TA Instruments).  
 
Bacteriolytic Activity Quantitation against S. pyogenes 





of wild-type PlyC and PlyC (PlyCA) N211H. In a 96-well microtiter plate, the purified 
endolysin at an initial concentration of 8.84 µM (1 μg/µl) was two-fold serial diluted in 
100 μl of PBS, pH 7.2-7.3, buffer. An equal volume of S. pyogenes D471 (see Thermal 
Inactivation Experiments for cell preparation) was then mixed with the different enzyme 
concentrations and the OD600 was monitored by means of a turbidity reduction assay 
every 6 s for 30 min at 37°C. The amount of time (s) to decrease the ODmax by 50% was 
then plotted against the enzyme molar concentration and fit with a one-phase exponential 
decay curve. 1 U of enzyme activity was equated to the amount of endolysin (μg) 
required to decrease the ODmax by 50% in 15 min. Each independent turbidity reduction 
assay was performed in triplicate.  
 
Constructing Arrhenius Plots for Calculating Activation Energy of PlyCA Unfolding  
 The rate constant k for PlyCA unfolding was derived from the corresponding DSC 
thermograms using the equation 
k = vCp/(Qt-Q) 
where v (K/min) is the scan rate, Cp the excess heat capacity, Qt  the total heat of the 
process and Q the heat evolved at a given temperature, T. The activation energy, EA, is 
determined by measuring the value of k at several temperatures and then using the 
Arrhenius equation k = Aexp(-EA/RT). That is, the corresponding Arrhenius plot, ln k 
versus 1/T, is used to calculate EA by using the equation 
m = -EA/R 









Thermodynamic Analysis of the Structural Components of PlyC 
 Results from a previous DSC analysis of several PlyC constructs, including PlyC, 
PlyCB, PlyCA, CHAP domain only and PlyCAΔCHAP (in a PlyCΔCHAP background), 
advocated the CHAP domain being the most unstable structural element of PlyCA (F. 
Schwartz, personal communication). Preliminary observations from a more recent study 
suggested the CHAP and GyH domains (isolated or in the context of the holoenzyme) are 
thermodynamically similar. Without an obvious region to target, epPCR was applied to 
the entire PlyCA subunit during the initial round of directed evolution (Heselpoth and 
Nelson, 2012).  
To further confirm the absence of a specific region in PlyCA that is responsible for 
intrinsic instability of the subunit, a more complete thermodynamic analysis of the 
various structural components comprised by the PlyC holoenzyme was constructed. Eight 
different PlyC constructs (PlyC, PlyCA, PlyCB, GyH domain, CHAP domain, 
PlyCΔGyH, PlyCΔCHAP, PlyCΔΔ) were expressed and purified to homogeneity based 
on SDS-PAGE analysis (Fig. 4-1, Table 4-1). The protein samples were then subjected to 
TG analysis at equal molar concentrations by DSC in 20 mM sodium phosphate buffer pH 
7.0. Results from the calorimetric experiments show the complete unfolding of the PlyC 
holoenzyme fulfills a five-state thermal transition model, with the unfolding of PlyCA 
and PlyCB each displaying two thermal transitions. When the PlyCA N-terminal GyH 
















Figure 4-1. SDS-PAGE analysis of the PlyC structural constructs. The solubility and 
purity of each of the protein samples was analyzed on a 4-15% gradient SDS-PAGE gel. 
The various lanes correlate to: (M) Molecular weight standard, (1) PlyC holoenzyme 
(composed of a 50 kDa PlyCA and 8 x 8 kDa identical PlyCB subunits), (2) PlyCA, (3) 
PlyCB, (4) GyH domain, (5) CHAP domain, (6) PlyCΔGyH, (7) PlyCΔCHAP and (8) 
PlyCΔΔ (note, the 7 kDa helical docking domain of PlyCA is indistinguishable from the 









were highly similar, depicting a ΔTG of ±0.07°C (Table 4-2). When each individual 
domain is linked to the central helical docking domain of PlyCA and simultaneously 
complexed to the PlyCB octomer, PlyCAΔGyH (GyH deletion) was stabilized by 1.34°C 
while PlyCAΔCHAP (CHAP deletion) was conversely destabilized by 0.43°C when 
compared to the stability of full-length PlyCA (TG = 48.27°C) complexed to the CBD. 
When directly comparing the stability of PlyCAΔGyH to PlyCAΔCHAP when 
complexed to the PlyCB CBD, the ΔTG was ±1.77°C. A decisive unfolding thermal 
transition for the isolated central helical docking of PlyCA when bound to the PlyCB 
CBD was not detected in the temperature range tested and therefore a distinct thermal 
transition temperature could not be assigned to this structural component of PlyCA. Due 
to comparable stability profiles of the uncomplexed and complexed GyH and CHAP 
domains (ΔTG ≤ 2°C) coupled with the unknown stability of the central helical docking 
domain, the focus of epPCR step of the PlyC directed evolution study continued to be the 
entire PlyCA subunit.  
 
Directed Evolution Screening Synopsis 
 Overall, 18,000 PlyC mutants were screened for enhanced kinetic stability over a 
total of 3 rounds of directed evolution (Fig. 4-2). For round 1, the lead candidate and 
template for epPCR was wild-type plyCA. 6,000 mutants were screened at 35°C and 35 
candidates were chosen for re-screening in order to remove false positives and identify a 
lead candidate. The lead plyCA mutant candidate from round 1 was then subjected to 
epPCR and subsequently 75 mutant candidates were chosen for re-screening after 





Table 4-2. DSC TG comparative analysis of PlyCA (columns 2 and 3) and PlyCB 













Figure 4-2. Flowchart of the PlyC directed evolution methodology. A total of 18,000 
PlyC mutants were screened at non-permissive temperatures over three rounds of directed 
evolution followed. The four amino acid mutations comprised by the round 3 lead 
candidate were isolated, with the most kinetically stable construct being labeled as the 






mutant candidate from round 2 served as a template for epPCR for round 3 of directed 
evolution. Another 6,000 mutants were then screened at 45°C, with 60 candidates being 
identified for re-screening. The lead candidate at the conclusion of directed evolution was 
termed PlyC 33D2, which encodes the four PlyCA amino acid mutations N211H, S224N, 
G249C and A407S.  
 The kinetic stability PlyC 33D2 was further dissected to determine if one or more 
of the amino acid mutations encoded by the mutant were responsible for the stability 
enhancement. To answer this question, wild-type PlyC, PlyC 33D2 and the four 
individual 33D2 point mutants (N211H, S224N, G249C, A497S) were constructed, 
expressed and purified to homogeneity for kinetic stability analysis (Fig. 4-3, lanes 1-6). 
The purified enzymes were incubated at equal molar concentrations for a total of 3 hours 
at 45°C. The residual activity was determined at 20 minute increments and normalized to 
the activity displayed when the sample was devoid of heat-treatment. At 45°C, the PlyC 
33D2 mutant displays a half-life (t1/2) of 44.59 min, which correlates to a 2.5 fold increase 
in kinetic stability when compared to the 17.84 min t1/2 of wild-type PlyC (Fig. 4-4a, 
Table 4-3). When four 33D2 point mutations were isolated, mutants S224N, G249C and 
A407S displayed similar t1/2 values. None of the three mutants were able to fully rescue 
the kinetic stability phenotype displayed by the PlyC 33D2 mutant (Fig. 4-4b, Table 4-3). 
Nonetheless, all three mutants displayed kinetic stability phenotypes that represented 
marginable improvements over wild-type. Conversely, the N211H mutation significantly 
improved the kinetic fitness of the enzyme nearly 19 fold, raising the t1/2 from 17.84 min 
to an extrapolated 335.04 min. When directly comparing the stability of 33D2 to the 







Figure 4-3. SDS-PAGE analysis of PlyC 33D2 constructs and PlyC (PlyCA) N211 
charge mutants. The solubility and purity of each of the mutants was analyzed on a 4-
15% gradient SDS-PAGE gel. The various lanes correlate to: (M) Molecular weight 
standard, (1) PlyC, (2) PlyC 33D2, (3) PlyC (PlyCA) N211H, (4) S224N, (5) G249C, (6) 

















Figure 4-4. Kinetic stability of the directed evolution round 3 lead candidate, PlyC 
33D2, and the isolated PlyC 33D2 point mutations. The rate of kinetic inactivation of 
wild-type PlyC at 45°C was compared to that of either (a) the round 3 lead candidate 
PlyC 33D2 or (b) the individual point mutants encoded by the PlyC 33D2 mutant. The 
enzymes were incubated at equal molar concentrations in PBS, pH 7.2-7.3, with the 







Table 4-3. Kinetic stability comparison at 45°C between wild-type PlyC, PlyC 33D2 






















This suggests that in a PlyC (PlyCA) N211H background, the combination of the N211H 
mutation with one or more of the other pre-existing 33D2 mutations is destabilizing. As a 
result, PlyC (PlyCA) N211H served as the final directed evolution lead candidate for 
further analysis. 
 
Structural and Thermodynamic Stability of the Directed Evolution Lead Candidate 
 The structural and thermodynamic stability of both wild-type PlyC and PlyC 
(PlyCA) N211H were next investigated. CD thermal denaturation experiments revealed 
both wild-type PlyC and PlyC (PlyCA) N211H display a single PlyCA unfolding 
structural transition corresponding to a T1/2 of 50.09°C and 51.61°C, respectively (Fig. 4-
5a). These results dictate that the N211H point mutant improved the structural stability of 
PlyCA by 1.52°C. DSC analysis of each holoenzyme confirmed the findings from the CD 
experiments, with PlyCA N211H (TG = 50.26°C, van’t Hoff enthalpy of unfolding 
(ΔHVH) = 199.25 kcal/mol) displaying a respective TG and ΔHVH increase of 1.99°C and 
28.02 kcal/mol when compared to wild-type PlyCA (TG = 48.27°C, ΔHVH = 171.23 
kcal/mol) (Fig. 4-5b). In addition to exhibiting intensified kinetic stability, results from 
two independent biophysical experimental approaches suggest that PlyC (PlyCA) N211H 
has enhanced structural and thermodynamic stability when compared to wild-type.  
 
Protonated H211 Employs a Charge-Mediated Stabilizing Mechanism 
 While biochemical and biophysical experiments demonstrated that the N211H 
mutation improved PlyCA thermal stability, it is unknown how this particular point 







           
 
Figure 4-5. Biophysical thermal analysis of wild-type PlyC and PlyC (PlyCA) 
N211H. The structural and thermodynamic stability of both holoenzymes were 
characterized at equal molar concentrations by (a) CD thermal denaturation experiments 
or (b) DSC in 20 mM phosphate buffer, pH 7.0, using a heating rate of 1°C/min. The 








Considering the mutation consisted of substituting an asparagine with a histidine, and 
hence, replacing a polar neutral amino acid with a polar basic amino acid, we 
hypothesized that the possible addition of the protonated side-chain of the histidine at this 
particular structural location within PlyCA could be increasing the stability of the subunit 
in a charge-mediated manner.  
 To first test this hypothesis, we performed a charge-dependent kinetic stability 
analysis focusing on residue 211 of PlyCA. The three mutants analyzed, PlyC (PlyCA) 
N211A (neutral charge), N211K (positive charge) and N211D (negative charge), were 
expressed and purified to homogeneity based on SDS-PAGE analysis (Fig. 4-3, lanes 7-
9). The neutral charge mutant PlyC (PlyCA) N211A displayed a t1/2 at 45°C that mimics 
the kinetic stability exhibited by wild-type (Fig. 4-6, Table 4-4). The positively charged 
mutant PlyC (PlyCA) N211K, which resembles the charge properties of the N211H point 
mutant, was kinetically stabilized 14.5 fold over wild-type. Reversing the charge of the 
residue 211 side-chain with the point mutation PlyC (PlyCA) N211D was significantly 
deleterious, decreasing the kinetic stability 2.5 fold when compared to wild-type. 
Therefore, replacing N211 with a positively charged basic amino acid at residue position 
211, such as N211H and N211K, improves the overall kinetic fitness of the catalytic 
subunit at elevated temperatures in a charge-dependent fashion.  
 To further establish the charge-dependence for stability, we investigated the 
structural and thermodynamic stability of the various charge mutants. Results from CD 
thermal denaturation experiments of PlyC (PlyCA) N211A, N211K and N211D produced 
ΔT1/2 values of +0.01°C, +1.12°C and -3.99°C, respectively, when compared to the 







Figure 4-6. Kinetic half-life calculation for charge-specific PlyC (PlyCA) N211 
mutants. The rate of kinetic inactivation at 45°C was elucidated for the mutants PlyC 
(PlyCA) N211A, N211K and N211D. The enzymes were incubated at equal molar 
concentrations in PBS, pH 7.2-7.3, with the residual lytic activity being analyzed every 







































      
Figure 4-7. CD and DSC thermal analysis of charge-specific PlyC (PlyCA) N211 
mutants. The structural and thermodynamic stability of PlyC (PlyCA) N211A, N211K 
and N211D were determined at equal molar concentrations by (a) CD thermal 
denaturation experiments or (b) DSC in 20 mM phosphate buffer, pH 7.0, using a heating 
rate of 1°C/min. The structural and thermal transitions depicted correspond to the 







Table 4-5. Thermal stability associated with the different N211 charge mutants of 
PlyCA as explicated by means of CD thermal denaturation experiments (columns 2 








mutants supports the findings of the CD thermal denaturation experiments. The 
thermally-induced PlyCA unfolding thermal transitions for PlyC (PlyCA) N211A, 
N211K and N211D consisted of a respective ΔTG values of -0.49°C, +1.34°C and -
3.08°C and a Δ(ΔHVH) of +15.15 kcal/mol, -0.26 kcal/mol and -54.01 kcal/mol. (Fig. 4-
7b, Table 4-5). Collectively, the CD and calorimetric results suggest that the increased 
structural and thermodynamic stability of PlyC (PlyCA) N211H is mediated through a 
charge-dependent mechanism. 
 Considering PlyC (PlyCA) N211H improves the stability of the enzyme due to the 
cationic properties of the protonated H211 side-chain, we hypothesized that altering the 
protonated state of this residue will have significant implications on stability. To address 
this hypothesis, we analyzed the structural and thermodynamic stability of both wild-type 
PlyC and PlyC (PlyCA) N211H in 20 mM phosphate buffer, pH 6.0-8.0. At pH 6.0, 
which represents the pH environment in our study where the mutated PlyCA N211H 
side-chain is at its most protonated state, CD thermal denaturation results showed that 
PlyCA N211H exhibits a ΔT1/2 of +3.45°C when compared to wild-type PlyC (Fig. 4-8a). 
Results from CD thermal denaturation experiments at pH 6.5, 7.0, 7.5 and 8.0 revealed 
that PlyC (PlyCA) N211H consisted of a respective ΔT1/2 of +3.28°C, +1.52°C, +0.19°C 
and +0.06°C. The same trend was observed after carrying out calorimetric experiments at 
pH 6.0-8.0. At pH 6.0, PlyC (PlyCA) N211H displayed a ΔTG1 and ΔHVH1 of +4.10°C 
+19.97 kcal/mol and a ΔTG2 and ΔHVH2  of +4.44°C and +29.58 kcal/mol over wild-type 
(Fig. 4-8b and c). When compared to the TG values of wild-type PlyCA at pH 6.5, 7.0, 7.5 
and 8.0, the PlyCA N211H ΔTG1 is +3.20°C, +1.99°C, +0.48°C and +0.21°C, while the 

















Figure 4-8. pH-dependent thermal stability of wild-type PlyC and PlyC (PlyCA) 
N211H. The stability of the two endolysins was investigated as a function of pH using 
biophysical thermal analysis. Equal molar concentrations of the enzymes were heated at a 
1°C/min rate in 20 mM phosphate buffer, pH 6.0-8.0. The resulting (a) CD thermal 
denaturation data, (b) overlaid DSC thermograms and (c) TG vs pH plots specific to the 







PlyC (PlyCA) N211H increasingly mimics that of wild-type as you increase the pH of the 
system as a direct result of transitioning the H211 side-chain from a positive to neutral 
charged state. 
 
H211 Electrostatically Interacts with E113 and D150 of the GyH Domain  
 Experimental results suggest the protonated H211 side-chain of the PlyC (PlyCA) 
N211H mutant is stabilizing the catalytic subunit, but it remains elusive how the positive 
charge at this particular location within the structure is stabilizing. One possibility is 
H211, which is located at the beginning of the flexible linker structure that interconnects 
the N-terminal GyH domain to the central helical docking domain (Fig. 4-9a and b), is 
forming a favorable electrostatic interaction with another localized amino acid residue. 
With this in mind, three acidic amino acids (E113, D150 and D208) within a 10-15 Å 
radius of H211 were identified as potential electrostatic interaction partners (Fig. 4-9c).  
 To determine if E113, D150 or D208 forms a stabilizing charge-mediated 
interaction with H211 of PlyCA, a mutational CD and DSC thermal analysis was 
undertaken. The PlyC (PlyCA) E113A, D150A and D208A point mutants in a ± N211H 
background were expressed and purified to homogeneity based on SEC (data not shown) 
and SDS-PAGE analysis (Fig. 4-10, lanes 1-6). The CD and DSC heating experiments 
consisted of two steps. The first step involves analyzing the thermal stability of PlyC 
(PlyCA) E113A, D150A and D208A. The next step consisted of inserting the N211H 
mutation into a PlyC (PlyCA) E113A, D150A or D208A background to determine 
whether the N211H could provoke the same augmentation in structural and 
























































Figure 4-9. Modeling H211 into the 3.3-Å crystal structure of PlyC. The PlyC 
holoenzyme structure consists of eight identical PlyCB monomers that interact to form 
the octomeric CBD structure (a, gray). The N-terminal GyH domain (blue) of the PlyCA 
subunit is linked to a central helical docking domain (a, yellow). The carboxyl end of the 













residue (pink sticks) was modeled into the PlyCA subunit and was shown superimposed 
with the endogenous N211 residue (green sticks). The superimposed H211 residue is 
shown (a) macroscopically with the holoenzyme viewable or (b) zoomed-in on the N-
terminal region of PlyCA. The hypothesized β-carbon side-chain distance between H211 
and the three nearby acidic residues in the GyH domain that are hypothesized to 


















Figure 4-10. SDS-PAGE analysis of the putative H211 electrostatic interaction 
mutants. The solubility and purity of each of the construct was analyzed on a 4-15% 
gradient SDS-PAGE gel. The various lanes correlate to: (M) Molecular weight standard, 
(1) PlyC (PlyCA) E113A, (2) E113A N211H, (3) D150A, (4) D150A N211H, (5) 















from CD thermal denaturation experiments showed that PlyC (PlyCA) E113A, D150A 
and D208A displayed PlyCA T1/2 values of 49.34°C, 50.76°C and 50.91°C, respectively 
(Fig. 4-11a, b and c). When the N211H mutation was added to these three mutants, 
PlyCA was stabilized by 0.92°C, 0.80°C and 1.31°C, respectively (Fig. 4-11a, b and c). A 
similar trend was observed when using DSC to analyze the thermodynamic stability of 
the aforementioned mutants. Adding N211H to PlyC (PlyCA) E113A, D150A or D208A 
increased the respective TG values of PlyCA by 0.60°C, 0.39°C and 1.86°C.  With PlyC 
(PlyCA) N211H displaying improvements in PlyCA T1/2 and TG of 1.52°C and 1.99°C 
over wild-type PlyC, mutating the D208 residue had little effect on the stabilizing 
potential of H211. Alternatively, while H211 could still improve the stability of PlyCA in 
an E113A or D150A background, the absence of either acidic residue significantly 
impeded the full stabilizing potential of H211.  
 Collectively, results from the thermal analysis imply that while E113, D150 and 
D208 all seem to electrostatically interact with H211, the PlyCA subunit is mainly 
stabilized by the simultaneous additive electrostatic interactions formed between E113-
H211 and D150-H211. To determine if this is true, the effect of H211 on PlyCA stability 
was evaluated in an E113A D150A background. The double mutant PlyC (PlyCA) 
E113A D150A and triple mutant PlyC (PlyCA) E113A D150A N211H were expressed 
and purified to homogeneity based on SDS-PAGE analysis (Fig. 4-10, lanes 7-8). 
Elucidating the structural stability of PlyC (PlyCA) E113A D150A and E113A D150A 
N211H by CD thermal denaturation experiments revealed both constructs encompass 
comparable PlyCA T1/2 values of 50.72°C and 50.69°C, respectively (Fig. 4-11d).  DSC 










Figure 4-11. Structural stability determination for the acidic amino acid candidate 
mutants in a ± N211H background. CD thermal denaturation experiments were 
conducted to determine the structural stability of (a) PlyC (PlyCA) E113A, (b) D150A, 
(c) D208A and (d) E113A D150A in a ± N211H background. All experiments were 
performed at equal molar concentrations in 20 mM phosphate buffer, pH 7.0, using a 










(PlyCA) E113A D150A N211H exhibiting a near identical PlyCA TG of 47.52°C and 
47.59°C, respectively. Therefore, without the presence of both E113 and D150, the H211 
has no effect on the structural or thermodynamic stability of PlyCA.  
 
Bacteriolytic Activity Comparison Between Wild-type PlyC and PlyC (PlyCA) N211H 
 An inverse relationship between activity and stability is commonly observed 
when engineering progressed thermal stability to macromolecules, especially at reduced 
temperatures. The activity displayed by thermophilic enzymes at lower temperatures is 
regularly compromised when compared to their psychrophilic or mesophilic homologs 
(Giver et al., 1998; Meiering et al., 1992; Shoichet et al., 1995; Somero, 1975). To 
overcome an unwanted activity-stability trade-off, the screening component of the 
directed evolution protocol was designed to identify kinetically stabilized bacteriolytic 
enzyme variants that retain their original catalytic efficiency.  
 To confirm the bacteriolytic activity of the thermostabilized PlyC (PlyCA) 
N211H mutant was comparable to that of wild-type, serial dilutions of each enzyme were 
prepared and measured for lytic activity against S. pyogenes by means of turbidity 
reduction assay (Fig. 4-12). The time (s) to decrease the ODmax by 50% for each enzyme 
at the various molar concentrations tested were nearly identical, correlating to lytic 
activities of 45350 and 51950 U/ml for wild-type PlyC and PlyC (PlyCA) N211H, 
respectively. The introduction of the N211H mutation to PlyCA did not result in any loss 









Figure 4-12. Bacteriolytic activity evaluation against S.pyogenes in vitro. The lytic 
activity of wild-type PlyC and PlyC (PlyCA) N211H against S. pyogenes D471 in PBS, 
pH 7.2-7.3, was compared by means of turbidity reduction assay. The time (s) at which 
the ODmax was reduced by 50% was plotted against the corresponding enzyme 














Combining Beneficial Mutations from Different Engineering Approaches is Additively 
Thermostabilizing 
 Previously we reported results from a computational-based bioengineering study 
where we utilized the FoldX and Rosetta protein folding algorithms to successfully 
improve the thermal stability of PlyC (Chapter II). The identified CHAP domain point 
mutant T406R thermostabilized the PlyCA subunit by ≥ 2.2°C in 20 mM sodium 
phosphate buffer, pH 7.0, translating to a 21.45 kcal/mol improvement in ΔHVH, an 11 
kcal/mol progression in the EA of PlyCA unfolding and a 16 fold decrease in kinetic 
inactivation at 45°C. H211 and its hypothesized electrostatic interaction partners, E113 
and D150, are located independently within PlyCA when compared to R406 and its 
predicted inter-domain hydrogen bonding partner Q106 (Fig. 4-13). With this in mind, 
we next investigated whether combining PlyC (PlyCA) N211H and PlyC (PlyCA) T406R 
could have additive ramifications on the thermal stability of PlyC. 
 Wild-type PlyC, PlyC (PlyCA) N211H and PlyC (PlyCA) N211H T406R were 
expressed and purified to homogeneity based on SDS-PAGE analysis (Fig. 4-14a). The 
thermodynamic stability of the three enzymes was analyzed at equal molar concentrations 
by DSC in 20 mM sodium phosphate buffer, pH 6.0. As described previously, the N211H 
mutant improved the respective TG and ΔHVH values by 4.1°C  and 19.97 kcal/mol at pH 
6.0 when compared to wild-type (Fig. 4-8 and 4-14b, Table 4-6). Combining the N211H 
and T406R mutations had additive effects with respect to the thermodynamic stability of 
the enzyme, enhancing the TG and ΔHVH of the double mutant by 7.46°C and 22.60 
kcal/mol when compared to wild-type, respectively (Fig. 4-14b). The double mutant also 








Figure 4-13. Modeling H211 and R406 into the PlyCA subunit. The H211 residue 
(pink sticks, top) was modeled into the linker structure stemming from the GyH domain 
(blue), with the proposed electrostatic interactions with E113 and D150 (green sticks, 
top) depicted. The R406 residue (pink sticks, bottom) was modeled onto the surface of 
the CHAP domain (red), with the hypothesized inter-domain hydrogen bond with Q106 

















Figure 4-14. Thermodynamic and kinetic stability of PlyC (PlyCA) N211H T406R. 
The solubility and purity of wild-type PlyC (a, lane 1), PlyC (PlyCA) N211H (a, lane 2) 
and N211H T406R (a, lane 3) were analyzed on a 4-15% gradient SDS-PAGE gel. The 
thermodynamic stability of wild-type PlyC (b, black trace), PlyC (PlyCA) N211H (b, 
blue trace) and N211H T406R (b, red trace) was dissected by DSC in 20 mM phosphate 
buffer, pH 6.0, using a heating rate of 1°C/min. The unfolding of the PlyCA subunit is 
shown. Using the PlyCA calorimetric data, the rate constant (k) for was calculated for the 





) to generate Arrhenius plots for elucidating PlyCA EA values of unfolding. 
The Arrhenius plot for the catalytic subunits for wild-type PlyC (c, black), PlyC (PlyCa) 



















Table 4-6. Calorimetric (columns 2-5) and kinetic (columns 6 and 7) stability 


























 Next, the unfolding kinetics of PlyCA were elucidated by constructing Arrhenius 
plots using the PlyCA calorimetric data from wild-type PlyC, PlyC (PlyCA) N211H and 
PlyC (PlyCA) N211H T406R. The natural log of the rate constant, k, was plotted against 
the inverse of the temperature to determine the EA of PlyCA unfolding. When compared 
to wild-type PlyC at pH 6.0, the N211H mutation increased the EA of PlyCA unfolding by 
17.52 kcal/mol (Fig. 4-14c, Table 4-6). The N211H T406R double mutant had additive 
implications on the kinetic fitness of the holoenzyme, improving the respective EA of 




 Meager inherent thermal stability appears to be a common characteristic 
associated with endolysins derived from mesophilic bacteriophage (Bustamante et al., 
2012; Filatova et al., 2010; Sanz et al., 1993; Varea et al., 2004). With a long-term goal 
of developing these enzymes as a translational antimicrobial for industrial application, the 
Arrhenius equation advocates the poor structural stability of endolysins correlates to 
transient shelf life expectancy, thereby impeding the feasibility of furthering the 
development of the antimicrobial (Anderson and Scott, 1991). Despite exhibiting a highly 
robust bacteriolytic mechanism and being validated in vitro and in vivo against a variety 
of streptococcal species known to generate both human and animal health complications 
(Hoopes et al., 2009; Nelson et al., 2001; Nelson et al., 2006a), the thermolabile structure 
of the streptococcal endolysin PlyC hinders its antimicrobial potential due to the 48.27°C 





 The lead candidate at the summation of directed evolution screening was the point 
mutant PlyC (PlyCA) N211H. The H211 residue is located at the beginning of the linker 
structure that interconnects the N-terminal GyH domain to the central helical docking 
domain (Fig. 4-9a and b). This mutation increased the kinetic stability of the enzyme 18.8 
fold at 45°C in PBS, pH 7.2-7.3 (Fig. 4-4b), and improved the TG by 4.10°C and the EA of 
PlyCA unfolding by 17.52 kcal/mol in 20 mM phosphate buffer, pH 6.0 (Fig. 4-8b and c, 
Fig. 4-14c). Moreover, the PlyC (PlyCA) N211H mutant did not manifest any reduction 
in bacteriolytic activity when compared to wild-type PlyC (Fig. 4-12). This was an 
important finding because there is typically a significant trade-off between enzymatic 
activity and thermal stability when thermostabilizing proteins (Arnold et al., 2001; 
Beadle and Shoichet, 2002; Giver et al., 1998; Meiering et al., 1992; Mukaiyama et al., 
2006; Yutani et al., 1987). 
 Based on side-chain distance estimations, there were three initial acidic amino 
acid candidates (E113, D150 and D208) that could feasibly interact electrostatically with 
the protonated H211 side-chain. While other electrostatic interactions with H211 could be 
stabilizing, such as alpha helical dipole, solvation and van der Waals interactions, we 
simplistically hypothesized for these experiments that an electrostatic attraction between 
H211 and a nearby anionic acidic residue could be the primary molecular interaction 
responsible for the improved thermal stability of the directed evolution lead candidate. 
The similar ΔT1/2 values depicted by PlyC (PlyCA) N211H (when compared to wild-
type) (Fig. 4-5a) and PlyC (PlyCA) D208A N211H (when compared to PlyC (PlyCA) 
D208A) (Fig. 4-11c) ultimately eradicated D208 as a primary stabilizing electrostatic 





with each other; however most significant stabilization effects are greatest when the two 
interacting residues are distant in sequence. If D208 and N211H are indeed interacting, 
the close sequence proximity of the two would have little effect on the global stability of 
the PlyCA subunit. Adding N211H to a PlyC (PlyCA) E113A or D150A background 
only partially restored the ΔT1/2 value exhibited by PlyC (PlyCA) N211H over wild-type 
(Fig. 4-5a, 4-11a and b). When both E113 and D150 were simultaneously mutated, H211 
had no effect on the structural (Fig. 4-11d) or thermodynamic stability (data not shown) 
when added to a PlyC (PlyCA) E113A D150A background. This finding infers both E113 
and D150 electrostatically interact with H211 to considerably intensify the thermal 
stability of PlyCA in an additive manner. The electrostatic fields formed between the 
cationic H211 and the anionic E113 and D150 residues most likely anchored a segment 
of the linker to the surface of the GyH domain. As a result, the enthalpic gains associated 
with this molecular reorganization could account for the improvement in thermal 
stability. 
 While the formation of an electrostatic field between E113-H211 and D150-H211 
seems to be the likely mechanism of stabilization, the possibility of a salt-bridge 
interaction between either E113-N211H or D150-N211H cannot be completely ruled out. 
Although the estimated distance between E113-N211H and D150-N211H are 
comparable, a salt-bridge interaction between D150-N211H is improbable because D150 
is not as flexible as E113 and appears to have an unfavorable structural conformation. 
Conversely, E113 could possibly form a salt-bridge given the normal torsional freedom 





 Combining the mutation comprised by the directed evolution lead candidate, 
N211H, with the mutation derived from the lead candidate from a previous rationale-
based in silico screen (Chapter II), T406R, had additive effects on the thermal stability of 
the enzyme (Fig. 4-13 and 4-14, Table 4-7). While the N211H mutation appears to 
improve the stability of PlyCA by promoting favorable electrostatic interactions in the N-
terminal region of the subunit, the C-terminal CHAP domain T406R mutation was 
hypothesized to stabilize PlyCA through the formation of an inter-domain hydrogen bond 
with Q106 of the N-terminal GyH domain (Chapter II). The PlyC (PlyCA) N211H 
T406R double mutant featured TG, ΔHVH and PlyCA unfolding EA improvements over 
wild-type PlyC and PlyC (PlyCA) N211H of 7.46°C, 22.60 kcal/mol, 28.72 kcal/mol, and 
3.36°C, 2.63 kcal/mol, 11.20 kcal/mol at pH 6.0, respectively. This finding was not 
unexpected because the different stabilizing mechanisms employed by H211 and R406 
would be seemingly unaffected when both mutations were simultaneously present due to 
the independent locations and unique interaction partners associated with the two 
mutations. 
 Using the PlyC X-ray crystal structure as a guide (McGowan et al., 2012), future 
rationale-based engineering efforts could be implemented to further stabilize PlyCA. 
Seeing as H211 possibly improved the thermal fitness of PlyCA through electrostatic 
interactions with E113 and D150, these charge-based interactions can be substituted with 
a stronger, more enthalpically favorable covalent interaction. An inter-domain covalent 
bond could also be engineered to replace the hypothesized stabilizing hydrogen bond 
formed between Q106 of the GyH domain and R406 of the CHAP domain. Alternative 





glycine → alanine or Xxx → proline mutations, inserting intra-domain disulfide bonds 
and salt-bridges, “helix capping” by introducing amino acids that interact with the alpha-
helix dipole, replacing residues in left-handed helical structures with glycine or 
asparagines, or engineering clusters of aromatic-aromatic interactions (Anderson et al., 
1993; Burley and Petsko, 1985; Clarke and Fersht, 1993; Kawamura et al., 1996; Kimura 
et al., 1992; Makhatadze et al., 2003; Mansfeld et al., 1997; Marshall et al., 2002; 
Matsumura et al., 1989; Matthews et al., 1987; Nicholson et al., 1991; Nicholson et al., 
1988; Pace et al., 2000; Puchkaev et al., 2003; Sali et al., 1988; Schwehm et al., 2003; 
Serrano et al., 1991; Serrano and Fersht, 1989; Serrano et al., 1990; Strop and Mayo, 
2000; Sun et al., 1991; Waldburger et al., 1995).  
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 The CDC conservatively estimates that antibiotic-resistant bacteria annually cause 
at least 2 million illnesses and 23,000 deaths domestically, with combined national 
economic ramifications totaling $55 billion (Roberts et al., 2009). The morbidity and 
mortality affiliated with these microorganisms will increase as drug-resistance 
continuously becomes more prevalent. In addition to the persistent loss in antimicrobial 
efficacy, antibiotic use has instigated illnesses and deaths associated with a number of 
opportunistic pathogens. For instance, the nonspecific killing of commensal bacteria that 
comprise the colonic microflora by broad spectrum antibiotics has directly aided to the 
pathogenicity of C. difficile, a microorganism that causes 250,000 illnesses and 14,000 
deaths annually in the United States. Consequently, the CDC has assigned C. difficile as 
an urgent threat to human health.   
 Endolysins derived from lytic phage have been shown experimentally to be 
suitable alternative chemotherapeutics to classical antibiotics. The antimicrobial efficacy 
of these enzymes have been demonstrated in vitro and/or in vivo against a variety of 
Gram-positive pathogens (e.g. L. monocytogenes, S. aureus, S. pneumoniae, S. pyogenes, 
B. anthracis, etc.) known to cause serious health complications and economic distress. 
The uses of endolysins have been implicated for a variety of applications, including 
medicine, food safety and agriculture. Unlike antibiotics, resistance to these translational 





sensitive and –resistant bacterial species susceptible to these enzymes. Moreover, the 
high specificity of the CBD modules of endolysins allows them to be utilized in 
antimicrobial strategies that only target pathogenic bacteria of interest. This prevents 
toxicity issues that arise from indirect harming of the commensal microflora and 
eukaryotic cells and hence removes the possibility of obtaining antimicrobial-induced 
secondary infections. 
 As antibiotic resistance becomes more widespread, the pressure to transition 
endolysins from discovery to the developmental phase will to continue to expand in 
parallel. An assortment of engineering techniques explicit to optimizing the therapeutic 
potential of these enzymes has been described in the literature. Rationale-based 
engineering techniques, such as chimeragenesis (Croux et al., 1993b; Diaz et al., 1990) 
and structure-guided SDM (Low et al., 2011; Resch et al., 2011b), and random 
techniques, like directed evolution (Cheng and Fischetti, 2007), have been demonstrated 
to effectively enhance the catalytic kinetics and/or alter lytic specificity and biochemical 
characteristics (pH-, salt- and divalent cation-dependence) of endolysin EADs. 
Importantly, constructing chimeric endolysins with multiple EADs encompassing 
different peptidoglycan cut site specificities is an engineering strategy currently being 
employed to reduce the risk of bacterial resistance formation. Endolysin CBDs are also 
being subjected to chimeragenesis (Croux et al., 1993a; Diaz et al., 1991; Donovan et al., 
2006a; Schmelcher et al., 2011) and structure-guided SDM (Diez-Martinez et al., 2013) 
for the purpose of improving binding kinetics and modifying endolysin catalysis and 





 Besides properties attributable to the catalysis and binding of these enzymes, 
structural thermal stability is another characteristic associated with endolysins that is 
critical to their antimicrobial potential and development. In correspondence with the 
Arrhenius equation, which relates the rate of a chemical reaction to activation energy and 
temperature, the stability of a macromolecule directly equates to shelf life (Anderson and 
Scott, 1991). Elucidating the thermal properties of several Gram-positive endolysins 
derived from mesophilic phages revealed these enzymes appear to be relatively unstable 
and thus possess transient shelf life expectancies (Bustamante et al., 2012; Filatova et al., 
2010; Sanz et al., 1993; Varea et al., 2004). While the intrinsic thermolability is an 
obvious trend for the several endolysins that have been thermally characterized, this list is 
far from extensive and thus currently assigning instability as a universal property to all 
endolysins would not be statistically justified. Furthermore, there are examples of Gram-
positive endolysins derived from mesophilic phage that are thermodynamically and/or 
kinetically stable. For example, heating experiments involving four different Listeria 
endolysins revealed that several of these enzymes were kinetically thermoresistant (Fig. 
5-1). Three of the four endolysins exhibited > 50% residual lytic activity after 50°C 
incubation (HPL118, HPL500 and HPL511; Fig. 5-1a, b and c) and remained 
catalytically active after incubating at 90°C (HPL118, HPL511 and HPLP35; Fig. 5-1a, b 
and d). In a set of experiments specific to elucidating the thermal characteristics of the B. 
anthracis endolysin PlyG, thermodynamic analysis of PlyG by means of DSC showed the 
enzyme irreversibly unfolds to fit a three-state thermal transition model, with a 
thermostable TG of 63.53°C (Fig. 5-2a). In addition, heating PlyG for 10 minutes in pH 







Figure 5-1. Kinetic stability of different Listeria endolysins. L. monocytogenes 
endolysins (a) HPL118, (b) HPL500, (c) HPL511 and (d) HPLP35 were incubated at 
different temperatures for 5, 10 or 30 minutes, cooled on ice and then assayed for residual 
activity by means of turbidity reduction assays. Lytic activity values are expressed 










Figure 5-2. Thermodynamic and kinetic stability of B. anthracis endolysin PlyG. (a) 
The thermodynamics of PlyG were investigated using DSC. The enzyme at 0.5 mg/ml 
was heated in 20 mM sodium phosphate buffer pH 6.0 from 15°C to 105°C at 1°C/min. 
(b) PlyG in 50 mM sodium phosphate buffer pH 6.0-8.0 supplemented with 200 mM 
NaCl and 10 mM tris-(2-carboxyethyl)phosphine (TCEP) was heated at various 
temperatures for 10 minutes, cooled on ice and then assayed for residual lytic activity by 
turbidity reduction assay. Data was normalized to the activity displayed by the unheated 
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well as 18% activity after being heated-treated at 100°C (Fig. 5-2b). Nevertheless, when 
collectively comparing the stability of endolysins that have been at least partially 
thermally characterized, endolysins like PlyG and the several thermoresistant Listeria 
endolysins (HPL118, HPL500, HPL511, HPLP35) appear to be evolutionary outliers. 
Overall, a number of characterized thermolabile endolysins with validated antimicrobial 
efficacy exist (e.g. Cpl-1, Pal, Cpl-7 and PlyC), with more undoubtedly being discovered 
in the coming years. To this end, effective strategies geared towards thermostabilizing 
bacteriolytic enzymes are needed from a commercialization perspective. 
 Prior to the bioengineering studies mentioned in Chapters II-IV in this 
dissertation, there were no published studies definitive to the discipline of modifying the 
structure of peptidoglycan hydrolases (i.e. endolysins, autolysins and exolysins) to 
improve stability. Thermodynamic characterization of PlyC in 2008 revealed that, while 
the CBD of the enzyme (i.e. the PlyCB octomer) exhibited a TG of 75.0°C and thus was 
endogenously thermostable, the EAD (i.e. PlyCA) was relatively unstable, comprising a 
TG of 46.2.0°C. Results from comparing the thermodynamics of the isolated C-terminal 
CHAP domain of the EAD to that of PlyCAΔCHAP in a PlyCΔCHAP background 
suggested the CHAP domain was the most heat-susceptible structural constituent of 
PlyCA. With concentration on the thermosusceptible EAD of the streptococcal endolysin 
PlyC, the work presented in this dissertation focuses on independently subjecting a phage 
endolysin to two established protein engineering methodologies with the overall goal of 
increasing the stability. Using the 2008 PlyC thermodynamic data in combination with 
the solved X-ray crystal structure of the holoenzyme as a guide, the first engineering 





that utilized the FoldX and Rosetta protein folding algorithms to identify 
thermodynamically beneficial mutations to the C-terminal CHAP domain of the catalytic 
subunit of PlyC (Chapter II). Next, a novel directed evolution protocol was constructed 
specific to thermostabilizing bacteriolytic enzymes, with PlyC being used as the enzyme 
of choice (Chapter III). Preliminary results from a more recent (2012) and thorough 
thermodynamic analysis of PlyC suggested that the N-terminal GyH and C-terminal 
CHAP domains had similar thermal properties.  Without an obvious region of PlyCA to 
focus on, the entire PlyCA subunit was targeted when initially constructing this novel 
directed evolution protocol. Once the random mutagenesis and screening components 
were validated following one round of screening, the methodology was then expanded to 
additional rounds of screening to further elucidate stabilizing mutations to PlyCA 
(Chapter IV).  
 While the rational and random protein engineering methods used were successful 
at enhancing the thermodynamic and kinetic stability of PlyC, using this particular 
endolysin for these studies was far from ideal. We ultimately decided on using PlyC for 
several reasons. First, our lab possessed the clone for expressing this particular endolysin 
and had extensive experience working with the enzyme. Secondly, the molecular, 
biochemical and biophysical characteristics of PlyC were explicated through previous 
and current experiments, as well as ongoing collaborations. Third, the 3.3-Å crystal 
structure of the enzyme had been solved, providing the structural insight and atomic 
coordinates necessary for formulating thermostabilizing engineering methodologies. 
However, devising effective strategies was difficult and laborious due to the complexity 





deploy a synergistic bacteriolytic mechanism. Using a traditional Gram-positive 
endolysin with the simplistic monomeric architecture of an N-terminal EAD linked to a 
C-terminal CBD would have made designing and performing engineering experiments 
more straightforward and efficient. For example, when using computational protein 
folding algorithms to simulate the folding of highly complex proteins, such as PlyC, there 
is a greater propensity for folding and subsequent atomic interaction inaccuracies, 
causing imprecise free energy predictions. Accordingly, stabilizing mutations may be 
overlooked or a more voluminous list of candidates may need to be experimentally 
characterized in order to identify beneficial mutations.  In a more simplistic system, such 
as a monomeric endolysin, free energy values calculated by simulating the three-
dimensional folding of the protein will be more reliable. This would decrease the chances 
of excluding potentially stabilizing mutations during computational screening and 
additionally limit the number of incorrectly identified candidates for experimental 
characterization.  
 Expanding to the directed evolution screening methodology created in Chapter 
III, using a traditional monomeric Gram-positive endolysin instead of PlyC would have 
simplified the protocol. Due to PlyC being composed of PlyCB and PlyCA subunits, it 
was necessary to utilize a dual expression system. This first required making a stable and 
highly competent E. coli DH5α strain harboring the expression construct pBAD33: 
plyCB, for which mutagenized pBAD24: plyCA constructs were then transformed into. 
Unfortunately, as a direct consequence of co-expressing PlyCA and PlyCB on separate 
and unique expression plasmids, the resulting holoenzyme population displays significant 





expression system could have been avoided by applying epPCR to plyCA and then re-
inserting the gene into the context of the plyC operon. However, due the absence of 
intrinsic endonuclease restriction sites at the 5’ and 3’ ends of plyCA, this would have 
required additional overlap-extension PCR (OE-PCR) steps. Not only is this more time 
consuming, but DNA recombination techniques further increase the chances of 
incorporating additional unwanted nucleotide mutations in the plyC operon. 
Alternatively, a co-expression system could have been avoided altogether using a single 
subunit protein, and, with the exception of targeting specific regions of the enzyme for 
epPCR, subsequent OE-PCR steps could be omitted as well.  
 The kinetics pertaining to the EAD and CBD modules of endolysins along with 
the CBD specificity can be altered by modifying the directed evolution methodology 
discussed in Chapter III. Amending the directed evolution protocol for increasing the 
bacteriolytic kinetics of an endolysin by either amplifying the catalytic efficiency of the 
EAD or, since it is believed endolysins bind irreversibly to their explicit cell wall ligand 
to prevent other potential host cells from being lysed (Loessner et al., 2002), enhancing 
CBD binding affinity, can be achieved through three alterations. First, the heating step 
initially installed in the methodology would be removed since you would no longer be 
screening for variants with improved kinetic stability. Second, epPCR can be applied to 
the full-length endolysin gene or to the individual domains. Finally, the criteria used for 
identifying enzyme variants with increased catalytic efficiency after turbidity reduction 
kinetic analysis would have to be adapted. Previously, the screening component of the 
directed evolution protocol was formulated for identifying kinetically stabilized PlyC 





spectrophotometrically lyse at least half of the S. pyogenes population (i.e. ≥ 50% 
reduction of the initial OD600) in less than 900 seconds. To transition from screening for 
kinetic stability to catalytic efficiency, one would need to first obtain a reasonable 
estimation of the amount of time (seconds) required for the wild-type endolysin to 
achieve a spectrophotometric-based 50% reduction in cell population. After this value is 
identified, then one would select a time point considerably lower to serve as the baseline 
criteria for discerning endolysin mutants with or without significantly progressed 
catalytic efficiency. For example, if the wild-type pneumococcal endolysin Cpl-1 was 
able to lyse half of the S. pneumoniae cell population in 1000 seconds, then one could 
progressively identify Cpl-1 variants with improved catalytic efficiency by using the 
screening requirements of: 
 Round 1: 50% decrease in initial OD600 in less than 800 seconds 
 Round 2: 50% decrease in initial OD600 in less than 600 seconds 
 Round 3: 50% decrease in initial OD600 in less than 400 seconds 
 Round 4: 50% decrease in initial OD600 in less than 200 seconds 
 Shuffle kinetically advantageous mutations, final evolved Cpl-1 variant(s) must 
display a 50% decrease in initial OD600 in less than 100 seconds 
 Adjusting the directed evolution methodology for generating endolysin variants 
with revised bacterial specificity can also be accomplished by introducing several 
changes to the protocol. Once again the heating step would be removed since the focus of 
the screening portion of the protocol is not geared towards identifying stabilized enzyme 





mutagenized PCR products would be genetically combined with the rest of the endolysin 
gene through either OE-PCR or utilizing endogenous endonuclease restriction sites at the  
polar ends of the CBD gene. The last modification focuses on the assay used to determine 
bacterial lysis. Considering the objective is to identify endolysin variants that display 
altered lytic specificity, one could use spot-on-lawn (i.e. plate lysis) assays (e.g. Fig. 5-3) 
(Donovan et al., 2006a; Schuch et al., 2002) as an alternative to spectrophotometric 
turbidity reduction assays. These assays consist of plating exponentially growing target 
bacterial cells on an agar plate, followed by spotting the endolysin on the air-dried plate. 
Incubating the plates overnight allows for the growth of the bacterial lawn. If the 
endolysin spotted on the agar plate is active against the bacteria, then the antimicrobial 
activity will be represented by a clear lysis zone. 
 Chimeragenesis is an alternative engineering approach that can be adequately 
applied to Gram-positive endolysins due to their modular composition. Domain swapping 
has proven to be practical for refining the kinetics and specificity of both the EAD and 
CBD modules (Croux et al., 1993a, b; Diaz et al., 1990, 1991; Donovan et al., 2006a; 
Schmelcher et al., 2011), however this practice has never been utilized for the purpose of 
improving the thermal stability of endolysins. In order for chimeragenesis to be effective, 
the thermal stability of the EAD and CBD modules that comprise the unstable endolysin 
of interest need to be understood. This can be achieved by expressing and purifying the 
individual domains separately, followed by thermal characterization (e.g. CD, DSC, 
differential scanning fluorimetry (DSF) or spectrophotometric-based assays measuring 
protein aggregation at OD360 as a function of temperature). If a thermosusceptible domain 







Figure 5-3. Plate lysis assay example. The GBS B30 endolysin and S. aureus exolysin 
lysostaphin were fused together to expand the lytic specificity of the antimicrobial. Crude 
E. coli lysates were prepared from cells harboring the various pET21a-derived expression 
vectors. Spots of cleared lawn represent lysis of the target organisms. Lysostaphin was 
spotted as a control. B30-90 is an inactive truncation of B30 and thus served as a negative 
control. S. agal, S. agalactiae; S. aur, S. aureus; S. uber, S. uberis; S. dys, S. dysgalactiae. 












originating from any peptidoglycan hydrolase or a CBD specific to the target bacterial 
species. 
 The scarcity of characterized thermostable EAD and CBD modules from 
mesophilic phage currently limits the practicality of the chimeragenesis approach for 
thermostabilizing endolysins. One way to address this limitation is to utilize 
peptidoglycan hydrolases derived from thermophilic phage or bacteria. These enzymes 
and their catalytic domains can be identified from literature (if characterized) or 
bioinformatic sources (if uncharacterized), such as the National Center for Biotechnology 
Information (NCBI) and Pfam databases. Once a thermophilic peptidoglycan hydrolase is 
selected as a candidate, the gene encoding the enzyme can be synthetically constructed to 
use as a template for chimeragenesis. For example, the following six catalytic domains 
were identified from thermophilic bacteria or phage as possessing similar size (~20 kDa) 
and putative cell wall hydrolytic activities to EADs derived from phage endolysins (Table 
5-1). Future chimeragenesis approaches could utilize these or similar domains for 
thermostabilizing endolysins (Appendix D).  
 Although the general theme of this dissertation was to progress the intrinsic 
structural stability of phage endolysins, stabilizing chemical components for protein 
formulations need to also be considered, including polyols, sugars, amino acids, salts, 
polymers/proteins, surfactants and preservatives. Polyols and sugars act through a 
preferential exclusion mechanism and were initially exploited by pharmaceuticals in 1993 
(Timasheff, 1993). The preferential exclusions of the polyols and sugars from the protein 
promotes a stronger protein hydration, which then minimizes the energetically 















packing. Moreover, this preferential exclusion reduces the chemical potential of the 
protein and thus lessens the risk of oxidation (Kendrick et al., 1997). Sugars can 
additionally improve protein stability by removing metal salts from solution in order to 
prevent these metals from acting as antioxidants, or to decrease chemical degradation 
processes catalyzed by metal ions (Lam et al., 1997). Furthermore, polyols and sugars 
have shown to be effective cryoprotectants and lyoprotectants, with the concentrations of 
each determining the degree of stabilization. Proteins can be stabilized during freeze-
thawing by including lactose, glycerol, xylitol, sobitol and mannitol at molar 
concentrations of 0.5-1.0 M (Carpenter et al., 1990), as well as sucrose, maltose, glucose 
and inositol (Carpenter et al., 1986).  When freeze-drying protein samples, sugars can act 
as a water replacement by providing hydroxyl functions to the protein (Crowe et al., 
1993a, b; Schule et al., 2008). Disaccharides (e.g. trehalose, sucrose, maltose and lactose) 
are equal to or better lyoprotectants than monosaccharides (e.g. glucose and galactose). In 
particular, the tendency of sucrose and trehalose to form amorphous cakes makes them 
superlative bulking agents when freeze-drying protein samples (Arakawa and Prestrelski, 
1993; Chang et al., 1996).  
 Amino acid additives (e.g. histidine, arginine and glycine) stabilize proteins using 
a variety of mechanisms. For example, several amino acids were shown to stabilize pig 
heart mitochondrial malate dehydrogenase by preferential exclusion (Jensen et al., 1996), 
histidine was able to prevent oxidation of papain (Kanazawa et al., 1994), and cysteine 
and (partially) methionine were able to increase the stability of recombinant human 





1996). Other amino acids used as formulation excipients include proline, lysine, glutamic 
acid and arginine mixtures. 
 The stabilizing potential of salts depends on several factors, including the type 
and concentration of salt, the nature of the ionic interactions and the charged residues that 
comprise the protein of interest (Kohn et al., 1997). By increasing the ionic strength of a 
solution, protein stability can be augmented by enhancing the strength of hydrophobic 
interactions. Additionally, salts can be preferentially excluded from proteins, making 
their structures more compact and stable. Buffer salts are a required component of protein 
storage solutions for the purpose of maintaining pH values best for retention of the native 
state of the protein.  
 Hydrophilic polymers (e.g. PEGs, polysaccharides and inert proteins) 
nonspecifically interact with the proteins to induce steric hindrance and enhance protein 
assembly. Hydrophobic moieties of various polymers (e.g. those comprised by PEGs and 
Pluronics) alter surface activity by decreasing the water surface tension, which suppresses 
protein aggregation caused by surface absorption. Other mechanisms of stability 
affiliated with the use of polymers/proteins include preferential exclusion and decreased 
protein flexibility provoked by enhanced viscosity (Wang, 1999). 
 Pharmaceutical companies commonly use surfactants in protein formulations to 
compete for interfaces that could possibly cause unfolding and aggregation (Piatigorsky 
et al., 1977). These interfaces are mainly between the aqueous protein solution on the 
side of container walls, stoppers (coated or uncoated), ice-crystals from freezing or 
storage, filter materials, tubes and air-water interfaces. Surfactants can also act as 





(Rozema and Gellman, 1996). Examples of surfactants include Tween 20 and 80, Brij 35, 
Triton X-10, Pluronic F127 and SDS. 
 Approximately 25% of all protein formulations include preservatives that prevent 
microbial growth, particularly for multi-dose, single container formulations. M-cresol, 
phenol and benzyl alcohol are the most widely used antimicrobial agents. These 
antimicrobial are typically used independently, although insulin-protamine suspension 
products, for example, contain both m-cresol and phenol. However, many times these 
compounds are not compatible with the protein itself, often promoting aggregation 
(Hutchings et al., 2013), as well as the particular processing and packaging materials.  
 
Summary and Conclusions 
 In this dissertation, rationale-based (Chapter II) and directed evolution (Chapters 
III and IV) protein engineering methods were applied to streptococcal endolysin PlyC 
with the goal of improving the thermal stability of the enzyme. The motivation behind 
this work was to elongate the shelf life expectancy to enhance the antimicrobial potential 
of the endolysin for industrial application. Guided by previously elucidated structural and 
biophysical data, mutations were computationally modeled into the thermolabile C-
terminal CHAP domain of the PlyCA subunit using the protein folding algorithm FoldX 
in order to identify mutants that are thermodynamically advantageous (Chapter II). Next, 
a novel directed evolution methodology was developed and validated for improving the 
kinetic stability of bacteriolytic enzymes (Chapter III).  This directed evolution protocol 
was devised for identifying enzyme variants that concurrently exhibit progressed kinetic 





the methodology, several rounds of directed evolution were then applied to PlyC in order 
to significantly enhance the thermal properties of the enzyme (Chapter IV).  
 In conclusion, it has been determined that: 
1) Computationally screening thermolabile regions of endolysins, such as the C-
terminal CHAP domain of PlyCA, using the FoldX algorithm in combination with 
Rosetta and visual inspection can effectively identify stabilizing mutations. For 
example, the PlyC (PlyCA) T406R mutant, which is hypothesized to generate an 
enthalpic gain due to an inter-domain hydrogen bond formed between the side-
chains of Q106 of the GyH domain and R406 of the CHAP domain, displayed a 
2.27°C increase in thermodynamic stability, 16 fold decrease in thermally-
induced kinetic inactivation at 45°C and an 11 kcal/mol improvement in EA of 
PlyCA unfolding. These types of in silico strategies can be applied to specific 
regions or the entire subunit of other endolysins for increasing thermal stability. 
2) Directed evolution methodologies can be devised to significantly augment the 
stability of bacteriolytic enzymes while preserving their native catalytic 
efficiency. The validated directed evolution protocol we developed consists of 
several steps, including: 
o Determining the optimal heating conditions to use during screening 
o Generating the mutant library using, for example, epPCR with a desired 
low nucleotide mutation rate 
o 96-well microtiter plate preparation and subsequent cell growth conditions 
o Replica plating, protein expression induction and lysate preparation 





Although multiple rounds are generally used in directed evolution studies, 
implementing only one round of epPCR and screening can result in the 
identification of mutants with decidedly improved kinetic stability and wild-type 
catalytic activity. For example, when compared to wild-type, the PlyC 29C3 
mutant exhibited a ~2 fold decrease in thermally-induced kinetic inactivation at 
45°C, while showing no significant difference in lytic activity at room 
temperature. 
3) Expanding the directed evolution methodology to incorporate multiple rounds of 
mutagenesis and screening can yield bacteriolytic enzymes with considerably 
evolved kinetic and thermodynamic stability. Screening a total of 18,000 mutants 
over three rounds of directed evolution yielded a lead candidate, termed PlyC 
33D2. Isolating the four amino acid mutations that comprised this construct 
subsequently produced a final thermally evolved PlyC variant, termed PlyC 
(PlyCA) N211H, with a 4.10°C increase in TG, an 18.8 fold enhancement in 
kinetic stability at 45°C and a 17.52 kcal/mol gain in EA of PlyCA unfolding. The 
H211 residue appears to stabilize the EAD of PlyC through the enthalpic gains 
generated by anchoring a segment of the flexible linker 1 structure to the surface 
of the GyH domain. This hypothesized structural alteration seems to be induced 
by electrostatic interactions formed between E113, D150 and H211.  
4) Combining thermally advantageous mutations identified from independent 
bioengineering techniques can additively enhance the stability of bacteriolytic 
enzymes. Using PlyC as an example, combining the stabilizing mutations N211H 





double mutant (i.e. PlyC (PlyCA) N211H T406R) that displayed additive 
improvements in both thermodynamic (+7.46°C ΔTG) and kinetic (+28.72 




Computational Screening of the GyH and Helical Docking Domains of PlyCA
 Considering how effective it was to utilize protein folding algorithms to identify 
thermostabilizing mutations to the C-terminal CHAP domain of PlyCA, I would like to 
expand the in silico screening to the other regions of the subunit, namely the N-terminal 
GyH domain and the central helical docking domain. When initially designing 
computational screening strategies specific for PlyC, it was believed that the CHAP 
domain was the most heat-labile domain of PlyCA and thus was an obvious region to 
target. With a more detailed thermodynamic understanding of the PlyC holoenzyme 
structure, it appears the GyH and CHAP domains have similar thermodynamic stability. 
As such, the thermostability engineering potential for the GyH domain is comparable to 
that of CHAP.  Modeling mutations into the central helical docking domain could also be 
thermodynamically rewarding. The helical docking domain interacts with four adjacent 
PlyCB N-termini to promote the formation of the holoenzyme structure. Computationally 







Further Structural Characterization and Thermostabilization Strategies using PlyC 
(PlyCA) N211H, T406R and N211H T406R 
 A combination of biochemical and biophysical experimental approaches has been 
used in an attempt to understand the mechanism of stability for the PlyCA mutations 
N211H and T406R. It is believed that H211 stabilizes PlyCA by electrostatically 
interacting with E113 and D150, whereas R406 is hypothesized to form an inter-domain 
hydrogen bond with Q106 of the GyH domain. To structurally determine the stabilizing 
molecular interactions associated with H211 and R406, I plan on collaborating with 
Travis Gallagher at the National Institute of Standards and Technology (NIST) to obtain 
an X-ray crystal structure of PlyC (PlyCA) N211H T406R. Elucidating these mechanisms 
can be helpful for devising future structure-guided rational engineering strategies for 
PlyC and other endolysins. 
 Additional engineering strategies can be directed towards PlyC (PlyCA) N211H 
T406R to continue enhancing the thermal stability of the endolysin. With potential 
interaction partners for both H211 and R406 being identified, these interactions can be 
strengthened through the insertion of disulfide bonds. For example, with H211 
hypothesized to electrostatically interact with E113 and D150, the constructs PlyC 
(PlyCA) N211C E113C or PlyC (PlyCA) N211C D150C can be synthesized to substitute 
the weaker electrostatic interaction with a stronger covalent interaction. Furthermore, a 
PlyC (PlyCA) Q106C T406C construct can be made in an attempt to covalently link the 
GyH and CHAP domains, although this may not be feasible due to the distance between 
the two mutagenized cysteine side-chains. In terms of the PlyC (PlyCA) N211H mutant, 





segment of the linker 1 structure to the surface of the GyH domain. To this end, future 
engineering studies can focus on decreasing the flexibility of the linker 1 and linker 2 
structures of PlyCA. This can be accomplished several ways, including substituting the 
highly flexible glycine and serine residues that comprise these linkers with proline 
residues, anchoring the linkers to the surfaces of either the GyH or CHAP domains by 
engineered disulfide bonds, or deleting amino acids to shorten the linker structures. 
Finally, additional rounds of directed evolution can be applied to PlyC (PlyCA) N211H 
T406R. 
 
Applying Chimeragenesis to Other Gram-Positive Endolysins 
 Preliminary experimental results show chimeragenesis can be an efficient 
engineering strategy for increasing the thermal stability of Gram-positive endolysins 
(Appendix D). Unfortunately, while the gain in stability is significant, the complex 
synergistic bacteriolytic mechanism employed by PlyC makes this endolysin a poor 
candidate for chimeric engineering. Without the simultaneous presence of fully-
functional GyH and CHAP domains, PlyC displays < 1% activity compared to wild-type. 
Thus, removing both domains and inserting a foreign thermostable catalytic domain in 
their place results in a streptococcal endolysin with drastically reduced lytic activity. 
Traditional Gram-positive endolysins that constitute a single EAD would be better suited 
for this protein engineering approach. First, I would like to thermodynamically 
characterize the EAD and CBD modules from a variety of Gram-positive endolysins. For 
the endolysins that are comprised of an EAD that is significantly less stable than the 





thermostable catalytic domain candidates, such as Nor1, PlyG EAD and Ply511 EAD. 
The resulting chimeras would then be biochemically and biophysically characterized in 










































































Protein Sequence (Holoenzyme is 1032 AA, 113.11 kDa) 
 
















Primers and Template 
 




plyC operon with 5’ and 3’ UTRs was cloned into pBAD24 using SmaI and HindIII 




























Primers and Template 
 
PlyCB KpnI F 5’ CCCGGTACCATGAGCAAGATTAATGTAAACG 3’ 

































































Primers and Template 
 
PlyCA MfeI F 5’ CTTCTTCAATTGATTATGAGTAAGAAGTATACACAACAACAATACG 3’  








































































Primers and Template 
 





















pBAD24: glycosidase (3’ 6x His-tag) 
 





















Primers and Template 
 
PlyCA MfeI F- 5’ CTTCTTCAATTGATTATGAGTAAGAAGTATACACAACAACAATACG 
3’  







glycosidase domain of  PlyCA (AA 1-205) was cloned into pBAD24 using EcoRI and 
XbaI restriction sites with a 3’ 6x His-tag.  The glycosidase gene is also referred to as gyh 






































Protein Sequence (Holoenzyme is 809 AA, 88.87 kDa) 
 













Primers and Template 
 
PlyCB MfeI F 5’ CTTCTTCAATTGATTATGAGCAAGATTAATGTAAACGTAG 3’ 





lil+PlyCAΔChitinase R 5’ CTTCTCTCTGTTAGCTTCCATTAAATAAATTCTCCCTTTC 3’ 






plyCΔglycosidase was cloned into pBAD24 using EcoRI and XbaI restriction sites. 
Amino acids 1-225 (includes initial methionine) were deleted from PlyCA, which 
correlates to the glycosidase domain dictated by the crystal structure of PlyC. The two 
PCR products (plyCB+lil+First 20 nucleotides of helical docking domain, last 20 



























































Protein Sequence (Holoenzyme is 865 AA, 95.23 kDa) 
 




















PlyCB MfeI F 5’ CTTCTTCAATTGATTATGAGCAAGATTAATGTAAACGTAG 3’ 






plyCΔchap was cloned into pBAD24 using EcoRI and XbaI restriction sites. Amino acids 
299-464 (including the initial methionine) were deleted from PlyCA. This results in the 
removal of the CHAP domain beginning with the start site lysine 299 as predicted by 































pBAD24: plyCΔΔ (3’ 6x His-tag) 
 
















Protein Sequence (Holoenzyme is 640 AA, 70.9 kDa) 
 










Primers and Template 
 
PlyCB MfeI F 5’ CTTCTTCAATTGATTATGAGCAAGATTAATGTAAACGTAG 3’ 







plyCΔΔ 6x His-tag was cloned into pBAD24 using EcoRI and XbaI restriction sites. 
Amino acids 1-225 corresponding to the N-terminal glycosidase domain and linker 1 













































pBAD24: nor1 (3’ 6x His-tag) 
 


















Primers and Template 
 




nor1 was cloned into pBAD24 using EcoRI and XbaI restriction sites. nor1 contains a 3’ 














pBAD24: plyCΔΔnor1_N (3’ 6x His-tag) 
 

























Protein Sequence (812 AA, 89.76 kDa) 
 













Primers and Template 
 





DeltaDelta 6His XbaI R 5’ 
CCCTCTAGATTAGTGATGGTGATGGTGATGCGATCCCTGTAAGTTAACATCAGC 3’ 
 




plyCΔΔnor1_N was cloned into pBAD24 using EcoRI and XbaI restriction sites. Nor1 
was fused to the N-terminus of the helical docking domain of PlyCA by the endogenous 
22 amino acid linker 1 of PlyCA. A 6x His-tag was added to the C-terminus of the 
































pBAD24: ply511 EAD only (5’ 6x His-tag) 
 




















Primers and Template 
 
Ply511 MfeI F 5’ CTTCTTCAATTGATTATGCGTGGTAGCCATCATC 3’ 
Ply511 EAD XbaI R 5’ CCCTCTAGATTAACCGCTAACTTTGGCCAGATCGCTTGCAAAC 
3’ 
 




ply511 EAD only contains amino acids 1-175 of Ply511 and was cloned into pBAD24 
using EcoRI and XbaI restriction sites. There was a 5’ 6x His-tag added to ply511 EAD 
using the amino acid sequence (MRGSHHHHHHGS) outlined by Loesnner et al. 1996. 
Modified Listeria  Bacteriophage Lysin Genes (ply) Allow Efficient Overexpression and 
One-Step Purification of Biochemically Active Fusion Proteins. Appl. Environ. 



































Protein Sequence (828 AA, 90.86 kDa) 
 













Primers and Template 
 





lil/Ply511 F 5’ GAAAGGGAGAATTTATTTAATGGTGAAATATACCGTGGAAAAC 3’ 
lil/Ply511 R 5’ GTTTTCCACGGTATATTTCACCATTAAATAAATTCTCCCTTTC 3’ 
Ply511/Dock F 5’ CGAGTACCCCGAGCACCAATAACAGAGAGAAGTTAAAG 3’ 
Ply511/Dock R 5’ CTTTAACTTCTCTCTGTTATTGGTGCTCGGGGTACTCG 3’ 
Dock R 5’ CCCTCTAGATTACTGTAAGTTAACATCAGCTATTAATTGAAG 3’ 
 




plyCΔΔply511_N was cloned into pBAD24 using EcoRI and XbaI restriction sites. 
Ply511 EAD was fused to the N-terminus of the helical docking domain of PlyCA by the 
25 amino acid proline-rich linker derived from Ply511. Three PCR products 
(plyCB+lil+first 20 nucleotides of ply511, last 20 nucleotides of lil+ply511 EAD+first 20 
nucleotides of helical docking domain, last 20 nucleotides of ply511 EAD+helical 
docking domain) were fused together by means of overlap extension PCR to yield the 
















pBAD24: plyG (5’ 6x His-tag) 
 
























Primers and Template 
 
PlyG EcoRI F 5’ CCGGAATTCATTATGCGTGGTAGCCATCATCATC 3’ 
PlyG XbaI R 5’ CCCTCTAGATTATTTCACTTCATACCACCAACC 3’ 
 




plyG was cloned into pBAD24 using EcoRI and XbaI restriction sites. There was a 5’ 6x 
His-tag added to plyG using the amino acid sequence (MRGSHHHHHHGS) outlined by 
Loesnner et al. 1996. Modified Listeria  Bacteriophage Lysin Genes (ply) Allow Efficient 
Overexpression and One-Step Purification of Biochemically Active Fusion Proteins. 






pBAD24: plyG EAD only (5’ 6x His-tag) 
 


















Primers and Template 
 
PlyG EcoRI F 5’ CCGGAATTCATTATGCGTGGTAGCCATCATCATC 3’ 
PlyG EAD XbaI R 5’ CCCTCTAGATTATGCCACATTACCATTTTTCACTTTC 3’ 
 




plyG EAD was cloned into pBAD24 using EcoRI and XbaI restriction sites. There was a 
5’ 6x His-tag added to plyG EAD using the amino acid sequence (MRGSHHHHHHGS) 
outlined by Loesnner et al. 1996. Modified Listeria  Bacteriophage Lysin Genes (ply) 
Allow Efficient Overexpression and One-Step Purification of Biochemically Active 








pBAD24: plyG CBD only (5’ 6x His-tag) 
 













Primers and Template 
 
PlyG CBD EcoRI F 5’ 
CCGGAATTCATTATGCGTGGTAGCCATCATCATCACCATCATGGTAGCAATGGTAATGT
GGCAACCACCAGTCCG 3’ 
PlyG XbaI R 5’ CCCTCTAGATTATTTCACTTCATACCACCAACC 3’ 
 




plyG CBD was cloned into pBAD24 using EcoRI and XbaI restriction sites. There was a 
5’ 6x His-tag added to plyG CBD using the amino acid sequence (MRGSHHHHHHGS) 
outlined by Loesnner et al. 1996. Modified Listeria  Bacteriophage Lysin Genes (ply) 
Allow Efficient Overexpression and One-Step Purification of Biochemically Active 












SDM Primers for PlyC FoldX Computational  
Screening Studies (Chapter II) 
 
D330Y F 5’ [Phos]CGGTAAGTATATTGGTTACGGTCAATGTTATG 3’ 
D330Y R 5’ [Phos]ACTTGCGCCTGTGCATTGGCTAAGTTTGCTGC 3’ 
 
 
Q332H F 5’ [Phos]TATTGGTGACGGTCACTGTTATGCTTGGGTT 3’ 
Q332H R 5’ [Phos]TACTTACCGACTTGCGCCTGTGCATTGGC 3’ 
 
 
Q332V F 5’ [Phos]ATATTGGTGACGGTGTATGTTATGCTTGGG 3’ 
Q332V R 5’ [Phos]ACTTACCGACTTGCGCCTGTGCATTGGCTA 3’ 
 
 
C345T F 5’ [Phos]GGTCAGCTAGGGTAACTGGTTATTCTATTTC 3’ 
C345T R 5’ [Phos]ACCAACCAACCCAAGCATAACATTGACCGTC 3’ 
 
 
D375Y F 5’ [Phos]ATCCATCTTGGTTGGTATTGGTCAATCGCAAA 3’ 
D375Y R 5’ [Phos]AGAATGAGCGTTCATACCATCACCAATTAAC 3’ 
 
 
T381Y F 5’ [Phos]GGTCAATCGCAAATTATGGTATTGTTAACTAC 3’ 
T381Y R 5’ [Phos]AATCCCAACCAAGATGGATAGAATGAGCG 3’ 
 
 
V384Y F 5’ [Phos]GCAAATACTGGTATTTATAACTACCCAGTTGG 3’ 
V384Y R 5’ [Phos]GATTGACCAATCCCAACCAAGATGGATAGA 3’ 
 
 
C404I F 5’ [Phos]GTCGGCGCGATATGGATTGCTACAGCATTCTC 3’ 
C404I R 5’ [Phos]TCTCAAATCTTCCTTGCGTCCAACAGTACC 3’ 
 
 
T406R F 5’ [Phos]CGATATGGTGCGCTAGAGCATTCTCTGGCGC 3’ 







T421I F 5’ [Phos]GACAATACGGCCATATTGGTATCATTGAAAG 3’ 




























SDM Primers for PlyC Directed Evolution Studies (Chapter IV) 
 
N211H F 5’ [Phos]CAGGTGATGGAAAACATCCTAGTGTTGGCAC 3’ 
N211H R 5’ [Phos]TAATTGAACCACCTGTAAACGGGTCAGCTC 3’ 
 
S224N F 5’ [Phos]CTACCGTTTCTGCTAACTCGGAAGCTAACAG 3’ 
S224N R 5’ [Phos]CATTCCCAGTGCCAACACTAGGATTTTTTCC 3’ 
 
G249C F 5’ [Phos]CTAGAACATCTATCATGTGAATTCTACGGTAAC 3’ 
G249C R 5’ [Phos]GTTGTTGTTGAATAAATCTGTTAGGGCTTTC 3’ 
 
A407S F 5’ [Phos]GATATGGTGCGCTACATCATTCTCTGGCGC 3’ 
A407S R 5’ [Phos]GCGCCGACTCTAAATCTTCCTTGCGTCCAAC 3’ 
 
N211A F 5’ [Phos]CAGGTGATGGAAAAGCTCCTAGTGTTGGC 3’ 
N211A R 5’ [Phos]TAATTGAACCACCTGTAAACGGGTCAGCTCC 3’ 
 
 
N211D F 5’ [Phos]CAGGTGATGGAAAAGATCCTAGTGTTGGC 3’ 
N211D R 5’ [Phos]TAATTGAACCACCTGTAAACGGGTCAGCTCC 3’ 
 
 
N211K F 5’ [Phos]CAGGTGATGGAAAAAAACCTAGTGTTGGC 3’ 
N211K R 5’ [Phos]TAATTGAACCACCTGTAAACGGGTCAGCTCC 3’ 
 
 
N211R F 5’ [Phos]CAGGTGATGGAAAAAGGCCTAGTGTTGGC 3’ 
N211R R 5’ [Phos]TAATTGAACCACCTGTAAACGGGTCAGCTCC 3’ 
 
 
E113A F 5’ [Phos]CATGGCGTCTGGGCAACTTATTTTCCACC 3’ 
E113A R 5’ [Phos]TATGTATTGTAAATCGTGTTCCAAACACTC 3’ 
 
 
D150A F 5’ [Phos]GCCGAACATGGGGTGCTGTTATGATACCTAG 3’ 
D150A R 5’ [Phos]CTGGTAGCGATTGATAAAATCTATCTAAAGC 3’ 
 
 
D208A F 5’ [Phos]GTTCAATTACAGGTGCTGGAAAAAATCCTAG 3’ 






D208A N211H F 5’ [Phos]GTTCAATTACAGGTGCTGGAAAACATCCTAG 3’ 

























Unpublished Dissertation-Related Preliminary Data 
 
 
 Chimeragenesis directed towards thermostabilizing Gram-positive endolysins is 
listed as a future goal in this dissertation; however, preliminary studies using this 
bioengineering strategy have already begun. While not fully developed into a complete 
chapter or publication, this appendix contains preliminary chimeragenesis studies 
involving the identification of thermostable EAD and CBD candidates (e.g. PlyG 
EAD/CBD and Nor1) and subsequently swapping these modules for their thermolabile 
counterparts from various Gram-positive endolysins. Here we focus on performing 
chimeragenesis on PlyC, where the GyH and CHAP domains are removed from the 
catalytic subunit and replaced with a thermostable catalytic domain. 
 As previously mentioned, our lab has recently investigated the thermal behavior 
of the PlyG endolysin. Thermodynamically characterizing the individual EAD and CBD 
modules of PlyG revealed that both domains are intrinsically thermostable, with the 
thermally-induced unfolding of the EAD and CBD each exhibiting a three-state thermal 
transition with respective TG values of 65.40°C and 68.06°C (Fig. D-1). As a result, these 
two domains would represent excellent candidates for use in constructing 
thermostabilized endolysin chimeras. The PlyG EAD could replace a thermosusceptible 
EAD of any Gram-positive endolysin and the PlyG CBD can be substituted for unstable 
CBDs belonging to endolysins that target B. anthracis. To illustrate this concept, our lab 
constructed a PlyC chimera using the EAD derived from the L. monocytogenes endolysin 







Figure D-1. DSC analysis of the isolated EAD and CBD of PlyG. The thermal 
properties of the purified EAD and CBD modules that constitute the B. anthracis 
endolysin PlyG were analyzed using DSC. The EAD (left) at 0.5 mg/ml and CBD (right) 
at 0.25 mg/ml were heated from 15°C to 105°C in 20 mM sodium phosphate buffer pH 
















literature as being highly kinetically stable (Fig. 5-1c) (Schmelcher et al., 2012c). Using 
the PlyC crystal structure depicted in Fig. 1-8 as a guide, the N-terminal GyH domain, 
linker 1, linker 2 and the C-terminal CHAP domain were deleted from PlyCA. The 
Ply511 EAD was then N-terminally fused to the helical docking domain of PlyCA using 
the endogenous proline-rich linker of the Ply511 endolysin (i.e. the linker that naturally 
conjoins the EAD and CBD of Ply511). The resulting chimera, termed 
PlyCΔΔPly511_N, was then expressed, purified and thermally characterized. Kinetic 
inactivation analysis at 45°C showed that the PlyCΔΔPly511_N chimera still retained 
~93% residual lytic activity at the conclusion of the 3 hour experiment, whereas wild-
type PlyC, with a t1/2 of 17.84 minutes, only maintained 5% residual activity after 3 hours 
(Fig. D-2). The thermodynamic stability of the isolated Ply511 EAD, which was still 
unknown, and PlyCΔΔPly511_N were elucidated using DSC. The thermally-induced 
unfolding of the Ply511 EAD exhibited a three-state thermal transition, with a TG of 
54.08°C (Fig. D-3a), while PlyCΔΔPly511_N exhibited a five-state thermal transition, 
with an EAD (i.e. PlyCAΔΔPly511_N) TG of 54.21°C (Fig. D-3b). Considering the wild-
type PlyCA subunit in a holoenzyme background yields a TG of 48.27 at pH 7.0, the 
chimeric EAD subunit displayed a significant 5.94°C enhancement in thermodynamic 
stability. 
 With the limited availability of thermostable EAD candidates for chimeragenesis, 
a bioinformatic and literature search was conducted to identify additional peptidoglycan 
hydrolase catalytic domains from thermophilic bacteria or phage (Table 5-1). One 
peptidoglycan hydrolase catalytic domain candidate was encoded by the thermophile 





































Figure D-2. Kinetic inactivation of wild-type PlyC and PlyCΔΔPly511_N at 45°C. 
PlyC (44 nM) in PBS pH 7.2 or PlyCΔΔPly511_N (1.1 µM) in Tris pH 8.0, 200 mM 
NaCl were incubated at 45°C for a total of 3 hours. At 20 minute time intervals, an 
aliquot of each sample was removed and cooled on ice. The heat-treated enzyme samples 
were then assayed for residual lytic activity against S. pyogenes in a turbidity reduction 
assay. The activity displayed by each sample was normalized to the activity displayed by 









Ply511 EAD in 20 mM Phosphate Buffer pH 7.0


































PlyCPly511_N in 20 mM Phosphate Buffer pH 7.0


































Figure D-3. Thermodynamic characterization of Ply511 EAD and PlyCΔΔPly511_N. 
The (a) isolated Ply511 EAD and (b) PlyCΔΔPly511_N chimera were 
thermodynamically investigated using DSC. Each enzyme at 1 mg/ml was heated from 








Basin at Yellowstone National Park (Sokolova et al., 2004). This particular catalytic 
domain, termed Nor1, was experimentally shown by DSC to be exceedingly 
thermostable, with a TG of 84.8°C (Fig. D-4a). In a PlyCΔΔ background (PlyC 
holoenzyme with PlyCA GyH domain, CHAP domain, and linker 1 or linker 2 deletions), 
Nor1 was fused N-terminally to the helical docking domain of PlyCA using linker 1. The 
resulting chimera, PlyCΔΔNor1_N, was then expressed, purified and thermally 
characterized. Results from a CD thermal denaturation experiment revealed the chimera 
had a resulting T1/2 of 72.8°C (Fig. D-4b). Compared to wild-type PlyC, the chimera had 
ΔT1/2 improvement of ~23°C. 
 Chimeragenesis offers yet another powerful protein engineering tool to 
compliment rationale-based computational screening and directed evolution when 
seeking to increase the thermal stability of Gram-positive endolysins. This particular 
engineering methodology will become more practical as the list of thermostable EAD and 
CBD modules expands. Nonetheless, there are several EAD and CBD candidates 
currently available that can be utilized to significantly enhance the thermal stability of 












Nor1 in 20 mM Phosphate Buffer pH 7.0































































Figure D-4. Biophysical characterization of a thermostabilized streptococcal 
chimera endolysin. (a) Nor1 at 1 mg/ml was thermodynamically characterized by DSC 
in 20 mM sodium phosphate buffer from 15°C to 105°C using a heating rate of 1°C/min. 
(b) The thermal stability of 1 mg/ml PlyCΔΔNor1_N in 20 mM sodium phosphate buffer 
pH 7.0 was analyzed using CD spectroscopy by monitoring the α-helical content at 222 
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High Throughput Structural Analysis of Yeast  
 
Ribosomes Using hSHAPE 
 
This appendix contains the abstract for the following co-authored publication: 
 
Jonathan A. Leshin, Ryan Heselpoth, Ashton Trey Belew, and Jonathan Dinman (2011). 




 Global mapping of rRNA structure by traditional methods is prohibitive in terms 
of time, labor and expense. High throughput selective 2' hydroxyl acylation analyzed by 
primer extension (hSHAPE) bypasses these problems by using fluorescently labeled 
primers to perform primer extension reactions, the products of which can be separated by 
capillary electrophoresis, thus enabling long read lengths in a cost effective manner. The 
data so generated is analyzed in a quantitative fashion using SHAPEFinder. This 
approach was used to map the flexibility of nearly the entire sequences of the 3 largest 
rRNAs from intact, empty yeast ribosomes. Mapping of these data onto near-atomic 
resolution yeast ribosome structures revealed the binding sites of known trans-acting 





Refinement of this technology will enable nucleotide-specific mapping of changes in 
rRNA structure depending on the status of tRNA occupancy, the presence or absence of 
other trans-acting factors, due to mutations of intrinsic ribosome components or extrinsic 






















X-ray Crystal Structure of the Streptococcal Specific Phage Lysin PlyC 
 
This appendix contains the abstract for the following co-authored publication: 
 
Sheena McGowan, Ashley M. Buckle, Micheal S. Mitchell, James T. Hoopes, D. Travis 
Gallagher, Ryan D. Heselpoth, Yang Shen, Cyril F. Reboul, Ruby H. Law, Vincent A. 
Fischetti, James C. Whisstock, and Daniel C. Nelson (2012). X-ray Crystal Structure of 




 Bacteriophages deploy lysins that degrade the bacterial cell wall and facilitate 
virus egress from the host. When applied exogenously, these enzymes destroy susceptible 
microbes and, accordingly, have potential as therapeutic agents. The most potent lysin 
identified to date is PlyC, an enzyme assembled from two components (PlyCA and 
PlyCB) that is specific for streptococcal species. Here the structure of the PlyC 
holoenzyme reveals that a single PlyCA moiety is tethered to a ring-shaped assembly of 
eight PlyCB molecules. Structure-guided mutagenesis reveals that the bacterial cell wall 
binding is achieved through a cleft on PlyCB. Unexpectedly, our structural data reveal 
that PlyCA contains a glycoside hydrolase domain in addition to the previously 
recognized cysteine, histidine-dependent amidohydrolases/peptidases catalytic domain. 
The presence of eight cell wall-binding domains together with two catalytic domains may 





Crystal Structure of ORF210 from E. coli O157:H7 Phage  
CBA120 (TSP1), a Putative Tailspike Protein 
 
This appendix contains the abstract for the following co-authored publication: 
 
Chen Chen, Patrick Bales, Julia Greenfield, Ryan D. Heselpoth, Daniel C. Nelson, and 
Osnat Herzberg (2014). Crystal Structure of ORF210 from E. coli O157:H7 Phage 
CBA120 (TSP1), a Putative Tailspike Protein. PLoS One 9, e93156. 
 
Abstract 
 Bacteriophage tailspike proteins act as primary receptors, often possessing 
endoglycosidase activity toward bacterial lipopolysaccharides or other 
exopolysaccharides, which enable phage absorption and subsequent DNA injection into 
the host. Phage CBA120, a contractile long-tailed Viunalikevirus phage infects the 
virulent Escherichia coli O157:H7. This phage encodes four putative tailspike proteins 
exhibiting little amino acid sequence identity, whose biological roles and substrate 
specificities are unknown. Here we focus on the first tailspike, TSP1, encoded by the 
orf210 gene. We have discovered that TSP1 is resistant to protease degradation, exhibits 
high thermal stability, but does not cleave the O157 antigen. An immune-dot blot has 
shown that TSP1 binds strongly to non-O157:H7 E. coli cells and more weakly to K. 
pneumoniae cells, but exhibits little binding to E. coli O157:H7 strains. To facilitate 
structure-function studies, we have determined the crystal structure of TSP1 to a 





elongated homotrimers. The receptor binding region of each subunit adopts a right-
handed parallel β helix, reminiscent yet not identical to several known tailspike 
structures. The structure of the N-terminal domain that binds to the virion particle has not 
been seen previously. Potential endoglycosidase catalytic sites at the three subunit 
interfaces contain two adjacent glutamic acids, unlike any catalytic machinery observed 
in other tailspikes. To identify potential sugar binding sites, the crystal structures of TSP1 
in complexes with glucose, α-maltose, or α-lactose were determined. These structures 
revealed that each sugar binds in a different location and none of the environments 
appears consistent with an endoglycosidase catalytic site. Such sites may serve to bind 



















Characterization of AlgMsp, an Alginate Lyase  
 




This appendix contains the abstract for the following co-authored manuscript that has 
been submitted for publication: 
 
Steve M. Swift, Jeffrey W. Hudgens, Ryan D. Heselpoth, Patrick M. Bales, and Daniel 




 Alginate is a polysaccharide produced by certain seaweeds and bacteria that 
consists of mannuronic acid and guluronic acid residues. Seaweed alginate is used in food 
and industrial chemical processes, while the biosynthesis of bacterial alginate is 
associated with pathogenic Pseudomonas aeruginosa. Alginate lyases cleave this 
polysaccharide into short oligo-uronates and thus have the potential to be utilized for both 
industrial and medicinal applications. An alginate lyase gene, algMsp, from 
Microbulbifer sp. 6532A, was synthesized as an E.coli codon-optimized clone. The 
resulting 37 kDa recombinant protein, AlgMsp, was expressed, purified and 
characterized. The alginate lyase displayed highest activity at pH 8 and 0.2 M NaCl. 
Activity of the alginate lyase was greatest at 50°C; however the enzyme was not stable 
over time when incubated at 50°C. The alginate lyase was still highly active at 25°C and 





not dependent on the presence of divalent cations. Comparing activity of the lyase against 
polymannuronic acid and polyguluronic acid substrates showed higher specific activity 
towards polymannuronic acid. However, AlgMSP exhibited greater binding affinity to 
the polyguluronic acid substrate. Prolonged AlgMsp-mediated degradation of alginate 




































Biochemical and Biophysical Characterization of PlyGRCS, a 




This appendix contains the abstract for the following co-authored manuscript that has 
been submitted for publication: 
 
Sara B. Linden, Helena Zhang, Ryan D. Heselpoth, Yang Shen, Mathias Schmelcher, 
Fritz Eichenseher, and Daniel C. Nelson. Biochemical and Biophysical Characterization 
of PlyGRCS, a Bacteriophage Endolysin Active against Methicillin-Resistant 
Staphylococcus aureus. (Submitted) 
 
Abstract 
 The increasing rate of resistance of pathogenic bacteria, such as Staphylococcus 
aureus, to classical antibiotics has driven research towards identification of other means 
to fight infectious disease. One particularly viable option is the use of bacteriophage-
encoded peptidoglycan hydrolases, called endolysins or enzybiotics. These enzymes lyse 
the bacterial cell wall upon direct contact, are not inhibited by traditional antibiotic 
resistance mechanisms, and have already shown great promise in the areas of food safety, 
human health, and veterinary science. We have identified and characterized an endolysin, 
PlyGRCS, which displays dose-dependent antimicrobial activity against both planktonic 
and biofilm S. aureus, including methicillin-resistant S. aureus (MRSA). The host range 





Gram-positive pathogens. The contributions of the PlyGRCS putative catalytic and cell 
wall binding domains were investigated through deletion analysis. The cysteine, 
histidine-dependent amidohydrolase/peptidase (CHAP) catalytic domain displayed 
activity by itself, though reduced, indicating the necessity of the binding domain for full 
activity. In contrast, the SH3_5 binding domain lacked activity but was shown to interact 
directly with the staphylococcal cell wall via fluorescent microscopy. Site-directed 
mutagenesis studies determined that the active-site residues in the CHAP catalytic 
domain were C29 and H92, and its catalytic functionality required calcium as a co-factor. 
Finally, biochemical assays coupled with mass spectrometry analysis determined that 
PlyGRCS displays both N-acetylmuramoyl-L-alanine amidase and D-alanyl-glycyl 
endopeptidase hydrolytic activities despite possessing only a single catalytic domain. 
These results indicate that PlyGRCS has the potential to become a revolutionary 






















HexNW is a Highly Thermostabile Glucosaminidase  
that Disperses S. epidermidis Biofilms  
 
This appendix contains the abstract for the following co-authored manuscript that has 
been submitted for publication: 
 
Patrick M. Bales, Ryan D. Heselpoth, and Daniel C. Nelson. HexNW is a Highly 
Thermostabile Glucosaminidase that Disperses S. epidermidis Biofilms. (Submitted) 
 
Abstract 
 Staphylococcus epidermidis is a bacterium that is found on the skin of almost all 
humans but is capable of opportunistic infection (often by colonizing medical implant 
devices). When it does so, it normally survives by growing as a biofilm. Biofilm-forming 
bacteria are notoriously difficult to eradicate due to the resistance to antimicrobials and 
other stressors provided by the extracellular polymeric substance (EPS). Polysaccharide 
intercellular adhesin (PIA) is a major constituent of Staphylococcus epidermidis EPS and 
is made up of partially deacetylated β-1,6-N-acetylglucosamine. A bioinformatics search 
of putative hexosaminidases and glucosaminidases that may be able to break up S. 
epidermidis biofilms revealed an uncharacterized enzyme produced by Neisseria 
wadsworthii, henceforth referred to as HexNW. It was found to be active against a 
synthetic substrate containing N-acetylglucosamine and had a Km of 1.13 mM and Vmax 
of 22.06 pmols/sec, but it did not display activity against chitin-like substrates. In 





after incubation at various temperatures and by performing circular dichroism and 
differential scanning calorimetry. Finally, HexNW was shown to be antagonistic to S. 
epidermidis biofilms by monitoring the release of amino sugars and colony-forming units 
from the surface of the biofilm. In addition, a 2-fold decrease in the minimum biofilm 
elimination concentration (MBEC) was observed when HexNW was used to supplement 
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